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Abstract 
 
Hepatocellular carcinoma (HCC) is the most common primary malignant tumour of 
the liver. Aflatoxin B1 (AFB1) is a potent hepatocarcinogen, and dietary iron overload 
has been shown to contribute to HCC development in black africans. Both are well 
studied hepatotoxins. The aim of this study was to use a Wistar rat model over a 12 
month period to investigate synergy and the extent thereof between AFB1 ingestion 
and dietary iron overload. 25ug/day of AFB1, reconstituted in DMSO, was 
administered by gavaging the animals, over a period of 10 days with a 2 day interval 
in between. The chow diet was supplemented with 0.75% (w/w) ferrocene iron. 
Experimental subjects were divided into 4 groups. Group 1 was fed the normal chow 
diet. Group 2 was fed 0.75% (w/w) ferrocene iron alone. Group 3 was gavaged 250μg 
AFB1 alone. Group 4 was fed the 0.75% (w/w) ferrocene iron and gavaged 250μg 
AFB1. A number of assays were conducted to investigate synergy. Colorimetric assays 
were used to measure serum iron, total-iron binding capacity, ALT, AST, GGT, nitrite 
production, lipid peroxidation and hydroxyproline concentrations. ELISA’s were used 
to determine ferritin, 8-isoprostane and 8-hydroxyguanosine concentrations. Non-
transferrin bound iron was measured using an HPLC method. A chemiluminescent 
assay was used to measure superoxide anion production. Cytokines were measured 
using a suspension array system. Mutagenicity was assessed using the Ames 
mutagenicity assay using salmonella typhimirium strains TA97, TA98, TA100 and 
TA102. Iron profiling indicated that iron overloading occurred with the ingestion of 
the ferrocene diet. Biomarkers of oxidative stress, as illustrated by the measurement 
of 8-hydroxyguanosine and lipid peroxidation, showed additive synergistic effects 
between the two carcinogens. The anti-inflammatory interleukin-10 was shown to be 
markedly elevated with the co-administration of the two carcinogens, indicating the 
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elevated inflammatory processes. Additive synergistic effects were noted in terms of 
the liver disease marker ALT. The salmonella typhimirium strain TA102 used in the 
Ames mutagenicity test showed increased colony counts with respect to the co-
administration of carcinogens (P<0.05), although no synergistic effect was noted. In a 
few of the presented parameters, the AFB1 group was not significantly different to the 
control group, although significant differences between the Fe group and the Fe + 
AFB1 groups were noted. The implication of which is that the presence of AFB1 is 
increasing the activity of Fe as a carcinogen, thereby acting as a co-carcinogen. 
Examples of such parameters illustrating this are presented in the results section 
including serum ALT, serum nitrite, liver and serum lipid peroxidation, liver and 
serum 8-hydroxyguanosine, some of the mutagenicity assays, and interleukin-10.   
The conclusion of this study suggests that AFB1 acts as a co-carcinogen in the 
presence of iron overloading, implying that a synergistic relationship between these 
two toxins exists. 
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1.0. Introduction 
 1.1.HCC, Dietary Iron Overload and Aflatoxin B1 exposure 
1.1.1. Historical and Clinical Perspective 
Hepatocellular carcinoma (HCC) is the most common primary malignant tumour of the 
liver, it ranks as the 5th and 8th most common cancer among men and women, 
respectively. HCC also accounts for 4% of all newly diagnosed cancers in both sexes 
and is regarded as one of the major malignant diseases in the world today (Stewart et 
al., 2003). Among the reasons for this are its high incidence in several of the world’s 
most populous regions, its grave prognosis, and the fact that a number of potentially 
preventable risk factors for the turnover have been identified. Men are more likely than 
women to develop HCC, and its prevalence generally increases with increasing age, 
except in black Africans where there is a shift towards younger age groups (Kew, 
1994). Certain viral, environmental, and hereditary causes of cirrhosis have a strong 
correlation with HCC. Chronic viral hepatitis as a cause of cirrhosis and HCC is well 
known. Hepatitis B virus infection is the leading cause HCC around the world and is 
the predominant cause of cancer in high-risk areas including China and Africa (Yeh et 
al., 1989; Kew et al., 1997). Hepatitis C virus (HCV) is the major cause of HCC in 
industrialized countries (Dana et al., 1994). Alcohol use is also a common cause of 
cirrhosis, which can indirectly lead to HCC. A direct carcinogenic effect of alcohol on 
liver has, however not been proved (Donato F et al., 2002).  
 
Aflatoxin B1 (AFB1) is a hepatocarcinogen produced by the fungi Aspergillus flavus 
and A. parasiticus, which contaminates food stuffs in certain areas of the world. 
Exposure to aflatoxins and the rest of the mycotoxins occurs through the ingestion of 
mouldy foods which is a consequence of contamination of crops in the ground or poor 
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storage of susceptible grains. A causal association between repeated dietary exposure 
to AFB1 and the development of HCC is supported by epidemiological evidence from 
Africa and the Far East (Adamson et al., 1979). A prospective population-based cohort 
study in Shanghai, China, provided the first set of compelling human data linking 
dietary aflatoxin exposure to the development of HCC (Ross et al., 1992; Qian et al., 
1994). The carcinogenic effects of HCV and AFB1 are synergistic (Ross et al., 1992; 
Qian et al., 1994). 
 
Iron overloading has also been shown to be a high risk-factor in the development of 
HCC, whether it arises on a genetic basis or as a result of dietary exposure (Bradbear et 
al., 1985; Strachan, 1929). Hereditary haemochromatosis (HH) is an inherited disorder 
that increases the amount of iron that the body absorbs from a normal iron diet. HCC 
has been recognized as one of the major life-threatening complications of the disease. 
The risk for development of HCC in patients with HH has been estimated to be over 
200 (Bradbear et al., 1985; Strohmeyer et al., 1988). A mutation in the HFE gene is the 
most common cause of haemochromatosis. Other mutations involving the body’s iron 
transport system have also been implicated. The HFE gene is located on chromosome 
6, and a mutation leading to a cysteine to tyrosine substitution at position 282, is 
designated a C282Y mutation. In the mature HFE protein, the mutation is called 
C260Y, because during transcription 22 amino acids are cleaved to produce the mature 
protein. Mutant HFE is unable to bind to the iron-loaded transferrin receptor. Without 
this interaction, the receptor brings more iron into the cells. A H63D mutation in the 
HFE gene has also been denoted as causing haemochromatosis, albeit to a lesser extent. 
H63D heterozygotes have hepatic iron concentrations significantly higher than control 
subjects, but lower than C282Y homozygotes. No biochemical or histological evidence 
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of liver disease or clinical manifestations is present in H63D heterozygotes 
(Hellerbrand et al., 2003). Most HH patients who are not appropriately treated develop 
progressive iron overload and cirrhosis (Harrison & Bacon, 2005). It was originally 
believed that cirrhosis and not the iron itself was the cause of HCC, but there are 
reports that suggest HCC development may occur in the absence of cirrhosis in an HH 
patient (Brage et al., 2002). Such cases are relatively rare and continue to be the topic 
of case reports (Kowdley, 2004). 
 
Another major risk factor for developing HCC is the dietary form of iron overload. It 
was first described by Strachan in 1929, and it was known as Bantu visceral siderosis 
(Strachan, 1929). Strachan carried out necropsy analysis of blacks from southern and 
central Africa, and concluded that haemosiderosis was a common disease in this 
population. These findings were substantiated through a number of studies performed 
thereafter. (Higginson et al., 1953; Walker, 1953; Bothwell et al., 1960, 1962, 1964; 
Buchanan 1966, 1967, 1969; MacPhail et al., 1979a, 1979b; Gordeuk et al., 1986; 
Friedman et al., 1990; Gordeuk 1992b; Mandishona et al., 1998). The source of iron 
overload was shown to be derived from iron drums and pots used in brewing traditional 
alcoholic beverages, which were consumed in large quantities by the blacks (Bothwell 
et al., 1964). It was found that the bulk of iron deposition was in the liver and the 
mononuclear-macrophage system (Bothwell et al., 1965).  
 
The prevalence of dietary iron overload is still high in rural sub-Saharan African 
populations (Gordeuk et al., 1986), where the prevalence of this disease has been 
shown to be greater than 10%, and carries a relative risk factor for developing HCC of 
10.6, and a population attributable risk of 29 (Mandishona et al., 1998).  
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1.2. Putative Mechanisms of Iron-induced Carcinogenesis 
Dietary iron overload has recently been demonstrated to be a direct cause of HCC in 
experimental rat model (Asare et al., 2006a). Both direct and indirect effects of iron 
overload are considered to contribute to carcinogenesis. Direct mechanisms include the 
effects of iron on cellular proliferation, direct damage by non-transferrin-bound iron to 
DNA, with resultant inactivation of tumour suppressor genes such as p53 or their 
products through post transcriptional or posttranslational changes (Britton et al., 2002). 
Indirect causes include the effects of iron on the formation of reactive oxygen species, 
iron-induced lipid peroxidation, and acceleration of fibrogenesis in the liver (Kowdley, 
2004). There is also evidence that iron overload could lead to immunologic 
abnormalities that may be associated with decreased immune surveillance for 
malignancy (Deugnier et al., 2001; Green et al., 1988). 
 
1.3.Putative Mechanisms of AFB1-induced Carcinogenesis 
Metabolism plays a major role in deciding the degree of AFBB1 toxicity (Eaton et al., 
1994). After ingestion, AFB1 is metabolized by the cytochrome P450 group of enzymes 
in the liver, where it is converted into various metabolic products, depending on the 
genetic predisposition of the species. The amount of the metabolite, aflatoxin 8,9 
epoxide formed, determines the species susceptibility. This metabolite forms adducts 
with the guanine moiety in the DNA (Smela et al., 2001). A GC to TA transversion at 
the third position of codon 249 of the p53 gene is a striking mutational hotspot caused 
by the intercalation of this epoxide. This observation was made in most experimental 
HCC models, and it is presumed that this is the major reason for AFB1 carcinogenicity 
(Smela et al., 2001). 
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During its metabolic process an enhanced production of reactive oxygen species (ROS) 
has been reported (Sivakumar et al., 2001), and ROS have a major role in the 
mediation of cell damage. Furthermore, ROS damage initially induced by mycotoxins 
can be propagated and magnified by lipid peroxidation chain reactions (Atroshi et al., 
2000). The induction of lipid peroxidation by mycotoxins such as T-2 toxin, AFB1, and 
fumonisin B1, has been clearly elucidated by previous studies (Rizzo et al., 1994; Shen 
et al., 1994; Becognee et al., 1998, Lemmer et al., 1999. In addition, the role of ROS in 
the induction of chromosomal damage by AFB1 was significantly inhibited by ROS 
scavenging agents such as superoxide dismutase (SOD), catalase (CAT), and mannitol 
(Amstad et al., 1984). 
 
AFB1 has also been shown to influence the functioning of the immune system. It was 
found to markedly inhibit tumour necrosis factor alpha (TNF-α), interleukin-1 (IL-1) 
and interleukin-6 (IL-6) production by lipopolysaccharide stimulated macrophages. 
AFB1 was also found to inhibit the killing ability of murine macrophages (Moon et al., 
1999), decreasing various secretory molecules in those cells.  
 
It is clear that both iron overloading and AFB1 exposure individually have clear 
involvement in the pathology and induction of HCC.  
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1.4. Research Hypothesis 
1.4.1. Aims and Objectives 
It has been suggested that dietary iron overload leads to increased generation of ROS with 
mutagenic and carcinogenic activity, leading to DNA strand breaks and unwinding, and 
ultimately malignant transformation (Kowdley, 2004, Asare et al., 2006b). AFB1 is a well 
known carcinogen, and is one of the most potent liver cancer-forming chemicals known 
(Smela et al., 2001). Iron overloading and the presence of AFB1 have separately been 
shown to be carcinogenic, but a possible carcinogenic interaction between the two agents 
has not been studied. The primary aims of this study are to identify synergism between 
AFB1, and dietary iron overload in the development of HCC, using an experimental rat 
model. The objectives therefore are: 
1) to show if dietary iron overload and AFB1 exposure have synergistic effects on the 
pathogenesis of HCC. 
2) to determine the extent of the potential synergy, whether super additive or 
multiplicative. 
 
1.4.2. Experimental Design 
1.4.2.1. Subjects  
The Wistar albino rat (Rattus norvegicus) was selected for the study based on its higher 
growth and survival rate compared to the Fischer 344 and the Sprague Dawley rats (Figure  
1.1.). 
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         Wistar albino: Growth and Survival Curves 
 
 
       Sprague Dawley: Growth and Survival Curves 
 
 
       Fischer 344:  Growth and Survival Curves 
 
Figure 1.1. Growth Curves of three types of commonly used experimental rats 
(Harlan, 2000) 
Two hundred and twenty (220) Wistar albino rats were divided into 4 groups: Group 1 
was the control group consisting of 30 subjects; Group 2, the Fe group with 40 
subjects; Group 3, the AFB1 group with 40 subjects; Group 4, the AFB1 group with 110 
subjects (Figure 1.2.). Group 4 had a larger group of subjects because no previous data 
was available to indicate how these two carcinogens would interact. A high casualty 
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rate was expected. To determine synergy, of which no previous data was available, a 
high sample size was required to enable statistical accuracy. Group 1 was fed the 
normal chow diet. Group 2 was fed 0.75% (w/w) ferrocene iron alone. Group 3 was 
gavaged 250μg AFB1 alone. Group 4 was fed the 0.75% (w/w) ferrocene iron and 
gavaged 250μg AFB1. 
 
 The AFB1 was administered, in groups 2 and 4 as 25µg/day for 10 days in total; 5 days 
at a time, with a 2 day break in-between (Roebuck, 2004). 5 rats per group were 
sacrificed at 6 months and 12 months after commencement of the project. Rats were 
anaesthetized with anneket and chanazine, and then euthanased with euthanasia, and 
blood and liver samples were then harvested. The rats were studied for a total period of 
12 months. The remaining rats were kept for disease progression analysis to be 
conducted in further studies.                                                                
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 40 
 
 
Fe gp 
Fe 
 
 
 
 
 
40  
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AFB1
Fe + AFB1 gp 110 
Fe + AFB1 
 
KEY: 
C gp = Control group 
Fe gp = Iron group 
AFB1 gp = aflatoxin B1 group 
Fe + AFB1 gp = Iron + Aflatoxin B1 gp 
Fe = Iron 
AFB1 = Aflatoxin B1
Figure 1.2. Subject Categories 
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1.4.2.2. Diet 
1.4.2.2.1. Iron Diet (Ferrocene) 
Ferrocene Fe(C5H5)2 is a prototypical metallocene, a type of organometallic chemical 
compound, consisting of two cyclopentadienyl rings bound on opposite sides of a central 
iron atom and forming an organometallic sandwich compound. 
 
 
 
Figure 1.3. Ferrocene molecule 
In ferrocene, the pi electrons of both aromatic cyclopentadienyl rings are shared with the 
central iron ion, giving it an inert gas electron configuration, which makes ferrocene 
particularly stable. The redox behaviour of ferrocene is not easily influenced by external 
factors such as temperature and solvents. This stability makes ferrocene an attractive 
molecule for both basic study and applications. This redox behaviour exists because the 
highest occupied molecular orbitals (HOMO-1) of ferrocene have almost non-bonding 
characteristics, and the change of the coordination environment around the iron centre by 
oxidation is small. 
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The aromatic cyclopentadienyl rings of ferrocene are just like those of benzene and hence 
the reactivities of both molecules are similar to each other. Substitution groups can 
therefore be easily introduced to ferrocene by using an organosynthetic method. 
 
Large numbers of compounds utilizing ferrocene have been synthesized and their relative 
properties studied. Ferrocenium salts have an anticancer activity (Swarts et al., 2001; 
Vashisht et al., 2000), and a drug has been reported which is a ferrocenyl version of 
tamoxifen (Top et al., 2003).  
 
A dietary model for severe iron overload was produced by enriching rat diets with (3,5,5-
trimethylhexanoyl) ferrocene (TMH-ferrocene) (Nielsen & Heinrich, 1993). Three 59Fe-
labelled ferrocene compounds with different lipophylic characters were synthesized. 
Ferrocene had a bioavailability twice lower than that of TMH-ferrocene, but exhibited 
similar advantageous characteristics. These advantages included the observation that 
ferrocene iron is relatively independent of dose, indicating that absorption is not regulated 
by body iron stores. It is transported through portal blood to the liver, independent of 
transferrin (Nielsen & Heinrich, 1993). 0.5% TMH-ferrocene was found to be an adequate 
dosage. In this study a slightly higher dose of 0.75% ferrocene was incorporated and 
compounded into the chow diet because of ferrocene’s slightly lower bioavailability than 
TMH-Ferrocene. Epol (SA) certified that this diet was mutagen free. Ferrocene was 
obtained from Sigma, Germany. 
 
1.4.2.2.2. Aflatoxin B1
1000μg of lyophilized AFB1 was dissolved in 1000μl of 3% DMSO. AFB1 was 
administered to the subjects through the process of gavaging with the aid of a gavage 
needle. 250μg/day of AFB1 was administered per rat; hence 25μl/day for 10 days was 
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dispensed by gavaging from the reconstituted AFB1. AFB1 was obtained from Alexis 
Corporation, UK. 
 
1.4.2.3. Laboratory Methods 
A variety of methods was implored to determine the presence and quantitation of reactive 
oxygen and nitrogen species, lipid peroxidation, DNA mutagenicity bioassays, and iron 
profiling. Figure 1.4 is a depiction of parameters measured. 
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2.0. Iron  
2.1. Iron Chemistry 
Iron is of fundamental importance for the growth, development and well being of almost 
all living organisms. Multiple biological systems have been developed for the uptake, 
utilization, storage and homeostasis of iron in microbes, plants and mammals. Its 
bioavailability is generally limited and higher species often exhibit deficiency states. 
Paradoxically, iron overload conditions occur.  
 
In quantitative terms, iron is the most important essential trace element, being an important 
mineral for essential nutrition. Adult men and women contain approximately 55 and 45mg 
per kilogram of body weight of iron, respectively (Halliwell & Gutteridge, 1989). 
 
Iron is a d-block transition element that can exist in oxidation states ranging from -2 to +6. 
Within biological systems, iron exists in 3 oxidation states, namely ferrous (+2), ferric (+3) 
and ferryl (+4) states. Iron participates in reactions where there is a transfer of electrons 
(redox reactions), and in so doing it can reversibly bind to ligands by virtue of its 
unoccupied d orbitals. The electronic spin state and biological redox potential of iron can 
change according to the ligand to which it is bound. Iron is therefore particularly suited to 
participate in a large number of biochemical reactions (Webb,1992).When iron is 
complexed with water, it is readily hydrolysed and polymerized at a physiological pH of 7 
(Spiro & Saltman, 1974). When water molecules are replaced by other chelating ligands, 
stable complexes are formed. Under conditions of neutral or alkaline pH, iron is found in 
the Fe3+ state and at an acidic pH the Fe2+ state is favoured. The strongest complexes of 
Fe3+ tend to be with oxygen donor ligands, e.g. citrates, phosphates, phenols or 
carbohydrates, whereas Fe2+ prefers nitrogen or nitrogen with oxygen donors. The 
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complexes formed with Fe3+ are large, have poor solubility and upon their aggregation lead 
to pathological consequences (Halliwell & Gutteridge, 1989). 
 
2.2. Biochemical Functions of Iron 
The biochemical role of iron is largely manifest in the activity of its metalloproteins. These 
can be categorized into four main groups (Figure 2.1.). The first consists of those proteins 
that form reversible complexes with iron and whose primary function is one of iron 
transport and storage (transferrin and ferritin). The second group can be classified by their 
ability to bind oxygen reversibly (haemoglobin and myoglobin). The third and most 
extensive group, the iron-sulfur enzymes, is involved with redox reactions.  The fourth 
group of iron-containing enzymes is a catch-all group in which iron is not bound to a 
porphyrin ring structure or in iron-sulfur complexes. 
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Figure 2.1. Iron-containing Proteins. 
These metalloproteins are either metabolically active and functional or metabolically 
inactive and used for iron storage. 
 
2.2.1. Metabolically Active/ Functional Iron 
Metabolically active iron can be divided into three major groups, including iron involved 
in oxygen transport and storage, iron transport and the iron-containing enzymes. 
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2.2.1.1. Oxygen transport and storage 
2.2.1.1.1. Myoglobin 
Myoglobin (Mb) is a monomeric haem protein found mainly in muscle tissue where it 
serves as an intracellular storage site for oxygen. During periods of oxygen deprivation, 
oxyhaemoglobin releases its bound oxygen which is then used for metabolic purposes. Its 
tertiary structure is that of a typical water soluble globular protein. It has an α -helical 
secondary structure, comprising eight separate right-handed α-helices that are connected by 
short non-helical regions. Amino acid R-groups are packed into the interior of the 
molecule. They are predominantly hydrophobic in character, whereas those exposed on the 
surface of the molecule are generally hydrophilic, thus making the molecule relatively 
water soluble (Voet & Voet, 1995). 
 
Each Mb molecule contains a haem prosthetic group. Each haem residue contains one 
central coordinately bound iron atom that is normally in the ferrous state. Oxygen carried 
by haem proteins is bound directly to this ferrous iron atom. When the iron is oxidized to 
the ferric state, the molecule is rendered incapable of normal oxygen binding (Voet & 
Voet, 1995). 
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 Figure 2.2. Haem Molecule (Voet &Voet, 1995) 
 
2.2.1.1.2. Haemoglobin 
Haemoglobin (Hb) is a haemprotein found in erythrocytes and is responsible for binding 
oxygen in the lung and transporting the bound oxygen throughout the body, where it is 
used in metabolic pathways. It is the largest iron compartment. Iron binds to 
protoporphyrin to form haem, which then binds with globin chains to form haemoglobin. 
 
Hb is a tetrameric protein, consisting of two α and two β units. The α and β subunits are 
structurally and evolutionarily related to each other and to Mb. Each subunit has a haem 
prosthetic group identical to that of Mb. 
 
The four subunits are not covalently attached to each other but do react cooperatively with 
dioxygen with specific modulation of pH, pCO2, organic phosphates and temperature. 
These modulators of the affinity of haemoglobin for iron determine the efficiency of 
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transport of oxygen from the alveoli capillary interface in the lung to red cell – capillary – 
tissue interface in peripheral tissues. The allosteric effect of decreasing pH, the well-known 
Bohr Effect, decreases the binding affinity of haem-Fe for dioxygen through protonation of 
His-146 on β chains and Val-1 on α chains in the presence of Cl- and CO2. CO2 forms a 
Schiff base with terminal amino acids of each chain and decreases dioxygen affinity. This 
favors the unloading of oxygen in tissues in which the pH is lower and pCO2 is higher than 
in arterial blood. 2,3-Diphosphoglycerate is a product of a side pathway within 
erythrocytes and binds to a specific region of the β chain to decrease Hb-O2 binding 
affinity (Voet & Voet, 1995). 
 
2.2.1.2. Iron Transport compartments in blood 
2.2.1.2.1. Transferrin 
The major function of transferrin is to transport iron into cells. Eventually all circulating 
plasma iron is bound to transferrin. The amount of iron both attached to transferrin or free 
from transferrin is measured as the serum iron. The sum of all iron binding sites on 
transferrin constitutes the total iron binding capacity (TIBC) of plasma. Under normal 
circumstances, about one third of transferrin iron-binding pockets are filled. Consequently, 
with the exception of iron overload when all the transferrin binding sites are occupied, 
non-transferrin-bound iron (NTBI) in the circulation is virtually nonexistent. In iron 
overload, plasma iron concentrations rise significantly and leads to the appearance of 
NTBI. The accumulation of plasma NTBI has been shown to correlate with the appearance 
of oxidation products and a decrease in plasma antioxidant capacity (Cighetti et al., 2002; 
De Luca et al., 1999).  
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The chelation between transferrin and iron serves three purposes: it renders iron soluble 
under physiological conditions, it prevents iron-mediated free radical toxicity, and it 
facilitates transport into cells. 
 
Transferrin is the most important physiological source of iron for red cells (Ponka, 1997). 
It is synthesized in the liver and thereafter secreted into the plasma. Transferrin has also 
been found to be synthesized locally in the testes and the central nervous system. This local 
transferrin production could play a role in iron metabolism in these tissues. 
 
Transferrin is an 80kDa glycoprotein with homologous N-terminal and C-terminal iron-
binding domains (Huebers & Finch,1987). The molecule is related to several other 
proteins, including ovotransferrin in bird and reptile eggs (Williams et al., 1982), 
lactoferrin in extracellular secretions and neutrophil granules (Mazurier et al., 1983; Metz-
Boutigue et al., 1984) and melanotransferrin, a protein produced by melanoma cells 
(Brown et al., 1982). However, their main function is not delivery. Instead, they serve to 
protect cells from bacteria. Since they mop up any free iron ions, they restrict bacteria of a 
vital resource, slowing the growth of an infection. All members of the transferrin protein 
superfamily have similar polypeptide folding patterns. N- and C-terminal domains are 
globular moieties of about 330 amino acids. Each of these is divided into two sub-domains, 
with iron- and anion-binding sites in the intersubdomain cleft. The binding cleft opens with 
iron release, and closes with iron binding (Voet & Voet, 1995).  
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 Figure 2.3. Ribbon Diagram of Mammalian Transferrin 
(http://www.iupac.org/news/prize/2005/Dhungana.pdf) 
 
2.2.1.3. Iron-containing Enzymes 
2.2.1.3.1.  Enzymes involved in Electron Transport and Energy Metabolism 
Cytochromes are haem-containing compounds that are critical to cellular energy 
production through their roles in mitochondrial electron transport. They serve as electron 
carriers during the synthesis of ATP, the primary energy-storage compound in the cells. 
Cytochrome P450 is a family of enzymes that functions in the metabolism of a number of 
important molecules, as well as the detoxification and metabolism of drugs and pollutants. 
Nonhaem iron-containing enzymes, such as NADH dehydrogenase and succinate 
dehydrogenase, are also critical to energy metabolism (Yip et al., 1996). 
 
2.2.1.3.2. Enzymes involved in Antioxidant Functions 
Catalase and peroxidases are haem-containing enzymes that protect cells against the 
accumulation of hydrogen peroxide, a ROS, by catalyzing a reaction that converts 
hydrogen peroxide to water and oxygen. As part of the immune response, some leukocytes 
engulf bacteria and expose them to ROS in order to kill them. The synthesis of 
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hypochlorous acid by neutrophils is catalyzed by the haem-containing enzyme 
myeloperoxidase (Yip et al.,1996; Brody, 1999). 
 
2.2.1.3.3. Enzymes Involved in Oxygen Sensing 
During a state of hypoxia, compensatory physiological responses are induced. This 
includes the increased formation of red blood cells, increased angiogenesis, and increased 
production of enzymes utilized in anaerobic metabolism. Transcription factors known as 
hypoxia inducible factors (HIF) bind to response elements in genes that encode various 
proteins involved in compensatory responses to hypoxia and hence increase their synthesis. 
Iron-dependent prolyl hydroxylase enzymes play a critical role in regulating HIF and 
consequently, physiological responses to hypoxia.  When cellular oxygen tension is 
adequate, HIF, is targeted by a prolyl hydroxylase enzyme, and is rapidly degraded. When 
cellular oxygen tension drops below a critical threshold, prolyl hydroxylase can no longer 
target HIF for degradation, allowing HIF to form active transcription factors that are stable 
to enter the nucleus and bind to specific elements on genes (Ivan et al., 2001; Jaakkola et 
al., 2001). 
 
2.2.2. Metabolically Inactive and Storage Iron 
2.2.2.1. Ferritin 
Unbound iron can be toxic, so the ability to store and release iron in a controlled manner is 
essential. Cells handle this problem of iron storage by developing ferritin, a family of iron-
storage proteins that sequester iron inside a protein coat as hydrous ferric oxide-phosphate 
mineral.  
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Ferritin is mainly a cytoplasmic protein and there are generally two or more genes that 
encode closely related subunits, designated H (heavy) and L (Light). Ferritin has a 
spherical shell that consists of 24 subunits folded into ellipsoids. Each subunit is an 
individual molecule that joins its neighbouring subunits through noncovalent interactions. 
The subunits have a combined molecular weight of 474000. These subunits pack to form a 
hollow sphere approximately 80 Angstroms (1.25x10-2 μm) in diameter with walls that are 
approximately 10 Angstroms (1x10-3 μm) thick. Among the important structural features of 
ferritin is the presence of two types of channels that occur in the protein wall. After iron 
enters the ferritin shell, iron ions are converted into the ferric state, where they form small 
crystallites along with phosphate and hydroxide ions. A ferritin molecule has the capacity 
to hold 4500 iron ions. 
 
Serum ferritin is measured as part of iron study profiles. The amount of ferritin in plasma 
is less than one thousandth of total body ferritin, but its concentration is directly 
proportional to total body iron ferritin quantities in conditions of health, iron deficiency 
and mild iron overload. An abnormally raised ferritin level is a marker for iron overload 
disorders. Although ferritin is also synthesized in the liver in response to inflammation 
(acute phase reactant), a normal C-reactive protein can be used to exclude elevated ferritin 
caused by acute phase reactions (Halliwell & Gutteridge, 1989). 
 
2.2.2.2. Haemosiderin 
Partially degraded and aggregated ferritin is called haemosiderin. It is insoluble in water 
and is not as accessible for cell use as is ferritin. It is most commonly seen as golden-
brown granular material in macrophages and is readily demonstrated to be iron by a 
Prussian-blue stain. The presence of haemosiderin in small amounts within iron rich tissues 
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such as the spleen, liver, and bone marrow is considered normal. Large aggregations of 
haemosiderin or its presence in tissues such as the lung or subcutaneous connective tissue 
suggest a pathological condition (Selden, 1980). 
 
2.3. Iron Transport Mechanisms 
Four major iron transport mechanisms have been identified.  
 
a) The differic-transferrin/transferrin receptor endocytic mechanism through clathrin 
coated pits.  
b) Divalent metal transporter (DMT1) and Natural resistance-associated macrophage 
protein (Nramp1) 
c) Iron-regulated transporter 1 (IREG1) , with the aid of hephaestin 
d) Ferrous ATPase 
 
DMT1 and Nramp1 are two homologous divalent metal/proton symport proteins. DMT1, 
also known as Nramp2, is an integral membrane protein expressed at cell surfaces and in 
cycling endosomes. It is induced by a low intracellular iron concentration. It appears to be 
indirectly involved in iron transport between blood plasma and tissues. High 
concentrations thereof are expressed at the lumenal surface brush border of the mature 
upper small intestine enterocytes found along the villus (Trinder et al., 2000). It is 
modestly expressed in the cytoplasm of the same cells. Nramp1 is an integral membrane 
protein, exclusive to macrophages, monocytes and polymorphonuclear leukocytes. It is 
induced in phagosomes or lysosomes of macrophages in response to bacterial endotoxins 
and cytokines (TNFα and IL-1), and transfers iron out of phagosomes into the cytosol of 
macrophages. Iron provided in the cytoplasm of macrophages by Nramp1 activity appears 
to enhance the stability of macrophage mRNA encoding cytokines, which in turn are 
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responsible for the recruitment of leukocytes to the site of an infection and their activation 
(Govoni & Gros, 1998). 
 
IREG 1 is also known as ferroportin 1 and metal transporter protein 1 (MTP1). It is highly 
expressed in the placenta and duodenum. It is a transmembrane protein that mediates iron 
efflux from cells. Iron deficiency increases IREG1 expression in the duodenum but 
decreases expression in the liver (McKie et al., 2000). The transport of iron by IREG1 
requires that Fe2+ be oxidized to Fe3+. This oxidation is proposed to be mediated by 
hephaestin. Hephaestin is a transmembrane-bound homologue of the copper-containing 
blood plasma ferroxidase caeruloplasmin. It is proposed to be a ferroxidase located at the 
basolateral membrane of enterocytes and required for transfer of iron from enterocytes to 
blood in conjunction with some other, unknown iron transport protein (Vulpe et al., 1999). 
 
Iron ATPase is an ATP-dependent Fe2+ transporter. It transports iron into microsomal 
vesicles and is in high concentration in the spleen. Fe2+ is its specific substrate. It has been 
proposed that the iron ATPase mediates the transport of iron from the cytoplasmic 
compartment of macrophages into the lumen of their microsomal vesicles to allow export 
of iron derived from the breakdown of haemoglobin (Baranano et al., 2000). 
 
2.4. Cellular uptake of Iron 
2.4.1. Iron Absorption 
Elemental iron or dietary haem iron is absorbed principally by the mucin lining the 
duodenum and to a lesser extent, the jejunum. Gastric acid plays an important role in 
keeping iron soluble and in the ferrous state. The mucin transfers iron to trans-membrane 
integrins. Once inside the cell, iron is transferred to mobilferritin. The iron passes to 
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ferritin and then to transferrin bound to the extracellular side of the protein and is then 
released into the plasma. Transferrin receptor (TfR) bound to the corporeal portion of the 
mucosal cell functions to bind transferrin from the plasma and bring it into the cell through 
clathrin-mediated endocytosis, where it may function to regulate iron absorption (Garrick  
et al., 1993). When the iron-bound transferrin enters the bloodstream, it is reabsorbed 
mainly by hepatocytes and erythroblasts, again by the TfR. 
 
The TfR is a disulfide-linked homodimer with each subunit containing 760 amino acids 
(Kuhn et al., 1984; Schneider et al., 1983; Jing & Trowbridge, 1987). It has a molecular 
mass of 90kDa per subunit, with 5% consisting of oligosaccharides. 3N-linked and 1O-
linked glycosylation sites exist (Hayes et al., 1992). The transmembrane domain functions 
as an internal signal peptide. A molecule of fatty acid covalently links each subunit to the 
internal edge of the transmembrane domain and could play a role in membrane 
localization. The expression of the TfR is increased on cells that are iron deficient, and 
decreased on cells that are iron overloaded. 
 
After binding to its receptor on the cell surface, transferrin is rapidly internalized by 
invagination of clathrin-coated pits with the formation of endocytic vesicles. A complex 
mechanism involving recycling endosomes follows. In plasma, differic-transferrin 
saturates transferrin receptors displayed on the surface of cells. The collection of 
iron/transferrin/transferrin-receptor complexes and its embedding membrane is internalized 
through a clathrin-coated pit to become a recycling endosome. Embedded in the membrane 
is also a DMT1. An ATP-dependent proton pump lowers the pH of the endosome to about 
5.5 (Van Renszoude et al., 1982; Dautry-varsat et al., 1983; Paterson et al., 1984; 
Yamashiro et al., 1984). The acidification of the endosome weakens the association 
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between iron and transferrin. Even at pH 5.5, Fe3+ would not normally dissociate from 
transferrin in the several minutes between its endocytosis and the return of transferrin 
apoprotein to the cell surface (Ciechanover et al., 1983). A plasma membrane 
oxidoreductase reduces transferrin bound iron from the Fe3+ state to the Fe2+, directly or 
indirectly facilitating the removal of iron from the protein (Low et al., 1987; Thorstensen 
& Romsolo, 1988; Nunez et al., 1990). Conformational changes in the transferrin receptor 
also play a role in iron release (Bali et al., 1991; Sipe & Murphy, 1991). 
 
The released iron is transferred to the cytoplasm by the DMT1, driven by the high proton 
concentration of the endosome. The released apotransferrin/transferrin-receptor is recycled 
back to the cell surface, where the apotransferrin is released into the plasma (Zak et al., 
1994). The re-use of transferrin is accomplished by the pH-dependent changes in the 
affinity of transferrin for its receptor (Van Renswoude et al., 1982; Klausner et al., 1983: 
Dautry-Varsat et al., 1983). Exported apotransferrin binds additional iron and undergoes 
further rounds of iron delivery into the cells. The average transferrin molecule, with a half-
life of eight days, may be used up to one hundred times for iron delivery (Harford et al., 
1994). 
 
Figure 2.4.  Illustration of clathrin-mediated endocytosis.  
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The primary role of the transferrin-transferrin receptor interaction is to bring iron into the 
vicinity of the cell surface, thereby increasing the likelihood of iron uptake. Following its 
release from transferrin within the endosome, iron must traverse the plasma membrane to 
enter the cytosol proper. The molecules effecting this transport have not been identified, 
but the process may be carrier-mediated (Egyed, 1988). 
 
Once inside the cell cytoplasm, iron appears to be bound by a low molecular weight carrier 
molecule, which may assist in delivery to various intracellular locations including the 
mitochondria (for haem biosynthesis) and ferritin (for storage). The amount of iron in 
transit within the cell at any given time is miniscule and defies precise measurement. This 
minute pool of transit iron, which is believed to be in the Fe2+ oxidation state, is the 
biologically active form of the element. Metabolically inactive iron, stored in ferritin and 
haemosiderin, is in equilibrium with exchangeable iron bound to the low molecular weight 
carrier molecule. 
 
The function of another protein, produced by a gene called the haemochromatosis gene, 
HFE, is still incompletely understood. TfR is itself regulated by a MHC type 1-like protein 
which forms a stable complex with the intracellular portion of TfR and β2-microglobulin. 
HFE, bound with β2-microglobulin, inhibits the absorption of transferrin, increasing the 
amount of iron-bound transferrin in the blood and down-regulating iron absorption (Feder 
et al., 1998). 
 
2.5. Post-transcriptional control of Proteins involved in Iron Metabolism 
Induction and repression of several iron-binding proteins are now known to be effected at 
the level of mRNA stability. Iron regulatory proteins (IRP) can bind iron but, in the 
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absence of iron they bind to iron responsive elements (IRE) found in mRNA transcripts of 
specific genes. In the case of mRNA encoding DMT1, transferrin, transferrin receptor and 
delta-aminolevulinic acid synthase, the IRE is in the untranslated  portion at the 3’end of 
the gene transcript. Each IRE forms a stem-loop structure in which the loop contains five 
specific bases and the stem contains adenine and uracil rich (AU-rich) sequences similar to 
those that destabilize cytokine mRNAs. When iron concentrations are adequate, these AU-
rich sequences are thought to promote degradation of TfR mRNA by the same mechanism 
that leads to rapid degradation of cytokine mRNAs. When the iron concentration falls 
slightly, the conformation of IRE – binding protein (IRP) changes so that it can bind to the 
IREs. Binding of IRPs to the IREs is thought to block recognition of the destabilizing AU-
rich sequences by the proteins that would otherwise degrade TfR mRNA (Eisenstein & 
Ross, 2003).  
 
 
 
Figure 2.5. Illustration of IRE and IRP activity in high and low iron concentrations 
(Eisenstein & Ross, 2003). 
 
 29
2.6. Iron Overload 
Chronic iron overload is characterized by increased focal or generalized deposition within 
the tissues. Iron is stored as ferritin and/or haemosiderin. Iron overloading was therefore 
known as haemosiderosis. When excess iron deposition is associated with tissue injury or 
the total body iron estimate is greater than 5g, the term haemochromatosis is applied.  
 
Several disorders may lead to pathological accumulation of iron in the body. Hereditary 
haemochromatosis is the most common genetic iron metabolism disorder. It is 
characterised by iron overload despite normal dietary iron intake. However, 
haemochromatosis in Sub-Saharan Africa is caused by increased dietary iron intake. Table 
2.1 summarizes many of the heritable and acquired disorders associated with iron overload. 
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Table 2.1. Heritable and Acquired Disorders Associated with Iron Overload
Heritable Disorder Cause of Iron Overload 
Haemochromatosis 
 Haemochromatosis Type 1 
(Adult) 
 Haemochromatosis Type 2A 
(Juvenile) 
 Haemochromatosis Type 2B 
(Juvenile) 
 Haemochromatosis Type 3 
 Haemochromatosis Type 4 
 Haemochromatosis Type 5 
(Japanese Iron Overload) 
 
HFE gene mutations 
 
Unknown 
 
Hepcidin gene mutations 
 
Transferrin receptor 2 inactivation 
Ferroportin gene mutations 
H-ferritin gene mutation 
 
 
 
 
Other Heritable Disorders 
 Porphyria cutanea tarda 
 African iron overload 
 Neonatal iron overload 
 Atransferrinaemia 
 
 Aceruloplasminaemia 
 Hereditary hyperferritinaemia 
cataract syndrome 
 Friedreich ataxia 
 B-Thalassemia major 
 
 Hereditary X-linked sideroblastic 
anaemia 
 Pyruvate kinase deficiency 
 G6PD deficiency 
 Congenital dyserythropoetic 
anaemia  
 Pantothenate Kinase – Associated 
Neurodegeneration 
 
 
 
Heterogenous 
Dietary 
In-utero iron transfer 
Transferrin gene mutations & red cell 
transfusions 
Ceruloplasmin gene mutations 
L-ferritin gene mutations 
 
Frataxin gene mutations 
B-glbin gene mutations, chronic 
hemolysis, red cell transfusions 
d-ALA synthase gene mutations 
 
Pyruvate kinase gene mutations 
G6PD gene mutation 
Ineffective erythropoeisis 
 
Pantothenate kinase 2 gene mutations 
Acquired Disorders 
 Transfusions 
 Medicinal Iron 
 Myelodysplasia with ring 
sideroblasts 
 Portocaval Shunt 
 
Red Cell iron transfusion 
Excessive iron ingestion 
Excessive iron absorption 
 
Excessive iron absorption 
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2.6.1. Iron overload in Experimental Animals 
Iron loading experimental rat models have only recently been optimized. Early studies 
used Jectofer injections to increase plasma iron concentrations (Hultcrantz et al., 1980). 
The preferred model, however, included the addition of carbonyl iron (CI) to the diet 
(Bacon et al., 1983; Pietrangelo et al., 1990; Britton et al., 1990; Tector et al., 1995). This 
protocol, however, demonstrated adverse side effects to the well-being of the animal, 
including retarded growth rates and diarrhoea. Various modifications of the feeding 
regimen were used where CI concentrations were varied throughout the study. No 
advantages were reported in relation to these modifications. 
 
In the early 1990’s investigators experimented with an alternative source of iron, known as 
ferrocene. A comparative study between ferrocene and CI iron-overload models concluded 
that ferrocene containing the lipophilic character 3,5,5-trimethylhexanoyl (TMH)  was the 
most encouraging animal model for experimental iron loading (Nielsen et al., 1993). 
Advantages of this ferrocene above the CI protocol included the indication that the 
intestinal absorption of TMH-ferrocene is independent from the dose. The absorption of 
ferrocene is also not regulated by body iron stores, and its bioavailability surpasses any 
other tried iron-loading agents. TMH-ferrocene showed whole body retention of 48%, 
twice as high as from ferrocene and six times higher than from (TMH)2-ferrocene and 
ferrous sulphate (Nielsen & Heinrich, 1993). The most efficient protocol, therefore, for 
inducing iron overload is a diet containing 0.5% TMH-ferrocene for a period greater or 
equal to 10 weeks (Nielsen & Heinrich, 1993). However, ferrocene without TMH can be 
used to achieve a slower iron loading pattern, which is advantageous in studies including 
synergy with other carcinogens with slower rates of intiation of carcinogenesis.  
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2.6.2. Iron overload at the ultrastructural level 
The study of iron-overloaded organisms at an ultrastructural level has produced certain key 
observations. Although ferritin has been shown to be the major iron storage protein, 
haemosiderin is predominant in iron overload (Seldon et al., 1980). Iron loaded cells have 
abundant and enlarged lysosomes containing ferritin and haemosiderin (Iancu et al., 1994). 
A close positive correlation has been shown between enhanced lysosomal fragility and 
haemosiderin content (Seymour & Peters, 1978). It has been suggested that the toxicity of 
iron could be mediated by haemosiderin-dependent damage to the lysosomal membrane, 
possibly by a lipid-peroxidation mechanism (Selden et al., 1980). Lysosomal fragility was 
also investigated through monitoring the activity of N-acetyl-glucosaminidase (NAGA), a 
lysosomal enzyme. In a study of thalassaemic patients, elevated serum NAGA levels were 
correlated with the degree of iron overload (Frigerio et al., 1984). When lysosomes 
increase beyond a cell line-specific concentration, signs of organelle alteration followed by 
cellular death are noted (Iancu, 1987). 
 
2.7. Iron-Induced Toxicity 
In conditions of iron overload, the liver is noted as being the most important organ, where 
elevated hepatic iron concentrations may result in hepatocellular injury. Two main 
hypotheses have been postulated to explain this phenomenon: the oxidative injury and 
lysosomal hypothesis (Arezzini et al., 2003). 
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2.7.1. The Oxidative Stress Hypothesis 
This hypothesis postulates that iron overload results in the formation of oxyradicals in the 
liver, which induces damage to cellular constituents and hepatocellular function 
impairment. 
 
Halliwell & Gutteridge (1992) provided initial evidence from in vitro experiments that iron 
in its redox-active state catalyzes the production of oxyradicals such as lipid radicals 
(LOO-) and hydroxyl radicals (˙OH). Lipid radicals are formed through the decomposition 
of preformed lipid hydroperoxides (LOOH). Ferrous ions react with LOOH to form 
alkoxyl radicals (LOO·) 
 
·OH radicals are extremely reactive and can attack many cell constituents, including lipids, 
nucleic acids, carbohydrates and proteins. Polyunsaturated fatty acids (PUFA’s) of 
membrane phospholipids are particularly susceptible to oxidative attack. Peroxidation of 
PUFA’s lead to the formation of highly reactive aldehydes, such as malondialdehyde 
(MDA) and 4-hydroxynonel (4-HNE), which may then form covalent links to proteins, 
phospholipids, and DNA (Sodum & Chung, 1989). Other by-products associated with the 
initiation of lipid peroxidation by ·OH have been reported, including conjugated dienes, 
lipid hydroperoxides, thiobabituric acid-reactants (TBARS). Isoprostanes have been 
recognised as suitable markers of oxidative stress (Reilly et al., 1998). 
 
Although oxyradicals have the potential to cause damage to cell constituents, protective 
mechanisms in the form of antioxidants exist in the cell to counteract the hazardous effects 
of oxyradicals. The net effect of this cellular function depends on the balance between 
radical production and cytoprotective agent response. 
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 2.7.1.1. Mitochondrial Damage 
Mitochondrial oxidative metabolism is susceptible to iron induced impairment. Studies 
show that chronic iron or copper overload in vivo results in an inhibitory defect in the 
mitochondrial electron transport chain (Sokol et al., 1993). Iron overload has been shown 
to achieve this through lipid peroxidation (LPO), impairing oxidative metabolism, 
decreasing cytochrome c oxidase, calcium sequestration and release (Britton et al., 1991; 
Britton et al., 1996), and decreasing the content of reduced pyrimidine nucleotides. 
 
2.7.1.2. Microsomal Damage 
Microsomal LPO has been illustrated in vivo in rats with chronic dietary iron overload 
(Bacon et al., 1986). Decreases in cytochromes have been suggested as a result of 
peroxidation damage (Waller et al., 1983). It has also been shown that calcium 
sequestration as a part of microsomal function is sensitive to peroxidation. This alters 
calcium homeostasis and contributes to cell injury. 
 
2.7.1.3. Plasma Membrane Damage 
Plasma membranes have also been shown to be affected by LPO. In iron overloaded rats, 
there is a decrease in unsaturated fatty acid content in the phospholipids for plasma 
membrane function. It seems that some enzymes in the plasma membrane of hepatocytes 
may be inhibited by iron overload. In accordance, it has been shown that some thiol-rich 
enzymes in plasma membranes of heart cells are sensitive to iron (Link et al., 1994). 
 
2.7.1.4. Hepatic DNA Damage 
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Evidence that chronic iron overload in vivo results in damage to hepatic DNA was 
provided by studies that showed an increased number of strand breaks in hepatic DNA 
from iron-loaded rats (Edling et al., 1990). Studies have also shown that when iron salts 
are incubated in vitro with purified DNA or isolated rat liver mitochondria or nuclei, DNA 
strand breaks are produced (Imlay et al., 1988; Hruszkewycz, 1988). Furthermore 
endogenous iron plays a key role in the DNA damage produced by hydrogen peroxide in 
mammalian cells (Mello et al., 1984). Finally, it has been suggested that when iron is 
bound to DNA in the presence of ·⎯O2 and H2O2, the formation of “site-directed” ·OH 
radicals that cause DNA damage is catalysed by iron (Halliwell et al., 1990). 
 
2.7.2. Lysosomal Injury Hypothesis 
The lysosomal injury hypothesis postulates that excess iron accumulation within lysosomes 
leads to lysosomal fragility, impaired lysosomal function, and eventually cellular injury 
through the release of hydrolytic enzymes and stored metals into the cytoplasm (Peters et 
al., 1985). 
 
During iron overload, the accumulation of iron in lysosomes is a common feature. It is 
thought that iron sequestration within lysosomes serves a protective role by  removing 
redox-active iron from the cytoplasm and by providing a route for removal from the liver 
through lysosome-mediated biliary excretion ( La Russo, 1989). 
 
2.8. Iron Induced Hepatocarcinogenesis 
The clinical, biological and pathological features of HCC complicating haemochromatosis 
are similar to those of other HCC’s (Deugnier et al., 1993). Iron free foci (IFF) are 
proliferative regions and as such are preneoplastic foci (Deugnier et al., 1993). They are 
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defined as clear-cut sublobular nodules of hepatocytes free of iron or significantly less iron 
than the surrounding parenchyma (Deugnier et al., 1993). Experimental (Hirota & 
Williams, 1979) and clinical (Deugnier et al., 1993) evidence has shown the involvement 
of IFF as an early step towards HCC development. It has been shown that cirrhosis is no 
longer a prerequisite for HCC development and hence that iron itself is a carcinogenic 
factor (Asare et al., 2006a). As stated previously, iron in its redox-active state is capable of 
inducing oxidative stress. Excessive oxidative stress as seen in iron overload may also 
cause DNA alterations and alter the methylation status of DNA and may lead to potentially 
mutagenic effects, such as oncogene activation and tumour suppressor gene inactivation. In 
one study, HH patients showed tumour suppressor gene mutations (60% A:T to G:C and 
40% A:T to T:A) (Vautier et al., 1999), suggesting that etheno-deoxyguanine or etheno-
deoxyadenine DNA adducts may be responsible for DNA damage. These DNA 
modifications are produced by the reaction with LPO products in the liver of HH patients 
(Nair et al., 1998). 
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3.0. Aflatoxin 
3.1. Introduction 
Aflatoxins (AFs) represent a group of mycotoxins produced by the common fungi 
Aspergillus flavus and Aspergillus parasiticus. Most mycotoxins have not been implicated 
in any health problems in animals or humans. However AFs, certain trichothecenes, 
fumonisins, and ochroatoxins have been associated with episodic outbreaks of lethal 
poisoning in animal and human populations (Beardall & Miller, 1994; Busby & Wogan, 
1985). 
 
AFs are found on improperly stored foods, such as peanuts, corn and to a lesser extent rice 
(Busby & Wogan, 1985). Figure 3.1 illustrates the conidial head of A.flavus. Because 
conidiophores and conidia of A.flavus are produced in abundance, their colour is the 
predominant one of the foodstuff they cover (Alexopoulos et al., 1996). (Figure 3.2). 
Conidia are conveyed by wind or insects to nearby plants (Dienier et al., 1987)). The major 
route for AF contamination is through ingestion, but occupational exposure to AF in 
agricultural workers, people working in oil mills, and granaries have been reported 
(Sorenson et al., 1984). 
 
Figure 3.1. Conidial Head of A.flavus 
(www.denniskunkel.com) 
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Figure 3.2. Conidia and Conidiophores of A.flavus on groundnuts. 
(www.nri.org/images/foodsafety1.jpg) 
 
Among at least 16 structurally related AFs characterized, there are only 4 major AFs, B1, 
BB2, G1 and G2 that contaminate agricultural commodities and pose a potential risk to 
livestock and human health (Bennett & Klich, 2004; Yu et al., 2004). Numerous 
epidemiological investigations have consistently indicated that dietary aflatoxin B1 (AFB1) 
exposure is one of the main etiologic factors causing human HCC (Groopman et al., 1988; 
Wogan, 1992; Eaton & Gallagher, 1994). Based on this evidence, the International Agency 
for Research on Cancer (IARC) designated AFB1 as a human carcinogen and later 
classified AFB1 a Group I carcinogen in humans (IARC, 1993). 
 
3.2. General Toxicity 
The adverse effects of AFB1 can be categorized into two general groups. Exposure to doses 
greater than 6000mg may cause acute toxicity with lethal effects, whilst exposure to 
smaller doses for prolonged periods (chronic toxicity) is carcinogenic (Groopman et al., 
1988). The severity of effects in animals varies with dose, length of exposure, species, 
breed, and diet or nutritional status (Eaton & Groopman, 1994). The metabolism of AFB1, 
however, plays a major role in deciding the degree of toxicity (Eaton & Gallagher, 1994). 
AFB1 has been shown to inhibit DNA synthesis, DNA dependent RNA polymerase 
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activity, messenger RNA synthesis, and protein synthesis (Busby & Wogan, 1985; McLean 
& Dutton, 1995). The liver is the major target organ (Busby & Wogan, 1985), although 
tumours have been found in lung, kidney and colon. AFB1 can be metabolically activated 
by cultured intact human tracheal epithelium from the bronchus, in human epitheliod lung 
cells, and by rabbit lung microsomes (Coulombe, 1994). 
 
3.3. AFB1 Metabolism 
AFB1-DNA adduct formation is the most important step in AFB1 carcinogenesis and 
mutagenesis (Eaton & Gallagher, 1994). 
 
 
 
Figure 3.3.  Aflatoxin B1 DNA Adduct (Griffiths et al., 2000) 
The initial step requires metabolic conversion of AFB1 to its exo-8,9-epoxide (Busby & 
Wogan, 1984), a process known as epoxidation. Two isomers of AFB1-8,9-epoxide exist. 
The intercalation of the AFB1 exo-epoxide in DNA orients the molecule properly for attack 
by N7 of guanine on C8 of the epoxide. Intercalation of the more chemically stable endo-
epoxide does not allow for this configuration (Figure 3.4).  
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 Figure 3.4.  AFB1 endo- and exo-epoxide (Massey, 1996) 
The bioactivation of AFB1 to AFB1-8,9-exo-epoxide is believed to be the ultimate DNA 
binding mutagenic/carcinogenic metabolite (Gurtoo & Dave, 1975; Essigmann et al., 
1982). The group of enzymes responsible for this conversion is known as the cytochrome 
P450’s. In addition to epoxidation, the primary metabolism of AFB1 also includes 
hydroxylation to aflatoxin M1 (AFM1) and aflatoxin Q1 (AFQ1), demethylation to aflatoxin 
P1 (AFP1), and reduction to aflatoxicol (Hsieh et al., 1977). All of these primary 
metabolites contain vinyl ether double bonds in the dihydrobisfuran ring, and can therefore 
be epoxidated and activated to form mutagenic species (Wong & Hsieh, 1976) (Figure 
3.5).  
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Figure 3.5.  Primary Metabolites of AFB1 Metabolism (Massey, 1996) 
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The amount of exo-8,9-epoxide formed decides the species susceptibility, as this 
metabolite has been identified as the active form of AFB1 which can induce mutations by 
intercalating into DNA, to form an adduct with the guanine moiety in the DNA (Smela et 
al., 2001; Essigmann et al., 1983). As a result of steric hinderence of the DNA backbone 
structure, exo-8,9-epoxide forms adducts with guanine in DNA specifically at the N7 
position (Loechler et al., 1988) forming the principal adduct 8,9-dihydro-8-(N7-guanyl)-9-
hydroxyaflatoxinB1 (AFB1-N7-Gua). A number of other DNA adducts are formed, but 
their mutational spectrum is dominated by one genetic change: the GC to TA transversion. 
These mutations are presumed to have arisen from a guanine adduct, because nearly all 
AFB1 adducts occur at the same base (Smela et al., 2001). 
 
The positively charged imidazole ring of this adduct promotes depurination, resulting in 
apurinic (AP) site formation (Fig 3.6). Alternately, under slightly basic conditions the 
imidazole ring of AFB1-N7-Gua opens to form the chemically and biologically stable AFB1 
formamidopyrimidine (AFB1-FAPY) (Busby & Wogan, 1984) (Fig 3.6). The epoxide also 
hydrolyses spontaneously or enzymatically to form a diol, which in turn undergoes ring 
opening to form a dialdehyde intermediate leading to a Schiff base formation with the 
primary amino groups of proteins (Sabbioni et al., 1987). Plasma albumin adducts of AFB1 
are potential markers of molecular dosimetry of AFB1 in humans (Gan et al., 1988). 
 
3.4. Mutagenicity and Carcinogenicity 
3.4.1. AFB1 Adducts 
The initial AFB1-N7-Gua adduct, the AFB1-FAPY and the AP site, individually or 
collectively, represent the likely chemical precursors to the genetic effects of AFB1. 
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 Figure 3.6.  AFB1 Adducts (Smella et al., 2001) 
The AP site tends to pair preferentially with adenine, resulting in a guanine to thymine 
transversion (Foster et al., 1983: Schaaper et al., 1983). The FAPY adducts, being resistant 
to repair and removal of the adduct, becomes a persistant lesion in the modified DNA that 
may possibly represent a non-conformational site. It is also preferentially paired by 
adenine during DNA replication (Wogan, 1989). DNA replication and chromosomal 
aberrations may also be impaired. The FAPY adducts in RNA may conceivably impair 
transcription and translation processes thereby altering gene expression. 
 
AFB1-DNA adducts’ mutagenic capacity can be summarized as being capable of forming 
subsequent repair-resistant adducts, depurination, or lead to error-prone DNA repair 
resulting in single-strand breaks, base pair substitution, or frameshift mutations (Hsieh, 
1986). 
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One of the most accurate and non-invasive methods for monitoring of AFB1 exposure lies 
in the detection of AFB1-DNA adducts in the urine. A dose-dependent correlation exists 
between AFB1 and AFB1-N7-Gua adducts excreted in urine of male F344 rats (Bennett et 
al., 1981). The AFB1-N7-Gua adducts have a half-life of about 7,5 hours in rats and are 
rapidly removed and exclusively excreted in urine. Only 80% of these adducts appear in 
urine and the remaining 20% of the DNA adduct is converted to AFB1-FAPY within 24hrs 
after initial dosing in the rat (Croy et al., 1981). Other processes such as DNA repair and 
apoptosis of heavily damaged cells are suggested to account for the low concentration of 
AFB1-N7-Gua adducts in urine (Loechler, 1994). 
 
The continuous presence of AFB1-DNA adducts in the body eventually leads to tumour 
formation has been well demonstrated in several experimental models (Yu et al., 1996; 
Schrager et al., 1990). This is accentuated by the roles these adducts play in the multistage 
carcinogenic processes such as tumour promotion and progression (Wang et al., 1995). A 
study correlating AFB1-FAPY persistence with AFB1 exposure and the risk of human 
hepatocellular carcinomas (HHC) was demonstrated by Santella et al. (1993). 
 
The formation of DNA adducts has been shown to be unevenly distributed. Niranjan et al. 
(1982) showed that AFB1-adducts bind covalently to liver mitochondrial DNA at 
concentrations of three to four times higher than nuclear DNA. Irvin & Wogan (1984) 
demonstrated the preferential binding of AFB1 adducts to ribosomal RNA gene sequences 
of rat liver DNA. It was hypothesized that ribosomal RNA regions are preferentially 
accessible to carcinogen modification because of the diffuse conformation maintained 
within transcribed genes. Yu (1983) showed that transcriptionally active regions of rat liver 
nucleolar chromatin had a higher susceptibility to AFB1-DNA adduct binding. 
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 3.4.2. AFB1 and HCC 
In many epidemiological studies, increased AFB1 ingestion corresponded to increased 
HCC incidence (IARC, 1993; Wang & Groopman, 1999). In regions where exposure to 
AFB1 is high, such as China, India, Gambia and Senegal, 44% of total HCC cases 
examined showed a GC to TA mutation predominance at the third position of codon 249 of 
the p53 gene (Katiyar et al., 2000; Kirk et al., 2000; Yang et al., 1997; Rashid et al., 
1999). This mutation is considered a hotspot for AFB1 modification and AFB1-induced 
mutation. However, 1% of HCC samples examined from populations in regions of low 
AFB1 exposure had this mutation (Katiyar et al., 2000; Shimizu et al., 1999; Vautier et al., 
1999; Boix-Ferrero et al., 1999). 
 
Aguilar et al., (1994) examined the role of AFB1 and p53 mutations in HCCs and in 
normal liver samples from the US, Thailand, and China where AFB1 exposures are 
negligible, low and high, respectively. It was found that the frequency of the AGG to AGT 
mutation at codon 249 paralleled the level of AFB1 exposure.  
 
AFB1 exposure occurs in the presence of other toxins and viruses. The most widely studied 
being the interaction between hepatitis B virus (HBV) infection and dietary AFB1 exposure 
(Kew, 2003). Epidemiological studies carried out in the Guangxi Autonomous Region of 
China yielded the following results: Individuals who were Hepatitis B s-antigen (HBsAg) 
positive and found to have heavy AFB1 exposure had an HCC incidence of 649 cases per 
100 000 (0.649%) compared with 66 cases per 100 000 (0.066%) in AFB1 lightly 
contaminated areas. HBsAg negative persons eating highly contaminated AFB1 diets had 
an HCC rate of 99 per 100 000 (0.099%). The relative risk (RR) factor for HCC in 
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individuals in Shanghai with both urinary AFB’s and positive HBsAg status was shown to 
be 59. The RR for HCC cases where only urinary AFB1 metabolites were detected was 3.4 
whilst for HBsAg positive only people was 7. These results clearly illustrate a causal 
relationship between the presence of HBV and AFB1 with HCC risk (Qian et al., 1994; 
Ross et al., 1992). 
 
3.4.3. p53 Tumour Suppressor Gene Mutations 
The relationship between AFB1 exposure and HCC development is highlighted by p53 
tumour suppressor gene mutations. The p53 protein encoded by this gene has vital 
biological functions including the control of the cell cycle, DNA repair and synthesis, cell 
differentiation, genomic plasticity, and apoptosis (Hollstein et al., 1991; Harris & 
Hollstein, 1993). 
 
3.4.4. AFB1 Attributed Activation of Protooncogenes 
The activation of protoncogenes after AFB1 exposure has been substantiated in a variety of 
studies using both animal and in vitro models (Tashiro et al., 1986; Bauer-Hofmann et al., 
1990; Bailey et al., 1996). Activated ras genes predominate the family of oncogenes 
isolated from solid tumours in animal models. ras genes code for small G-proteins of 
molecular weight 21000, and are related to proteins known as p21. These membrane bound 
proteins have GTPase activity and form complexes with other proteins. Additionally they 
play a crucial role in signal transduction, cell proliferation and differentiation (Barbacid, 
1990; Lowy & Willumsen, 1993). 
 
Three ras genes, designated H-ras, K-ras and N-ras, have been identified (Barbacid, 
1990). It was shown that putative activating mutations in the c-K-ras genetic locus 
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involved a single-base modification of either G-C base pair in codon 12 leading to 
aspartate or cysteine substitutions for glycine (Wogan, 1992). Although ras oncogene 
mutations have frequently been found in AFB1-induced liver cancer in experimental 
animal models, the occurrence of these mutations in human HCC’s is relatively rare (Bos, 
1989; Wogan, 1992). A report by Leon & Kew (1995) found no mutations in all 12 HCC’s 
from Southern African blacks, despite the fact that dietary AFB1 exposure is an important 
risk factor in this population. Other oncogenes such as myc and c-erb have been shown to 
be over-expressed in human primary liver cancer tissue (Tiniakos et al., 1989; Tashiro et 
al., 1986). 
 
3.4.5. AFB1 and Oxidative Stress 
Free radical damage initially induced by mycotoxins can be propagated and magnified by 
LPO chain reactions (Atroshi et al., 2000). LPO is one of the factors responsible for liver 
damage and necrosis induced by AFB1 (Souza et al., 1999). Oxidative DNA damage may 
be defined as structural and functional changes of DNA as a result of the interaction of 
reactive oxygen species (ROS) with DNA (Shen et al., 1994). During the 
biotransformation process of forming guanyl adducts, an enhanced production of ROS is 
reported (Heinonen & Fisher, 1996). ROS such as superoxide radicals (·⎯O2), hydrogen 
peroxide (H2O2), and hydroxyl radicals (·OH) could be generated by many pathways 
including aerobic cellular metabolism and the metabolic processes of many xenobiotics by 
cytochrome P450 system (Ames et al., 1995; Frenkel & Gleichauf, 1995; Boelsterli et al., 
1993). It is believed that the increased formation of ROS caused by AFB1 is closely related 
to the metabolic processing of AFB1 by cytochrome P450.This increased oxidative stress 
leads to increased LPO and the formation of the mutagenic 8-oxo-7,8-dihydro-2-
deoxyguanosine (8-OHdG) adducts with DNA (Shen et al., 1994; Shen et al., 1995). 
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 8-OHdG adduct formation is one of the well studied consequences of ROS, and is widely 
considered a key biomarker of oxidative DNA damage (Frenkel, 1992), and capable of 
changing the fidelity of DNA replication to induce mutations. Furthermore, various 
mutations caused by 8-OHdG (mainly G to T transversions) are located at the second 
position of codon 12 of the H-ras oncogene (Kamiya et al.,1992). Additionally, ROS and 
8-OHdG possess essentially the same mutagenic specificity as AFB1 in causing p53 and 
ras mutations (Aguilar et al., 1993).  
 
In conclusion, in addition to the well-known mechanisms of AFB1-DNA adduct formation, 
AFB1-induced ROS and 8-OHdG formation may also be involved in the induction of the 
hot-spot mutations found in human HCCs from AFB1-endemic regions (Shen & Ong, 
1996). 
 
3.4.6. AFB1 and Cytokines 
Cellular components produce various cytokines. Cytokines play a key role in the host 
resistance and protection against tumour progression. When an organ has been damaged by 
a toxic assault, cytokines are involved in the inflammatory mechanisms initiated by this 
damage (Batey & Wang, 2002). Dugyala & Sharma (1996) showed that AFB1 had a 
marked effect on macrophage-produced cytokines in a murine model. The mRNA levels of 
IL-1 and IL-6 were increased at low (0.03mg/kg) and high (0.7mg/kg) AFB1 doses 
respectively. Their corresponding protein levels were generally suppressed. Moon et al. 
(1999) found that AFB1 markedly inhibited TNF-α, IL-1 and IL-6 production by 
lipopolysaccharide stimulated macrophages. Hence, AFB1 inhibited the killing ability of 
murine macrophages.  
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 IL-10 inhibits the synthesis of  type 1 helper T cell (Th1) – derived cytokines, which 
includes IL-1β and IL-6 (Cortes & Kurzrock, 1997). In accordance with those studies 
showing a decrease in these cytokines, AFB1 weaned piglets also showed an increased IL-
10 mRNA expression. The down-regulation of inflammatory cytokines such as IL-1β and 
IL-6  could be a consequence of the induction of IL-10 (Marin et al., 2002). 
 
A considerable body of evidence from animal studies exists, suggesting that AFB1 
suppresses immune functions by affecting T-cell dependent immunity (Ghosh et al., 1990; 
Jakab et al., 1994; Raissuddin et al., 1993). A toxicant can induce immunosuppression 
through various mechanisms including decreased protein and/or DNA sythesis, changes or 
loss in enzymatic activity, and changes in metabolism or cell cycles, which may result in 
apoptosis or necrosis (Hinton et al., 2003). Studies conducted in a pig model show that 
AFB1 decreases the blastogenesis response to the mitogen, reduces complement titres, 
decreases macrophage activation, and depresses delayed hypersensitivity (Miller et al., 
1978; Sillvoti et al., 1997; Mocchegiani et al., 1998). Toxic effects on T-lymphocytes and 
other related lymphoid cells can have pronounced effects on tumourigenesis (Dugyala & 
Sharma, 1996). This is because these cells are involved with the direct or indirect killing of 
tumour cells. Immunosuppression can therefore result in a greater rate of tumour 
progression (Raisuddin et al., 1993). 
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3.5. Animal models of AFB1-induced HCC 
A large variability in susceptibility toward AFB1-induced hepatocarcinogenesis has been 
observed (Wogan, 1973). Mice were found to be resistant, and hamsters were moderately 
resistant, whereas rats readily develop liver cancer on exposure to AFB1 (Eaton & 
Gallagher, 1994). The major detoxification mechanisms for AFB1 oxides in rodents is 
catalyzed by glutathione S-transferase (GST) (Eaton & Gallagher, 1994). It is apparent that 
mice are protected from AFB1-induced hepatocarcinogenesis because of the relatively high 
constitutive expression of a hepatic GST isozyme (GST Yc) which has a high catalytic 
activity for AFB1 oxides (Buetler et al., 1992). In the rat model, a related enzyme (GST 
Yc2, subunit 10) is produced. It is also highly active towards AFB1 oxides. This enzyme is 
expressed however, only at very low levels in adult rat liver (Hayes et al., 1992). This is 
one of the reasons why the rat is of greater use as a model for AFB1-induced HCC. 
 
The use of animal models in the study of AFBB1-related p53 mutations is a common 
practice. The homology of the p53 gene needs to be taken into consideration however. p53 
is at least 92% homologous across commonly used laboratory animal species, such as 
primates, rats, mice, tree shrews etc. (Duflot et al., 1994; Smela et al., 2001). However, 
there are no analogous mutations to the human p53 codon 249 mutation (Arg to Ser) in 
these animals. A possible reason for the lack of analogous mutations may be attributed to a 
GC to TA transversion in the third position of the codon which may result in a silent 
mutation (Smela et al., 2001). In the rat model, codon 243 of the p53 gene corresponds to 
codon 249 in the human gene. Although a third base mutation of codon 243 does not result 
in an amino acid sequence change, mutations in codon 250, as seen in in vitro human 
systems, would be expressed in the rat p53 protein (Stanley et al., 1999). An in vivo and an 
in vitro variation in the oncogene activation in the same target organ or cell lines derived 
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from that organ does exist. This was demonstrated using a rat liver-derived cell line which 
was transformed with AFB1 in vitro, and an in vivo AFB1-induced hepatocarcinogenic 
rodent model (F344 male rats). It is therefore essential to verify and use well investigated 
extrapolation of data when using in vitro and non-human models to study p53 mutations 
(Stanley et al., 1999). 
 
A well characterized and quantitative, short-term rat model of liver cancer has been used 
extensively in studies of AFB1-induced hepatic carcinogenesis (Appleton & Campbell, 
1982; Kensler et al., 1986; Kensler et al., 1987; Roebuck et al., 1991; Kensler et al., 1992; 
Maxuitenko et al., 1993; Bolton et al., 1993). This protocol includes gavaging the rat 5 
days per week with 25μg AFB1/day. This is followed by a 2 day break, and a second 5-day 
series of AFB1 dosing. One of the major advantages of using this short term model is that 
studies can be completed in a short period of time and fewer rats are required to yield 
quantitative results (Roebuck, 2004). 
 
3.6. Modulation of AFB1-induced DNA damage 
Considering the mechanisms of AFB1-induced DNA damage, a variety of chemical agents 
including nutrients, antioxidants, herbs and pharmaceutical agents have been used to 
modulate this damage (Eaton & Gallagher, 1994). Furthermore, chemopreventative agents 
including phenolic antioxidants, ethoxyquin and dithiolethiones have been used to 
modulate AFB1 hepatocarcinogenesis in animals (Kensler et al., 1986). 
 
Oltipraz is a synthetic dithiolethione derivative initially used as an antischistosomal agent 
(Benson, 1993). However, it has been shown to protect laboratory animals from the 
hepatocarcinogenic effects of AFB1 (Kensler et al., 1995; Kensler et al., 1992; Roebuck et 
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al., 1991). Oltipraz induces Phase II drug-metabolizing enzymes in laboratory animals, 
most notably GSTs (Davidson et al., 1990; Meyer et al., 1993; Morel et al., 1993). GST-
catalyzed conjugation of activated AFBB1 is the most important detoxification system for 
prevention of epoxide binding to target macromolecules (Garner & Wright, 1973; Gurtoo 
& Bejba, 1974).  
 
The  inclusion of a 0.03% oltipraz in the diet, beginning 1 week prior to dosing with AFB1, 
resulted in substantially lower levels of hepatic AFB1-DNA adducts throughout the 
exposure period. Binding was reduced by 76% over the initial 18-day period (Kensler et al. 
1992). Rats fed with a diet supplemented with 0.075% oltipraz for a 4-week period around 
the time of AFB1 exposure, afforded complete protection against AFB1-induced HCC and 
hyperplastic nodules (Roebuck et al. 1991). In terms of AFB1-N7-Gua adduct excretion in 
the urine, it was found that the feeding of Oltipraz produced an overall reduction of 62% in 
the elimination of this adduct. This mirrored data on overall levels of hepatic AFB1-DNA 
adducts (Groopman et al., 1992). 
 
Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) is a powerful antioxidant 
commonly used as a preservative in the food processing industry. Ethoxyquin was shown 
to produced a dramatic reduction in AFB1 binding to hepatic DNA. Rats fed 0.4% 
ethoxyquin for 7 days showed a 5-fold increase in hepatic cytosolic GST specific activity 
(Kensler et al. 1986). This lead to the hypothesis that ethoxyquin’s inhibitory effect on 
AFB1 binding to DNA and tumourigenesis appeared to be related to the induction of 
detoxification enzymes. 
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4.0. Free Radicals 
Atoms are most stable in the ground state. An atom is considered to be “ground” 
when every electron in the outermost shell has a complimentary electron that spins in 
the opposite direction. A free radical is any atom with at least one unpaired electron in 
the outermost shell, and is capable of independent existence (Karlsson, 1997). A free 
radical may be formed through three major groups of reactions: 
 
1 – The loss of a single electron from a non-radical 
A: Æ A· +  · 
2 – By the gain of a single electron by a non-radical 
A: + ·  Æ A:· 
3 – When a covalent bond is broken one electron from each pair shared remains with 
each atom resulting in the formation of two radicals. This process is known as 
homolytic fission. 
A:B Æ A·  + B· 
Chemical substances may be converted into free radical by irradiation, or by additives 
called inhibitors. The ionizing process is well known for producing free radicals in 
biological systems, which consequently plays a role in the etiology of radiation 
injuries. 
 
In organic molecules of biological systems, there are many atoms which can exist as 
free radicals including oxygen, nitrogen, carbon, phosphorous and sulphur. With 
respect to tissue injury, the prevalence of oxygen makes the oxygen-centered radicals 
the most common and relevant in biological systems. The ground state of the oxygen 
molecule (O2) is itself a radical, with 2 unpaired electrons each located in a π 
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antibonding orbital. Most biomolecules are covalently bonded non-radicals, and the 
two electrons forming a covalent bond have opposite spins. Hence, the reaction of 
oxygen with biomolecules is spin restricted. In living organisms therefore, oxidative 
enzymes have developed, which circumvent the law of spin restriction and catalyze 
divalent and tetravalent reduction of oxygen, so that only small amounts of ROS &  
reactive oxygen intermediates (ROI) are formed. Spin restriction slows down the 
reaction of molecular oxygen. 
 
4.1. Reactive Oxygen Species (ROS) 
Any free radical involving oxygen can be referred to as ROS. Oxygen centered 
radicals contain two unpaired electrons in the outer shell. When free radicals abstract 
an electron from a surrounding compound or molecule a new free radical is formed in 
its place. In turn, the newly formed unstable radical then tends to its ground state by 
abstracting electrons with antiparallel spins from cellular structures or molecules 
(Goldfarb, 1999). The electron transport chain (ETC), found in the inner 
mitochondrial membrane, utilizes oxygen to generate energy in the form of adenosine 
triphosphate (ATP). Oxygen acts as the terminal electron acceptor within the ETC. 
Two to 5% of the total oxygen intake during both rest and exercise have the ability to 
form the highly damaging superoxide radical (O2-.) through electron escape (Sjodin et 
al., 1990). Free radicals of importance in living organisms include the hydroxyl 
radical (HO˙), superoxide anion (O2-.), nitric oxide (NO˙), thyl (RS˙) and peroxyl 
(ROO˙). Peroxynitrite (ONOO-), hypochlorous acid (HOCl), hydrogen peroxide 
(H2O2), singlet oxygen (1O2) and ozone (O3) are not free radicals. They can, however, 
lead to a free radical reaction. The most common ROS involved in iron overload 
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include the superoxide anion (O2-.), the hydroxyl radical (OH˙), singlet oxygen (1O2), 
and hydrogen peroxide (H2O2). 
 
 
Hydrogen Peroxide
Superoxide anion radical 
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O2-.  HO2˙
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Hydroperoxyl Radical 
Hydroxyl Radical 
Figure 4.1. Formation of Reactive Oxygen Species (ROS). 
 
4.1.1. Singlet Oxygen (1O2) 
Excitation of O2 to the singlet states can be achieved when several pigments are 
illuminated in the presence of O2. The pigment absorbs light, enters a higher 
electronic excitation state, and transfers energy onto the O2 molecule to make a singlet 
O2. 1O2 is thus likely to occur in many pigmented systems exposed to light, the lens of 
the eye and illuminated chloroplasts. As mentioned above, 1O2 is not theoretically 
termed a ROS. Two denotations of this molecule occur, namely 1∆gO2 or 1∑g+O2. The 
former has no unpaired electrons and hence doesn’t qualify as a free radical. 1∑g+O2 
has a set of unpaired electrons, so is theoretically a free radical, although short-lived 
since it decays to 1∆gO2 before it has a chance to exert its free radical effects on other 
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molecules. Porphyrias are defects usually attributed to inborn errors of porphyrin 
metabolism, which may be a result of excessive 1O2 formation. 
 
4.1.2. Superoxide Anion Radical (O2-.) 
When oxygen acts as an oxidizing agent, it gains one or more electrons from a 
substance. One electron reduction of oxygen produces the O2-.. This species is 
produced by a number of enzyme systems, by autooxidation reactions, and by non-
enzymatic electron transfers that univalently reduce molecular oxygen. The “leakage” 
of electrons onto oxygen from various components of the cellular ETC such as those 
in the mitochondria, endoplasmic reticulum and chloroplasts (in plants) is one of the 
electron sources triggering the required oxygen reduction to produce O2-. . O2-. is also 
produced during respiratory bursts of phagocytic cells such as neutrophils, monocytes, 
macrophages and eosinophils.O2-. production is activated when foreign particles touch 
the neutrophil surface and some O2-. escapes into the extracellular fluid. Extracellular 
fluid has little SOD activity, which results in an overproduction of O2-. and HOCl by 
activated phagocytes, hence imposing an oxidative stress on surrounding tissues. Its 
production in this case plays a key role in the killing of several bacterial strains. If this 
process is hampered, a syndrome of persistant infection, results as is the case of 
Chronic Granulomateous Disease (CGD) (Curnutte & Babior, 1987).  
 
4.1.3. Hydroperoxyl Radical (HO2˙) 
The HO2˙ radical results from the protonation of O2-.. At physiological pH values 
close to 7, only around 1% of O2-. radicals are in the HO2˙ form. The production of 
HO2˙ is favoured at a lower pH. A lowered pH occurs around phagocytic surfaces, 
and so some of the O2-. they generated exists as the more active HO2˙ radical. The 
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HO2˙ radical is considered a more active radical due to its ability to diffuse across 
lipid membranes with greater ease. The O2-. diffuses very slowly across lipid 
membranes, unless an anion channel is present. Charged species generally have a 
much lower solubility in lipids than uncharged molecules. 
 
4.1.4. Hydrogen Peroxide (H2O2 ) 
H2O2 has no unpaired electrons, and is not considered to be a free radical. The 
damage observed is due to the conversion of H2O2 into a more highly reactive species, 
the hydroxyl radical (HO˙). Pure H2O2 has limited reactivity, but it can cross 
biological membranes, unlike the O2-.. H2O2 has been shown to be produced in vivo 
when O2-dismutates and also by many oxidase enzymes, including amino acid 
oxidases. Xanthine oxidase converts hypoxanthine and xanthine to urate, O2 being 
simultaneously reduced to both O2-. and H2O2 (Granger, 1988). Levels of xanthine 
oxidase are normally low in human tissues, but they may increase after injury, such as 
trauma and ischaemia (Buckley, 1994). High levels of H2O2 have been shown to 
inactivate the glycolytic glyceraldehydes-3-phosphate dehydrogenase, an enzyme 
involved in the energy-producing system. H2O2 also forms the HO˙ in the presence of 
transition metal ions and O2 and can facilitate this reaction (Miller et al., 1990). While 
H2O2 is itself an oxidizing agent, it is the combination of H2O2 and O2-. which yields a 
much more reactive oxidizing agent, the HO˙. 
 
4.1.5. Hydroxyl Free Radicals (HO˙) 
HO˙ is produced when H2O2 and O2˙- react together: 
 
O2˙-  +  H2O2   Æ  O2  + HO˙ + OH-  --------------------------------Haber-Weiss Reaction 
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Human neutrophils and monocytes have been shown to generate HO˙ through 
myeloperoxidase-dependent mechanism, which could have microbicidal implications 
(Ramos et al., 1995). Most radical generation in vivo, except during excessive 
exposure to ionizing radiation, comes from the metal-dependent breakdown of H2O2 
according to the general equation based on the Fenton reaction: 
 
Mn+ +  H2O2 Æ Mn+1  + HO˙ + OH-
 
Fe2+ + H2O2 Æ Fe3+  + HO˙ + OH-  ----------------------------------------Fenton Reaction 
 
In terms of this Fenton-type chemistry, the extent of HO˙ formation is largely 
determined by the availability and location of the metal ion catalyst.  
 
The availability of free Fe is controlled in physiological systems. Fe that is not 
incorporated into iron-utilizing proteins is rendered largely unavailable for 
participation in free-radical reactions by sequestration in storage or transport proteins 
(Aisen & Listowsky, 1980). A minute pool of Fe is solubilized through chelation to 
low molecular weight biomolecules such as citrate and adenine nucleotides. This 
intermediate pool of Fe is considered available for pathological free-radical reactions. 
This is most likely only to occur in conditions of Fe overload. 
 
The HO˙ radical is several orders of magnitude more reactive towards cellular 
constituents than O2˙-, and H2O2. HO˙ is a highly reactive free radical with an 
estimated half-life of 10-9 seconds. 
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4.1.6. Peroxyl Radicals (ROO˙) 
The peroxyl radicals (ROO˙) are formed during LPO chain reactions, such as the 
oxidation of polyunsaturated (PUFA) and unsaturated fatty acids. Any ROS can 
initiate LPO, provided it has sufficient reactivity to abstract a hydrogen atom from a 
PUFA side chain. Arachidonic acid (AA), a PUFA, is a precursor of prostaglandins 
and leukotriens. It is particularly prone to hydrogen abstraction because of multiple 
methylene-interrupted double bonds (Dix & Aitkens, 1993; Esterbauer et al., 1993). 
AA peroxidation through ROO˙ isomers results in F2 isoprostane formation. F2 
isoprostane formation in vivo appears to be enhanced under conditions of oxidative 
stress (Nourooz-Zadeh et al., 1995; Morrow & Roberts, 1996). The end products of 
LPO have been linked with DNA damage, faulty DNA repair, protooncogene 
activation and hence the promotion of carcinogenesis (Cheeseman, 1993). 
 
Low-density lipoproteins (LDLs) contain PUFAs which, when oxidized results in 
numerous structural and functional changes (Esterbauer et al., 1993). LDL oxidation 
results in a hydrogen abstraction from a PUFA double bond. This results in the 
formation of conjugated double bonds, referred to as conjugated dienes (CD) 
(Esterbauer et al., 1993). LDL cholesterol can be oxidized to oxysterols. The 
propagation is followed by a decomposition phase, in which there is cleavage of 
double bonds resulting in the formation of aldehydes such as malondialdehyde 
(MDA) and 4-hydroxynonenal (4-HNE). These aldehydes are commonly used as 
biomarkers for LPO (Houglum et al., 1990). The aldehydic products of LDL 
oxidation are diffusible cytotoxins (Chisolm, 1991). 
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4.1.7. Nitric Oxide (NO) 
Intracellular Fe levels can regulate inducible (nitric oxide synthase) NOS transcription 
and nitric oxide (NO) formation, through binding to Fe-containing proteins, such as 
cytosolic Fe regulatory protein-1 (IRP-1), and activation of the Fe response element 
(IRE) (Weiss et al., 1997). Under these circumstances, post-transcriptional synthesis 
of ferritin is decreased and the intracellular Fe pool is increased (Cairo & Pietrangelo, 
2000). This allows for Fenton reactions to occur more readily, hence increasing HO˙ 
radical concentration. 
 
An alternative way for cells to generate HO˙ radicals requires the formation of NO 
through NOS. NO reacts in the presence of O2˙-  to form a peroxynitrite (ONOO-), 
which either spontaneously rearranges to form  nitrate  (NO3-) or undergoes cleavage 
to generate HO˙-like radicals and nitrogen dioxide (NO2) (Beckman et al., 1990). 
 
O2˙-  +  NO = ONOO-
 
In severe inflammatory events, increased NO levels have been shown to induce severe 
hypotension, along with pronounced cellular damage with subsequent loss of vital 
organ functions. Important metabolic mechanisms such as protein synthesis, 
glycogenolysis and detoxification capacity are impaired, which may lead to liver 
failure (Kuo & Slivka, 1994; Wang & Chaudry, 1996). 
 
4.2. Free Radicals and Iron Overload 
Fe overload causes substantial tissue damage and predisposes the individual to HCC 
development (McLaren et al., 1983). Fe is known to accelerate LPO, and also the 
formation of the highly reactive HO˙ from H2O2 in the presence of a O2˙-   (McCord & 
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Day, 1978; Halliwell, 1978). Fe-overloaded patients are known to have available Fe 
complexes in the plasma (Gutteridge et al. 1985). These complexes have been shown 
to be effective promoters of radical reactions (Floyd, 1983). Ferritin participates as an 
Fe source in the Haber-Weiss reaction, hence promoting LPO (Gutteridge et al., 1983; 
O’Connell et al., 1985). In Fe-overload, however, it is haemosiderin which 
predominates as the major Fe protein (Selden et al., 1980). Fe released from 
haemosiderin at pH 4.5 is capable of promoting LPO (O’Connell et al.,1985). 
Excessive haemosiderin accumulation within tissues could provoke lysosomal 
damage by increasing LPO (Selden et al., 1980).  
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4.3. Consequences of Free Radical Attack 
Free Radicals 
Interaction with target molecules 
Proteins, Sugars, DNA, Lipids 
Cell Response 
Biological Endpoints 
Disease State Adaptation to 
Oxidative Stress 
Cytotoxicity/ 
Cell Death 
Maintenance of 
Normal Function 
 
Figure 4.2. Effect of Free Radical Attack 
 
4.3.1. Free Radical Interaction with Target Molecules 
Figure 4.2 represents the sequence of events which result in the end-products of free 
radical attack and oxidative stress. Through free radical attack, the basic building 
blocks and biomolecules making up proteins, lipids and nucleic acids, are structurally 
modified and functionally impaired.  
 
The consequence of oxidative stress on proteins include altered enzymatic activities, 
cellular functions, and altered transport protein functioning. Cellular function 
alterations may occur resulting from aggregation and cross-linking of receptor 
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proteins. The alteration of transport proteins occur which affect homeostasis leading 
to calcium accumulation (Aust et al., 1985).  
 
Free radicals attack electrons from cell membranes, initiating LPO. ROS target the C-
C double bond of PUFAs. The double bond of the C weakens the C-H bond, allowing 
for easy dissociation of the H by a free radical. A free radical acquires the single 
electron from the H associated with the C at the double bond. This, in turn, leaves the 
C with an unpaired electron and hence becomes a free radical. The newly arranged 
molecule is called a conjugated diene (CD). The CD then very easily reacts with 
oxygen to form a ROO˙ which abstracts an electron from another lipid molecule in a 
process called propagation. A chain reaction follows (Halliwell & Gutteridge, 1985). 
One of the insidious properties of free radicals is that in interacting with other 
molecules to gain a stable configuration of electrons, they convert that target molecule 
into a radical. So a chain reaction begins that will propagate until radicals meet each 
other and each contributes its unpaired electron to form a covalent bond linking the 
two. The consequence of LPO results in altered lipid fluidity, changes in membrane 
permeability and the ability of the cell to maintain transmembrane ionic gradients. 
DNA radicals can react with protein radicals (in histones) to form crosslinks that 
interfere with chromatin unfolding, DNA repair, replication, and transcription. It is 
believed that iron ions complex with negatively charged phosphates in the DNA 
backbone, thus generating hydroxyl radicals within diffusion distance of reactive 
bonds in deoxyribose and nitrogen bases. Hydroxyl free radicals attack deoxyribose 
sugars, leading to single- and double-stranded breaks in DNA. Hydroxyl radicals also 
deaminate nucleotides, leading to point mutations, notably C>T, G>C and G>T 
changes (Aust et al., 1985). 
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In terms of cellular response, free radical attack is known to activate transcriptional 
modification. The activation of NF-κβ leads to increased IL-8 gene expression. 
Increased levels of p53, and proto-oncogenes c-fos and c-myc have been reported 
following free radical attack. 
 
4.3.2. Antioxidant Defenses against Free Radicals 
Oxidative stress is defined as the state in which the level of toxic ROS overcomes the 
endogenous antioxidant defences of the host (Bulger & Helton, 1998). Antioxidants 
are theoretically effective because they readily donate their own electrons to free 
radicals. When a free radical abstracts the electron from an antioxidant it no longer 
needs to attack the cell and the chain reaction of oxidation is broken (Dekkers et al., 
1996). By definition, an antioxidant becomes a free radical after donating an electron. 
Antioxidants in this state are not harmful because they have the ability to 
accommodate the change in electrons without becoming reactive. Two lines of 
antioxidant defense exist in the cell. The group of antioxidants found in the fat-soluble 
cellular membrane includes vitamin E, beta-carotene, and coenzyme Q (Kaczmarski 
et al., 1999). Vitamin E is considered the most potent chain breaking antioxidant 
within the membrane of the cell. The other group, made up of water soluble 
antioxidants scavengers includes vitamin C, SOD, CAT and glutathione peroxidase 
(Dekkers et al., 1996). Antioxidants at certain concentrations can be harmful 
however, as they can act as pro-oxidants. 
4.4. Biomarkers of Oxidative Stress 
4.4.1 Biomarkers of LPO 
Biomarkers for LPO in particular have been extensively studied. There are more 
biomarkers available for LPO than for DNA and protein oxidation combined. 
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4.4.1.1. Thiobarbituric acid-reactive substances (TBARS) 
TBARS is one of the earliest markers used in human and animal studies (Buege and 
Aust, 1978). It may be measured using a spectrophotometric assay that measures the 
chromogen produced by the reaction of thiobarbituric acid (TBA) with MDA, an end 
product of LPO. This is an easy method but non-specific because of other substances 
such as aldehydes reacting with TBA (Handelman and Pryor, 1999). The latter has 
rendered this approach obsolete. A modified version of this method uses HPLC to 
separate the MDA-TBA adduct from other interfering chromogens. This improves the 
specificity, sensitivity and reproducibility (Wong et al., 1987).  
 
4.4.1.2. Breath hydrocarbons 
The measurement of breath hydrocarbons is another commonly used non-invasive 
approach for investigating LPO in vivo (Knutson et al., 2000). Pentane and ethane, 
which are formed from peroxidation of (n-6) and (n-3) fatty acids, respectively, are 
volatile compounds released into the breath. Potential errors involve contamination 
with ambient-air pentane and ethane (Knutson et al., 2000).  
 
4.4.1.3. LDL oxidation 
The oxidative modification of LDL is thought to enhance atherogenicity. For this 
reason, susceptibility of LDL to induce oxidative stress ex vivo has been used as a 
possible bio-marker of oxidative defence, at least in the LDL particle itself. Lipid-
soluble antioxidants are known to be located in LDL in vivo. LDL susceptibility 
should therefore reflect the antioxidant defence system, particularly as it related to 
lipid substrates and lipid-soluble antioxidant compounds. When LDL is exposed to 
Cu2+ as a pro-oxidant, the lag time preceding onset of lipid peroxidation formation 
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indicates resistance of LDL to oxidative stress (Jialal et al., 1995). In interpreting 
results based on LDL oxidation, antioxidant efficacy and the choice of inducing 
agents used for both metal ion-dependent (i.e.. cupric ions) oxidation and metal ion-
independent [e.g. 2,2’-azobis(2-amidinopropane)dihydrochloride or AAPH] oxidation 
should be taken into account (Gaziano et al., 1995). 
 
4.4.1.4. F2 isoprostanes 
F2 isoprostanes are produced by free-radical induced peroxidation of arachidonic acid 
(Morrow et al., 1990). These compounds are formed in phospholipids and are cleaved 
and released into the circulation, before excretion into urine as free isoprostanes 
(Roberts and Morrow,1997). The most abundant F2 isoprostane is 8-isoprostaglandin 
F2α (8-iso-PGF2α), which has been suggested to be a promising marker of oxidative 
injury (Sodergren et al., 2000).  Methods of detection include gas chromatography/ 
mass spectroscopy (GS/MS) (Handelman and Pryor, 1999). Immunological assays, 
although available, may sacrifice specificity because of possible cross-reactions with 
other prostanoids.  
 
4.4.1.5. Ferrous Xylenol Orange (FOX) assay 
This method is simple and sensitive. Additionally, it is said to give highly 
reproducible results for biological samples. It is reported to outperform the iodometric 
assay, and other assays in terms of simplicity and reproducibility. Finally, very small 
quantities only of samples are required for this assay (Wolff, 1994). 
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4.4.1.6. Other Assays for Oxidative Biomarkers 
Oxygen radical absorbance capacity (ORAC) (Cao et al., 1993) and total ROO•-
trapping (TRAP) (Wayner et al., 1985) take into account the total antioxidant capacity 
of a system to scavenge or trap oxygen radicals. Assays such as ORAC allow 
investigators to use different ROS generators to measure total antioxidant capacity of 
a sample under different conditions.  Diene conjugation assays use the principle that 
the oxidation of unsaturated fatty acids is accompanied by an increase in UV 
absorbance at 230-235nm. Nitrone adducts of reactive short-lived free radicals may be 
determined using spin traps, which allow formation of stable nitroxides, which can be 
examined via electron spin resonance (ESR) (Gutteridge, 1995). 
 
4.4.2. Biomarkers of DNA Oxidation 
8OHdG is considered one of the most common markers used in assessing DNA 
damage. HPLC with electrochemical detectors (HPLC/ECD) and GC/MS methods are 
most widely used to detect 8-OHdG, although ELISA techniques are also being 
employed (Santella, 1999). Serum antibodies to 5-hydroxymethyl-2’-deoxyuridine 
(HMdU), a product of thymine oxidation has been proposed as a possible biomarker 
of oxidized DNA. Fenkel et al. (1998) found that humans produce antibodies to this 
compound, and titres of anti-HMdU can be measured in simple ELISA assays. The 
comet assay is able to perform rapid analysis of DNA fragmentation associated with 
DNA damage. The comet assay or single cell gel electrophoresis assay permits the 
quantification of DNA damage in individual cells based on the migration of DNA 
structures in an electric field. As a result of the migration, comets are formed and the 
amount of DNA in the comet tail as well as the distance of migration, can be a 
measure of damage. An intermediate step has been introduced using endonulcease III, 
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which induces breaks in the DNA at sites of oxidized pyrimidines (Collins et al., 
1993). Pool-Zobel et al. (1997) used this assay to demonstrate that supplementation 
with antioxidant-rich foods produced significantly reduced endogenous levels of 
strand breaks in lymphocyte DNA. 
 
4.4.3. Biomarkers of Protein Oxidation 
Increased markers of protein oxidation have been associated with several pathologies 
and diseases such as the aging process, diabetes, atherosclerosis and 
neurodegenerative diseases (Dean et al., 1997). Protein carbonyls are the biomarkers 
generally used to estimate protein oxidation. The conventional assay is a colorimetric 
procedure involving dinitrophenylhydrazine (Levine et al., 1990). Winterbourn & 
Buss (1999) have developed an ELISA which correlates well with the colorimetric 
assay. The detection of many other oxidative protein modifications exists including 
disulfide, thiyl radicals, glutathiolation, methionine sulfoxide and tryptophanyl 
detection (Dean et al., 1997). 
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5.0. Materials and Methods 
 
5.1. Serum Iron Determination 
5.1.1. Principle 
A colorimetric kit manufactured by Randox, UK, was used for the quantitative in 
vitro determination of iron in serum. Ferric iron is dissociated from its carrier protein, 
transferrin, in an acidic medium and simultaneously reduced to the ferrous form. The 
ferrous iron is then complexed with the chromogen ferene, a sensitive iron indicator, 
to produce a blue chromophore which absorbs maximally at 595nm. 
 
5.1.2. Reagents and Preparation 
The kit was made up of: 
a) Chromogen: Ferene (22.2 mmol/l) 
b) Reductant: Ascorbic Acid (1.3 mol/l) 
- The contents of one vial of reductant provided were diluted with 15ml 
of iron-free deionized water. 
c) Buffer: Acetate buffer (0.087 mol/l, pH 4.65), Dimethyl sulphoxide, surfactant 
d) Iron standard: 35.8 μmol/l or 200μg/dl 
 
5.1.3. Assay Procedure 
Disposable labware free of iron was used. 
a) The following was pipetted into Eppendorff tubes: 
 Reagent Blank Sample Standard 
Buffer 500μl 500μl 500μl 
Reductant 25μl 25μl 25μl 
Iron-free water 125μl - - 
Standard - - 125μl 
Sample - 125μl - 
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b) The solutions were mixed, and the initial absorbencies of the samples and the 
standard were read against the reagent blank. 
c) 25 μl of the chromogen was added to the reagent blank, standard, and samples. 
d) The solutions were vortexed and incubated for at least 15 minutes at room 
temperature (20 - 25°C). 
e) The final absorbance was read against the reagent blank. 
 
5.1.4. Calculations 
ΔA = Final Absorbance – Initial Absorbance 
Concentration = Δ Asample     x Concentration of Standard 
                          Δ Astandard   
An example of the respective spreadsheet: 
  With Chromogen   Without Chromogen       
  Abs1 Abs2 Ave Abs Abs1 Abs2 Ave Abs  Abs1-Abs2 Conc 
Blank 0 0 0 0 0 0  0 0 
Standard 0.062 0.09 0.076 0.003 0.007 0.005  0.071 35.8 
            
Samples           
4206 0.290 0.372 0.331 0.073 0.093 0.083  0.248 125.1 
4208 0.266 0.260 0.263 0.067 0.080 0.074  0.190 95.6 
4122 0.144 0.088 0.116 0.057 0.048 0.053  0.064 32.0 
4156 0.266 0.260 0.263 0.067 0.080 0.074  0.190 95.6 
4123 0.311 0.260 0.286 0.072 0.080 0.076   0.210 105.6 
 
5.2.Total-Iron Binding Capacity (TIBC) Determination 
5.2.1. Principle 
A colorimetric kit manufactured by Randox, UK, was used to determine the total-iron 
binding capacity (TIBC) of transferrin in serum samples. An excess of iron was added 
to the serum to saturate the transferrin. The unbound iron was precipitated with basic 
magnesium carbonate. After centrifugation the iron in the supernatant was determined 
using the Randox Serum Iron kit. 
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5.2.2. Reagents 
The kit was made up of: 
a) Iron solution: Iron (89.5μmol/l or 500μg/100ml) 
b) Basic magnesium carbonate 
5.2.3. Assay Procedure 
a) The following was pipetted into Eppendorff tubes: 
 Reagent Blank Sample 
Iron Solution 100μl 100μl 
Sample - 50μl 
Iron free water 50μl - 
 
b) This mixture was vortexed and allowed to stand for 5-30 minutes at room 
temperature. 
c) One small spatula-full of basic magnesium carbonate was then added to the 
mixture. 
d) This solution stood for 30-60 minutes at room temperature with frequent 
mixing. 
e) The tubes were centrifuged for 10 minutes at 3000 rpm. 
f) 25μl of the supernatant was then removed, and assayed for iron. 
5.2.4. Calculation for TIBC 
TIBC (μmol/l) = Asample    x 107.4 
                           Astandard
5.2.5. Calculation for PSAT 
The percentage saturation (PSAT) was calculated using the following formula: 
 
Total Serum Iron concentration   x 100(%) 
TIBC 
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5.3. Ferritin Determination 
5.3.1. Principle 
The ferritin quantitative test kit purchased from IBL, Hamburg, is a solid phase 
enzyme-linked immunosorbent assay (ELISA) utilizing rabbit anti-ferritin for the 
solid phase (microtiter wells) immobilization and mouse monoclonal anti-ferritin in 
the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is 
allowed to react simultaneously with the antibodies, resulting in the ferritin molecules 
being sandwiched between the solid phase and enzyme-linked antibodies. After 45 
minute incubation at room temperature, the wells are rinsed with double-distilled 
water or buffer to remove unbound labeled antibodies. A solution made-up of 
3,3’,5,5’-tetramethylbenzidine (TMB) is added and incubated for 20 minutes, 
resulting in the development of a blue chromophore. The reaction is terminated with 
the addition of 1N HCl, and the resulting yellow colour is measured 
spectrophotometrically at 450nm. The concentration of ferritin is directly proportional 
to the colour intensity of the test sample. 
 
5.3.2. Reagents and Preparations 
The kit was made up of: 
a) Antibody-coated wells: Microtiter wells coated with rabbit anti-ferritin. 
b) Enzyme Conjugate Reagent: Contains mouse monoclonal anti-ferritin 
conjugated to horseradish peroxidase. 
c) Ferritin Standards: Contain 0, 15, 80, 250, 500, and 1000ng/ml human liver or 
spleen ferritin in bovine serum with preservatives. 
d) TMB Reagent: Contains 3,3’,5,5’-tetramethylbenzidine stabilized in buffer 
solution. 
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e) Stop Solution: Contains diluted hydrochloric acid (1N HCl). 
 
All reagents were allowed to reach room temperature (18-25°C) before use. 
Reagents were mixed by gentle inversion or swirling prior to use. (Care was taken not 
to induce foaming) 
 
5.3.3. Assay Procedure 
a) 20μl of standards, samples, and controls was dispensed into the appropriate 
wells. 
b) 100μl of the enzyme conjugate reagent was dispensed into each well. 
c) Gentle mixing followed for 30 minutes. 
d) The plate was then incubated at room temperature for 45 minutes. 
e) The incubation mixture was then removed by flicking the contents into a 
suitable waste container. 
f) The wells were rinsed 5 times with distilled water. 
g) The microtiter plate was inverted and struck sharply on absorbent paper to 
remove residual water droplets from the wells. 
h) 100μl of TMB reagent was dispensed into each well, and gently mixed for 5 
seconds. 
i) The plate was then incubated in the dark for 20 minutes. 
j) The reaction was stopped by the addition of 100μl of the stop solution (1N 
HCl) into each well. 
k) Gentle mixing followed for 5 seconds. 
l) The absorbance was measured at 450nm within 15 minutes. 
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5.3.4. Calculations 
a) The mean absorbance values for each set of reference standards, controls and 
samples were calculated. 
b) A standard curve was constructed by plotting the mean absorbance obtained 
for each reference standard against its concentration in ng/ml, as shown below. 
c) Using the mean absorbance value for each sample, the corresponding 
concentration of ferritin in ng/ml was determined from the standard curve. 
(The graph axis was swopped so as to make calculations easier) 
d) A dilution factor of 4 was taken into account. 
 
Ferritin Standard Curve
y = -3E-06x2 + 0.0042x - 0.0538
R2 = 0.9841
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Fig. 5.3.4a. Ferritin Standard Curve 
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Ferritin Standard curve
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Fig. 5.3.4b. Ferritin Standard Curve 
 
Standards      
Conc.(ng/ml) Abs     
0 0     
15 0.039     
80 0.223     
250 0.686     
500 1.497     
1000 1.504     
       
Samples Abs  
Conc. 
(ng/ml) (X4-DF) 
4206 0.083  27.8 111.0 
4208 0.038  16.1 64.3 
4122 0.088  29.1 116.3 
4156 0.095  31.0 123.9 
4123 0.108  34.5 138.1 
 
5.4. Non-transferrin-bound iron (NTBI) Determination 
5.4.1. Principle 
This is a sensitive assay able to measure the low levels of this NTBI in serum 
(McNamara et al. 1999). The iron-nitrilo-triacetic acid complex formed (iron-NTA) is 
quantified as a measure of NTBI. NTA does not compete for transferrin-bound iron. 
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A high-pressure liquid chromatography (HPLC)-based method was used for the 
quantification of the iron-NTA complex. A flow cell was used to ensure that only the 
desired complex was measured, excluding the interference from any other substances 
that may have been present. 
 
5.4.2. Reagents and Preparation 
a) Nitrilo-triacetic acid 
b) Millipore Ultrafree filter unit 
c) HPLC system (The HPLC system used in this study was a Waters Quaternary 
System with a variable wavelength detector and chromatography data 
processor using APEX software (Waters Chromatography Products, Milford, 
MA, USA)). 
d) 6mol/l nitric acid 
e) 8mm x 10cm Novapak C-18 column (Waters Chromatography Products) 
f) 5mmol/l MOPS (4-morpholinpropanesulphonic acid) (Boehringer Mannheim, 
Mannheim, Germany) 
g) 5mmol/l L1 (1,2-dimethyl-3-hydroxy-pyrid-4-one) 
h) 5% acetonitrile, pH 7.0 
 
- Nitrilo-acetic acid: 800mmol/l was made up in iron-free water and 
adjusted to pH 7.0 with 1mol/l NaOH. 
- Millipore Ultrafree filter unit was prewashed with 100μl of 10mmol/l 
NTA, followed by 100μl of iron-free water. 
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- The HPLC system was passivated with 6mol/l nitric acid prior to use. An 
8mm x 10cm Novapak C-18 column was sued with a mobile phase of 
5mmol/l MOPS, 5mmol/l L1 and 5% acetonitrile at a flow rate of 1ml/min. 
 
5.4.3. Assay Procedure 
- 25μl of Nitrilo-acetic acid was added to 225μl serum and the mixture 
allowed to stand at room temperature for 20 minutes. 
- 150μl of the serum solution was then placed in a Millipore Ultrafree unit 
with a nominal molecular weight of 10 000Da and centrifuged at 8500g for 
20 minutes. 
- A 20μl aliquot of the ultrafiltrate was then injected directly onto the HPLC 
system using an iron-free syringe. 
- Detection was at 460nm. 
- A standard curve was generated by injecting 1,3,5,7 and 10μmol/l iron 
prepared in 80mmol/l NTA. 
- All injections were performed in duplicate and a standard curve was 
prepared with every run. 
- With this method of measurement, concentrations up to 2μmol/l are 
distinguishable from 0, and the presence of NTBI was therefore taken to 
be a concentration > 2μmol/l. 
-  
5.5. Alanine Aminotransferase (ALT)/ Glutamic-Pyruvic Transaminase (GPT) 
Determination 
5.5.1. Principle 
A colorimetric kit manufactured by Randox, UK based on the method of Reitman & 
Frankel (1957) was used for the determination of serum ALT. 
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 α-oxoglutarate + L-alanine                         L-glutamate + Pyruvate 
GPT
Glutamic-Pyruvate Transaminase (GPT) is measured by monitoring the concentration 
of pyruvate hydrazone formed with 2,4-dinitrophenyl-hydrazine. 
 
5.5.2. Reagents and Preparation 
The kit contained the following: 
a) Sodium Hydroxide 
b) GPT Buffer: Phosphate buffer (100 mmol/l, pH 7.4); L-alanine ( 200 mmol/l); 
α-oxoglutarate (2 mmol/l) 
c) 2,4-dinitrophenyl-hydrazine (4 mmol/l) 
d) Pyruvate Standard (2 mmol/l) 
 
- Sodium Hydroxide: 1 vial of the supplied sodium hydroxide was made up to 
1000ml with redistilled water in a volumetric flask. 
 
Preparation of Standard Curve: 
- Pyruvate Standard was used undiluted as follows: 
Tube Diluted 
Pyruvate Std 
(μl) 
Redistilled 
water (μl) 
GPT Buffer 
(μl) 
GPT (U/I) 
1 0 200 1000 0 
2 50 200 950 9 
3 100 200 900 18 
4 150 200 850 27 
5 200 200 800 37 
6 250 200 750 46 
7 300 200 700 56 
8 350 200 650 67 
9 400 200 600 77 
10 450 200 550 87 
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 a) 1ml of 2,4-dinitrophenyl-hydrazine was pipetted and mixed into each tube 
b) Tubes were incubated for 20 minutes at 20-25°C. 
c) 10ml of sodium hydroxide solution was added to each tube 
d) The solutions were mixed and the absorbance read against the blank (tube 1) 
after 5 minutes. 
5.5.3. Assay Procedure 
 Reagent Blank Sample Standard 
Sample - 50 μl - 
Standard - - 50 μl 
GPT Buffer 250 μl 250 μl 250 μl 
Distilled Water 50 μl - - 
 
a) The above was mixed and incubated for exactly 30 minutes at 37°C. 
b) 250 μl of 2,4-dinitrophenyl-hydrazine was added to each tube being used. 
c) Solutions were mixed and allowed to stand for exactly 20 minutes at 20-25°C. 
d) 2.5ml of sodium hydroxide was added to each tube. 
e) Solutions were mixed and the absorbance read against the reagent blank after 
5 minutes. 
f)  
5.5.4. Calculations 
a) The standard curve was obtained by plotting the measured absorbencies 
against the transaminase concentrations in U/I. 
b) Concentrations were calculated using the linear equation of the standard curve. 
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Fig. 5.5.4. ALT Standard Curve 
 
Sample Abs1 Abs2 
Ave 
Abs 
ALT 
Activity(u/i) 
4107 0.122 0.189 0.156 30.6 
4108 0.442 0.432 0.437 90.5 
4143 0.086 0.222 0.154 30.3 
4113 0.128 0.145 0.137 26.6 
4114 0.219 0.255 0.237 48.0 
4139 0.147 0.168 0.158 31.0 
4140 0.079 0.039 0.059 10.1 
4142 0.069 0.028 0.049 7.9 
 
5.6. Aspartate Aminotransferase (AST)/ Glutamic-Oxaloacetic Transaminase 
(GOT) Determination 
 
5.6.1. Principle 
A colorimetric kit manufactured by Randox, UK, based on the method of Reitman & 
Frankel (1957) was used for the determination of serum AST. The principle of the 
reaction is shown below. 
 
α-oxoglutarate + L-aspartate                         L-glutamate + Oxaloacetate 
GOT
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Glutamic-Oxaloacetate Transaminase (GOT) is measured by monitoring the 
concentration of oxaloacetate hydrazone formed with 2,4-dinitrophenyl-hydrazine. 
 
5.6.2. Reagents and Preparation 
The kit was made up of: 
e) Sodium Hydroxide: 1 vial of the supplied sodium hydroxide was made up to 
1000ml with redistilled water in a volumetric flask. 
f) GOT Buffer: Phosphate buffer (100 mmol/l, pH 7.4); L-aspartate ( 100 
mmol/l); α-oxoglutarate (2 mmol/l) 
g) 2,4-dinitrophenyl-hydrazine (2 mmol/l) 
h) Pyruvate Standard (2 mmol/l) 
 
Preparation of Standard Curve: 
- 1.5ml Pyruvate Standard was diluted with 4.5ml GOT Buffer. 
Tube Diluted 
Pyruvate Std 
(μl) 
Redistilled 
water (μl) 
GOT Buffer 
(μl) 
GOT (U/I) 
1 0 200 1000 0 
2 50 200 950 6 
3 100 200 900 11 
4 150 200 850 16 
5 200 200 800 20 
6 250 200 750 25 
7 300 200 700 31 
8 350 200 650 37 
9 400 200 600 44 
10 450 200 550 52 
 
e) 1ml of 2,4-dinitrophenyl-hydrazine was pipetted into each tube and mixed 
f) Tubes were incubated for 20 minutes at 20-25°C. 
g) 10ml of sodium hydroxide solution was added to each tube 
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h) The solutions were mixed and the absorbance read against the blank (tube 1) 
after 5 minutes. 
 
5.6.3. Assay Procedure 
 Reagent Blank Sample Standard 
Sample - 50 μl - 
Standard - - 50 μl 
GOT Buffer 250 μl 250 μl 250 μl 
Distilled Water 50 μl - - 
 
g) The above reactions were prepared and solutions mixed and incubated for 
exactly 30 minutes at 37°C. 
h) 250 μl of 2,4-dinitrophenyl-hydrazine was added to each reaction tube 
i) Solutions were mixed and allowed to stand for exactly 20 minutes at 20-25°C. 
j) 2.5ml of sodium hydroxide was added to each tube. 
k) Solutions were mixed and the absorbance read against the reagent blank after 
5 minutes. 
 
5.6.4. Calculations 
c) The standard curve was obtained by plotting the measured absorbencies 
against the transaminase activities in U/I. 
d) Concentrations for the test samples were calculated from the linear equation of 
the standard curve. 
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Fig. 5.6.4. AST Standard Curve 
 
Srl Abs 
X 10 
(DF) 
AST 
Activity 
        
blank 0     
        
Samples       
4105 0.034 0.34 44.7
4106 0.029 0.29 38.2
4107 0.032 0.32 42.1
4108 0.028 0.28 36.8
4109 0.029 0.29 38.2
4143 0.019 0.19 24.6
 
5.7. γ-Glutamyl Transferase (GGT) Determination 
5.7.1. Principle 
A colorimetric kit manufactured by Kat Medical (PTY) LTD based on the method of 
Szasz (1976) was used for the determination of plasma GGT. Optimised kinetic 
determination of γ-glutamyl transferase is dependent on the following reaction: 
 
L-γ-Glutamyl-3-carboxy-4-nitroanilide +   glycylglycine   
γ-GT 
L-γ-Glutamyl-glycylglycine +   p-Nitroanilide 
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The increase of absorbance at 405nm, as a result of the formation of the p-
Nitroanilide, is proportional to the Gamma GT activity. 
 
5.7.2. Reagents and Preparation  
The kit was made up of: 
a) Reagent 1: Tris Buffer, pH 8.25 (100mmol/l); glycylglycerine (100mmol/l). 
b)   Reagent 2: L-γ-Glutamyl-3-carboxy-4-nitroanilide (40mmol/l). 
c) The GGT reagent was made up by adding 1 volume of Reagent 2 to 5 volumes 
 of Reagent 1. 
 
5.7.3. Assay Procedure 
a)  50 μl of the sample was mixed with 500 μl of the GGT reagent and incubated 
 for 1 minute at 25°C. 
b) The initial absorbance was read at 400nm and the timer started 
 simultaneously. 
c) The absorbance was read at 1, 2 and 3 minutes. The change in absorbance was 
 then calculated. 
 
5.7.4. Calculations 
a) The average change in absorbance per minute was calculated. 
b) The following equation was used to determine the GGT concentration in the 
 sample: 
U/I = Average ΔAbsorbance/min x 1158 
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AveAbs-
1min 
Ave Abs-
2min 
Ave Abs-
3min 
Ave Abs 
difference U/I 
Sample           
4206 0.360 0.361 0.367 0.003 3.6 
4208 0.378 0.379 0.380 0.001 1.0 
4122 0.492 0.495 0.493 0.003 3.5 
4156 0.378 0.379 0.380 0.001 0.1 
4123 0.492 0.495 0.493 0.003 3.5 
 
 
5.8. Superoxide Radical (•-O2) Determination 
  
5.8.1. Principle 
 
Luminescence is the emission of light by non-thermal processes. In the case of 
chemiluminescence analysis, the light is generated by chemical reactions. Molecules 
responsible for emitting this light absorb free energy released by the chemical reaction 
and become ‘excited’. In this state some of the peripheral electrons of the molecule 
are raised to a higher energy level. When these electrons lose energy, they return to a 
lower energy level and the energy lost during this transition is emitted as photons. 
When the electrons lose all their absorbed energy, the molecule then returns to its 
stable ground state. 
 
The chemiluminophore used for this research is luminol.  
 
 
  
 
 NH2
NH 
NH + 
O2 
1O2 
.OH 
H2O2
COOH 
COOH 
+ 
N2  
 
LIGHT
LUMINOL OXIDANT α−AMINOPHTHALATE 
 
  
 
The luminol interacts with the oxidizing species to produce larger, more measurable 
amounts of light at a peak wavelength of approximately 425nm. This was measured 
by a four-channel luminometer interfaced with a computer. 
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5.8.2. Reagents and Preparation 
a) 10-4 M Luminol stock solution was prepared by dissolving 0.177g luminol in 
100 ml of 0.1M borate buffer. 
b) Borate buffer: 0.1M, pH 9.0 was prepared by dissolving 9.5g / 250 ml dH20. 
pH was adjusted to 9.0. 
c) 10-3 M N-formylmethionylleucinylphenylalanine (fMLP) (stock 10mM in 
DMSO). 
d) Phenol-free HBSS (Sigma). 
e) Heparinized whole blood was diluted 1:9 with phenol-free HBSS. 
 
5.8.3. Assay Procedure 
 
 
              Sample and Reagents          Volume 
 
                            Remarks 
1:9 Diluted blood sample 
 
500μl In luminometer cuvette 
10mM Luminol solution 
 
200μl 
 
Resultant solution was loaded onto 
luminometer 
10mm FMLP 300μl After baseline had advanced to about half 
the length of the next square 
 
 
- Graph: 15sec/division was used. 
- Temp. setting: 37oC 
- Graph was displayed on the screen and ensured that baseline had stabilized 
halfway across the first square. 
- Gain was adjusted as required so that the luminescence curves were within the 
range on the displayed graph. 
- Once the gain was established, the test was performed at that particular gain 
setting.  
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- The peak luminescence was recorded in mV from the point of fMLP addition 
to the end of the graph. 
- The results were determined by computer settings. 
 
 
Sample Neutrophil Tmax Tmax/Neutr Mean 
        Tmax/Neut 
          
4156 11.0 0.337 0.031   
4123 6.7 0.367 0.055   
4206 3.3 0.216 0.066   
4122 4.9 0.418 0.085   
4208 5.1 0.398 0.078 0.063 
 
 
 
5.9. Nitrite Determination – Griess Reagent System 
5.9.1. Principle 
One means to investigate nitric oxide formation is to measure nitrite (NO2-), which is 
one of two primary, stable and nonvolatile breakdown products of NO. This assay 
relies on a diazotization reaction that was originally described by Griess (1879). The 
Griess Reagent System developed by Promega is based on the chemical reaction 
shown in Figure 5.9.1, which uses sulfanilamide and N-1-napthylethylenediamine 
dihydrochloride (NED) under acidic (phosphoric acid) conditions to form the Azo 
compound. This system detects NO2- in a variety of biological and experimental 
liquid matrices such as plasma, serum, urine and tissue culture medium.  
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 Fig. 5.9.1 Griess Reagent System Reaction 
 
5.9.2. Reagents and Preparation 
The following chemicals were used: 
- N-1-napthylethylenediamine dihydrochloride (NED) 
- Sulfanilamide 
- Sodium Nitrite 
 
a) NED Solution: 0.1% NED was prepared by adding 0.1g NED into 100ml 
distilled water 
b) Sulfanilamide Solution: 1% sulfanilamide solution was prepared by adding 1g 
sulfanilamide into 100ml of 5% phosphoric acid solution 
c) Nitrite Standard: Stock 0.1M sodium nitrite was prepared by adding 3.45g 
sodium nitrite into 100ml of 5% phosphoric acid solution.  
d) The solutions for the standard curve was prepared as follows: (Standards were 
prepared in a 96-well flat-bottom enzymatic assay plate). 
- 1ml of a 100μM nitrite solution was prepared by diluting the 0.1M Nitrite 
Standard 1:1000 in distilled water. 
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- 3 columns (24 wells) were designated in the 96-well plate for the nitrite 
standard reference curve. 50μl distilled water was dispensed into well in rows 
B-H, as follows: 
A 100 100 100 ES ES ES ES ES ES ES ES ES 
B 50 50 50 ES ES ES ES ES ES ES ES ES 
C 25 25 25 ES ES ES ES ES ES ES ES ES 
D 12.5 12.5 12.5 ES ES ES ES ES ES ES ES ES 
E 6.25 6.25 6.25 ES ES ES ES ES ES ES ES ES 
F 3.13 3.13 3.13 ES ES ES ES ES ES ES ES ES 
G 1.56 1.56 1.56 ES ES ES ES ES ES ES ES ES 
H 0 0 0 ES ES ES ES ES ES ES ES ES 
ES, Experimental Sample 
- 100μl of the 100μM nitrite solution was added to the remaining 3 wells in row 
A. 
- A 6 serial 2-fold dilution (50μl/ well) was performed in triplicate down the 
plate to generate the nitrite standard reference curve: 
 
50μl 50μl 50μl 50μl 50μl 50μl 50μl 
 
12.5μM  6.25μM 3.13μM 1.56μM 25μM 50μM 100μM 
Discard 50μl 
 
 
 
 
- 50μl from the 1.56μM set of wells was discarded. No nitrite solution was 
added to the last set of wells (0μM). The final volume in each well was 50μl, 
and the nitrite concentration range is 0-100μl. 
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5.9.3. Assay Procedure 
 Reagent Blank Sample Standard 
Sample - 50μl - 
Standard - - 50μl 
Sulfanilamide 
Solution 
50μl 50μl 50μl 
Plate was protected from light and incubated at room temperature for 5 to 10 minutes 
NED Solution 50μl 50μl 50μl 
Plate was protected from light and incubated at room temperature for 5 to 10 minutes 
 
a) The absorbance of the purple/magenta colour was measured within 30 minutes 
in the plate reader at a wavelength of 550nm. 
b)  
5.9.4. Calculations 
A nitrite standard reference curve was generated as shown below: 
Nitrite Standard Curve
y = 0.0088x + 0.0416
R2 = 0.9999
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80 100 120
Nitrite Concentration (uM)
A
bs
or
ba
nc
e 
at
 5
50
nm
 
Fig. 5.9.4. Nitrite Standard Curve 
 
- The concentration of the test samples was calculated using the linear equation 
of the standard curve. 
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Std Abs1 Abs2 Abs3 Ave Abs 
Conc 
(uM) 
S1 0.912 0.926 0.938 0.925 100 
S2 0.476 0.479 0.477 0.477 50 
S3 0.261 0.260 0.264 0.262 25 
S4 0.155 0.157 0.152 0.155 12.5 
S5 0.103 0.097 0.097 0.099 6.25 
S6 0.070 0.069 0.069 0.069 3.13 
S7 0.054 0.052 0.050 0.052 1.56 
S8 0.061 0.031 0.037 0.043 0 
        
 Sample       
206 0.155 0.216  0.186 16.4 
208 0.149 0.139  0.144 11.6 
122 0.133 0.152  0.143 11.5 
156 0.109 0.115  0.112 8.0 
123 0.11 0.115   0.1125 8.1 
 
5.10. Lipid Hydroperoxide (LPO) Determination 
 
5.10.1. Principle   
Ferrous oxidation with xylenol orange (FOX VERSION II ) is based on the principle 
of the rapid peroxide-mediated oxidation of the Fe2+ to Fe3+ under acidic conditions. 
The latter in the presence of  Xylenol Orange, forms an Fe-Xylenol Orange complex 
which can be measured spectrophotometrically at 560nm (Nourooz-Zadeh et 
al.,1994). 
 
In this method, alkoxyl radicals generated in the ferrous oxidation step react rapidly 
with native lipid, generating further hydroperoxide in a chain reaction. Eqs. 1-4 
 
ROOH     +   Fe2+        ------>          Fe3+      +     RO•     +   OH-                           (1) 
 
RO•             + RH             ------>          ROH      +   R•                                               (2) 
 
R•            +  O2             ------>          ROO•                                                             (3)        
 
ROO•      +   RH           ------>          ROOH   +   R•                                               (4) 
 
R•            +    BHT       ------>          RH        +    BT                                              (5) 
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Inclusion of the chain-breaking antioxidant butylated hydroxytoluene (BHT) 
overcomes this problem. As shown in Eq.(5), BHT presumably repairs alkyl radicals 
produced by the reaction of alkoxyl radicals with unsaturated lipids [Eq. (2)]. 
Experimentally, BHT at a concentration of 4mM was found to provide a firm 
endpoint when measuring phosphatidyl-choline and low-density lipoprotein peroxide 
content. The FOX reagent was further adopted for the measurement of lipid 
hydroperoxides by the addition of methanol (90%, v/v) in order to solubilize the lipid 
and BHT. Sorbitol was omitted in the FOX reagent as the high concentration of 
methanol (>25M) in the revised method made the presence of sorbitol as an oxyl 
radical scavenger superfluous. 
 
5.10.2. Reagents and Preparation 
 
- Xylenol orange  (XO) 
- Ferrous ammonium sulfate   (Fe(NH4)2(SO4)2 
- Butylated hydroxytoluene   (BHT) 
- Sulphuric acid (H2SO4) 
- Methanol. HPLC grade. (MeOH) 
 
A. 250mM H2SO4 was prepared by diluting 13.88ml conc. H2SO4 (18M)  
with ddH2O to 1L. 
B. 4.4mM BHT /MeOH was prepared by dissolving 0.97g BHT in 1L HPLC 
grade MeOH. 
C. Stock FOX solution: 1mM XO / 2.5mM Fe(NH4)2(SO4)2 in 250mM H2SO4 
was prepared by dissolving 0.76g XO and 0.98g Fe(NH4)2(SO4)2 in 1L  
250mM H2SO4. 
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D. Working FOX II solution: 1ml stock FOX II solution was added to 9ml 
BHT/MeOH solution.  This was freshly prepared before use. 
E. The following concentrations of H2O2 were prepared (using 30% Sigma 
H2O2 which is equivalent to 8.82M): 
- Stock standard 8.82mM H2O2 was prepared by diluting 1ml 30% H2O2 
(8.82M) to 1L. Thereafter, the following standards were prepared: 
 
 4.4μl of stock standard was made up to 10ml  ≡ 3.9μM 
 8.8μl  “                ≡ 7.81μM 
 17.5μl  “    ≡ 15.62μM 
 35.0μl  “    ≡ 31.25μM 
 70.0μl  “    ≡ 62.50μM   
5.10.3. Assay Procedure 
 
 
             Sample and Reagents 
 
        Volume   
 
                      Remarks 
Plasma / Blank / Std              50μl 1.5ml microfuge vials were used 
and work done in duplicate 
Working FOX II reagent 
 
        
           950μl 
 
The solution was vortexed 
 
 
 
It was then incubated at room 
temp. for 30min 
       
       
 
Microfuge vials were centrifuged at 
12,000g for 5min. to remove all 
flocculated materials 
Absorbance of supernatant was read at 
540nm 
 
  
 
The blank included only the FOXII reagent 
 
 
5.10.4. Calculation 
The concentrations of the samples were calculated from the equation of the standard 
curve. An example of a spreadsheet follows. 
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Fig. 5.10.4. Lipid Peroxidation Standard Curve 
 
Standards Abs1 Abs2 Ave Abs (- blank) 
Conc 
(uM) 
Blank 0.323 0.330 0.327 0 0 
S1 0.322 0.350 0.336 0.010 3.9 
S2 0.337 0.329 0.333 0.007 7.8 
S3 0.345 0.340 0.343 0.016 15.6 
S4 0.360 0.392 0.376 0.050 31.3 
S5 0.421 0.435 0.428 0.102 62.5 
        
Samples       
4105 0.404 0.381 0.3925 0.066 41.1 
4106 0.415 0.474 0.4445 0.118 71.7 
4107 0.399 0.449 0.424 0.098 59.7 
4108 0.386 0.411 0.3985 0.072 44.7 
4109 0.434 0.574 0.504 0.178 106.7 
4143 0.469 0.469 0.469 0.143 86.1 
 
 
5.11. 8-Isoprostane (8-IP) 
 
5.11.1. Principle 
This ELISA procedure is based on the competition between 8-IP and an 8-IP-
acetylcholinesterase (AChE) conjugate (8-IP tracer) for a limited number of 8-IP-
specific rabbit antiserum binding sites. Because the concentration of the 8-IP tracer is 
held constant while the concentration of 8-IP varies, the amount of 8-IP tracer that is 
able to bind to the rabbit antiserum will be inversely proportional to the concentration 
of 8-IP in the well. The rabbit antiserum-8-IP (either free or tracer) complex binds to 
 95
the mouse monoclonal anti-rabbit IgG antibody that has been previously attached to 
the well. The plate is then washed to remove all unbound reagents and the Ellman’s 
reagent (which contains the substrate to AChE) is added to the well. The product of 
this enzymatic reaction has a distinct yellow colour that is measured 
spectrophotometrically at 412nm. The absorbance is directly proportional to the 
[Bound 8-IP Tracer] and inversely proportional to [8-IP]. 
 
5.11.2. Reagents  
8-IP kit (Cayman Chemicals, USA) was used. The kit contained the following: 
a)  Mouse anti-rabbit IgG coated plate. 
b) 8-IP EIA antisera 
c) 8-IP AChE tracer 
d) 8-IP EIA standard 
e) EIA buffer concentrate 
f) Wash buffer concentrate 
g) Tween 20 
h) Ellman’s Reagent 
 
5.11.3. Assay procedure 
 
- Reconstitution of reagents was done according to the manufacturer’s 
instructions using Ultra Pure water (from Cayman). Additionally, the 
mapping of the plate was designed as recommended by the manufacturer. 
Wells to cater for blanks, “Non-specific binding” (NSB), “minimum 
binding” (Bo) and “total activity or maximum binding” (TA) were 
incorporated. Assay was performed in triplicates. 
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- 50μl of standards and samples were added to the appropriate wells.  
- 50μl of 8-IP AChE Tracer was again added to each well except the TA and 
the blank wells. 
- 50μl 8-IP antiserum was  added to each well except the TA, NSB and 
blank wells.  
- The plate was covered with a plastic film and incubated for 18hrs at room 
temp. 
- Wells were emptied and washed 5x with the wash solution. 
- 200μl of Ellman’s solution was added to each well. 
- 5μl of Tracer was then added to the TA wells.  
- Plate was again covered with a plastic film and kept in the dark for 60-90 
min for the colour to develop. 
- The colour typically developed when Bo read 0.3-0.8A.U. at 405nm. 
5.11.4. Calculations 
 
8-isoprostane Standard Curve y = 2848.4e-0.0609x
R2 = 0.9536
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Fig. 5.11.4. 8-Isoprostane Standard Curve 
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  Abs1(mU) Abs2(mU) Corrected Corrected %Abs/Abs(max)   Mean A&B 
8IP 
conc.(pg/ml) 
      (-Av.NSB)   [%B/Bo] [%B/Bo] (%B/Bo)   
      (-0.011)           
S1 139 147 139.0 147.0 21.1 22.3 21.7 3000
S2 283 263 283.0 263.0 42.9 39.9 41.4 1500
S3 342 381 342.0 381.0 51.9 57.8 54.9 750
S4 438 601 438.0 601.0 66.5 91.2 78.8 375
S5 617 766 617.0 766.0 93.6 116.2 104.9 187.5
S6 1048 918 1048.0 918.0 159.0 139.3 149.2 93.8
S7 1160 1063 1160.0 1063.0 176.0 161.3 168.7 46.9
S8 1303 1252 1303.0 1252.0 197.7 190.0 193.9 23.4
                  
  Abs1 Abs2 Abs3 Mean Abs Corrected %B/Bo 
Mean 
%B/Bo 
8IP 
conc.(pg/ml) 
                  
4124 73 70 73 72.0 72.0 10.9   2973
4156 35 31 35 33.7 33.7 5.1 8.0 3470
4117 51 50 58 53.0 53.0 8.0   3209
4119 42 35 39 38.7 38.7 5.9   3401
4141 15 14 31 20.0 20.0 3.0   3667
4144 56 108 45 69.7 69.7 10.6   3001
4146 66 75 67 69.3 69.3 10.5   3005
4148 22 35 33 30.0 30.0 4.6   3522
4151 64 59 74 65.7 65.7 10.0   3049
4157 54 66 66 62.0 62.0 9.4   3095
4158 68 58 58 61.3 61.3 9.3 7.9 3103
 
 
5.12. 8-Hydroxy-2’deoxyguanosine (8OHdG) Determination 
 
5.12.1. Principle 
 
The 8OHdG test is a competitive in vitro enzyme-linked immunosorbent assay for the 
quantitative measurement of the oxidative DNA adduct 8-hydroxy-2’-deoxyguanosine 
(8OHdG) in tissue, serum and plasma. 8OHdG monoclonal antibody and the sample 
(liver tissue homogenate) are added to a microtiter plate that has been pre-coated with 
8OHdG. The 8OHdG monoclonal antibody reacts competitively with the 8OHdG in 
the tissue and that immobilized on the microtiter plate. Therefore, higher 
concentrations of 8OHdG in the tissue sample will lead to a reduced binding of the 
antibody to the 8OHdG on the plate. The antibodies that are bound to the 8OHdG in 
the tissue sample are washed away from the antibodies that are bound to the 8OHdG 
on the microtiter plate. 
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An enzyme-labelled secondary antibody that is added to the plate, binds to the 
monoclonal antibody that is bound to the 8OHdG coated on the plate. Unbound 
enzyme-labelled secondary antibody is removed by a wash step and the addition of a 
chromatic substrate results in the development of colour in proportion to the amount 
of antibody bound to the plate. Finally, the reaction is terminated by the addition of 
1M phosphoric acid and the absorbance read at 450nm on a microplate plate reader. 
 
5.12.2. Reagent Preparation 
8OHdG kit purchased from the Japanese Institute for the Control of Aging, Japan, 
was used. The kit contained the following: 
 
1. 8OHdG Micrtiter plate  : precoated with 8-OHdG (8x12 wells, split 
type). 
2. Primary antibody   : monoclonal antibody specific for 8OHdG. 
3. Primary antibody solution  : phosphate buffered saline. 
4. Secondary antibody  : horseradish peroxidase-conjugated antibody 
5. Secondary antibody solution : phosphate buffered saline. 
6. Chromatic solution   : 3,3’,5,5’-tetramethylbenzidine. 
7. Diluting solution   : H2O2 / citrate-phosphate buffered saline. 
8. Washing solution (5 times)  : 5 times concentrated phosphate buffered saline. 
9. Reaction terminating solution : 1M phosphoric acid 
10. 8-OHdG standards  : 0.5, 2.0, 8.0, 20.0, 80.0, 200.0 ng/ml 
 
5.12.3. Assay Procedure: 
 
The assay procedure is represented by a flow chart below. 
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Preparation of Reagent 
         Primary Antibody Incubation 
      Plate was washed
Preparation of  
Enzyme Substrate
    Absorbance Reading 
   Substrate Incubation
  Reaction Termination Step
      Secondary Antibody Incubation
     Plate was washed
50μl of primary antibody was added 
100μl of secondary antibody solution was added
250μl wash solution was added per wash 
3 times
100μl of reconstituted enzyme substrate was added
3 times
Incubated at room temp. for 15min in the dark.  
Light blue colour develops 
Incubated at room temperature for 1 hr. 
Incubated at 4oC for overnight 
100ul of reaction termination solution was added
The light blue colour changed to yellow 
Wavelength at 450nm
Secondary antibody 
250μl wash solution was added per wash
  
50μl of tissue sample or standard was added 
  Sample Pretreatment
Primary antibody 
 
 
Calculation of Results 
 
Well A1 on the plate was designated blank. Primary antibody was not added to this 
well. 
 
 100
5.12.4. Calculation 
A standard curve of absorbance against concentration was plotted as shown. 
Standard Curve for 8-OHdG
y = 1.6614e-0.2112x
R2 = 0.9964
0
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Fig. 5.12.4. 8-Hydroxyguanosine Standard Curve 
 
 Standards Abs1 Abs2 
Mean 
Abs 
8-OHdG 
(ng/ml) 
S1 1.683 1.615 1.649 0.125 
S2 1.456 1.59 1.523 0.25 
S3 1.532 1.49 1.511 0.5 
S4 1.396 1.31 1.353 1 
S5 0.705 0.721 0.713 4 
S6 0.293 0.522 0.408 10 
       
  Abs1 Abs2 
Mean 
Abs 
8-OHdG 
(ng/ml) 
Samples      
5 0.44 0.50 0.47 1.01 
37 0.83 0.80 0.8 1.08 
3 0.42 0.43 0.43 1.01 
4 0.48 0.50 0.49 1.02 
22 0.25 0.23 0.24 0.97 
25 0.44 0.46 0.45 1.01 
27 0.26 0.27 0.26 0.98 
29 0.53 0.46 0.50 1.02 
32 0.34 0.30 0.32 0.99 
38 0.62 0.60 0.61 1.04 
39 0.22 0.20 0.2 0.97 
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5.13. Ames Mutagenicity Assay (Maron DM and Ames BN, 1983) 
 
5.13.1. Introduction 
Normal metabolism produces oxidants that are by-products. These oxidants such as 
•O2 and H2O2, are the same mutagens produced by irradiation and cause damage to 
DNA, proteins and lipids. Two factors are critical for the formation of mutagens: 
lesions in DNA formed when DNA is damaged, and cell division which converts 
DNA lesions to mutagens.  
 
5.13.2. Principle 
A test for determining if a chemical is a mutagen is the Ames Mutagenecity Test 
named after Bruce N Ames. The Ames test is based on the assumption that any 
substance that is mutagenic (for the bacteria used in this test) may also turn out to be a 
carcinogen. However, some substances that cause cancer in laboratory animals do not 
give a positive Ames test (and vice-versa). The low cost of the test makes it 
invaluable for screening substances in our environment. 
 
The bacterium used in the test is a strain of Salmonella typhimurium that carries a 
defective (mutant) gene, making it unable to synthesize the amino acid histidine (His) 
from the ingredient in its culture medium. However, some types of mutations 
(including this one) can be reversed, (a back mutation) with the gene regaining its 
function. These revertants are able to grow in a medium lacking histidine. 
Furthermore, many chemicals are not mutagenic (or carcinogenic) by themselves, but 
become converted to mutagens (and carcinogens) as they are metabolized in the body. 
For this reason, the Ames test includes a mixture of liver enzymes. 
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5.13.3. The Bacteria Tester Strain 
A set of histidine-requiring strains is used for mutagenicity testing. Each tester strain 
contains a different type of mutation in the histidine operon. In addition to the 
histidine mutation, the standard tester strains contain other mutations that greatly 
increase their ability to detect mutagens. One mutation (rfa) causes partial loss of the 
lipopolysaccharide barrier that coats the bacteria and increases permeability to large 
molecules that do not penetrate the normal cell wall. The other mutation (uvrB) is a 
deletion of a gene coding for the DNA excision repair system, resulting in greatly 
increased sensitivity in detecting many mutagens. The deletion excising the uvrB gene 
extends through the bio-gene and consequently, these bacteria also require biotin for 
growth. The standard tester strains mostly used are TA97, TA98, TA100, TA102. 
TA97  }  Contains R-factor plasmid, pKM 101. This increases  
TA98  }  chemical and spontaneous mutagenesis by enhancing  
TA100  }  an error-prone DNA repair system. 
TA102  }  Contain multiple plasmid, pAQ1, which carries the hisG428 
      Mutation and the tetracycline resistant gene. 
Additionally,  
TA100  - hisG gene (encoding for the first enzyme of histidine biosynthesis)  
  hisG46 mutation. This mutation substitutes proline -GGG- for leucine -GAG-
  Therefore TA100, detects mutagens that cause base-pair  
substitutions primarily at one of these G-C pairs. 
TA98  - hisD gene (Coding for histidinol dehydrogenase) 
hisD3052 mutation. Detects various frame-shift (FS) mutations.  
These FS mutations can stabilize the shifted pairing that often occurs 
in repetitive sequences or ‘hot spots’ of the DNA, resulting in a frame-
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shift mutation which restores the correct reading frame for histidine 
synthesis. The his D3052 has the sequence -CGCGCGCG- , 8 repetitive –
GC residues near the site of a FS mutation in the hisD gene.  The 
mutation is reverted by i.e. 2-nitrosofluorene, daunomycin. 
TA97  - hisD6610 mutation, plus a second ‘hot spot’ of alternating -GC-  
base pairs near the run of the cytosines. It is sensitive to some of the 
mutagenes that revert TA98. 
TA102 - hisG gene contains the ochre mutation -TAA- . This strain detects 
efficiently a variety of mutagens such as formaldehyde, glyoxal, 
hydroperoxides, bleomycin, X-rays, UV light.   
 
5.13.4. Reagent List and Preparation 
Oxoid Nutrient Broth     No. 2 
Bacto Difco Agar 
NaCl 
L-Histidine 
D-Biotin 
KCl 
MgCl2.6H2O 
NaH2PO4
Na2HPO4
NADP 
G-6-PO4
MgSO4.7H2O 
K2HPO4
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NaHNH4PO4.4H2O 
Citric acid monohydrate 
Glucose 
Daunomycin 
Ampicillin 
Crystal Violet 
DMSO 
Nutrient Broth  (autoclaved) 
- Oxoid nutrient broth  - 1.25g 
- dH2O    - 50ml 
Nutrient Agar Plates (contains histidine)  (autoclaved) 
- Oxoid nutrient broth  - 4.8g 
- Bacto agar   - 9.0g 
- dH2O    - 600ml 
Top Agar  (autoclaved) 
- Bacto agar   - 0.6g 
- NaCl    - 0.5g 
- dH2O    - 100ml 
Vogel-Bonner Medium E (VB medium)  (autoclaved) 
- ddH2O    - 670ml 
- MgSO4.7H2O   - 5g 
- Citric acid monohydrate - 50g 
- K2HPO4  or  K2HPO4.5H2O - 250g or 327.59g 
- NaHNH4PO4.4H2O  - 78.5g 
were added in the above order. 
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were added after each compound had dissolved. 
Minimum Glucose Plates   
- Bacto agar    - 15g 
- dH2O    - 910ml 
The above-mentioned was autoclaved. 
added 25X VB medium E  - 40ml 
added 40% glucose   - 50ml 
Histidine / Biotine Soln (autoclaved)  
Per 250ml 
- D-Biotin (FW 247.3)  - 30.9mg 
- L-Histidine   - 24.0mg 
0.1M Hitidine Soln (autoclaved) 
- L-Histidine   - 1.55g/100ml 
0.5mM Biotin Soln  (autoclaved) 
- D-Biotin   - 0.012g/100ml 
0.1% Crystal violet Soln
- Crystal violet   - 0.01g 
- ddH2O    - 10ml 
Daunomycin  (daunorubicin hydrchloride)  
- Daunomycin   - 1mg / ml 
Glucose-6-phosphate (G-6-P) 
- G-6-P    - 2.82g/10ml 
 
Nicotine adenine dinucleotide phosphate (NADP) Soln  
- NADP (FW 765.4)  - 383mg / 5ml 
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1.65M KCl / 0.4M MgCl2 Salt Soln  (Per 100ml) 
- KCl    - 12.3g 
- MgCl2.6H2O   - 8.14g 
0.2M Sodium phosphate buffer  ( 60ml  A + 440ml B) 
- 0.2M NaH2PO4.H2O  - 13.8g/500ml………A 
- 0.2M Na2HPO4  - 14.2g/500ml………B 
S9 Mix (rat liver microsomal enzymes + co-factors)  
-  Purchased from Moltox (Molecular Toxicology Inc., Boone, USA). 
-  S9 Mix was diluted 1:3 in 0.15M KCl 
 
5.13.5. Preparation of Liver Tissue for Ames Test 
- 3g of liver tissue was homogenized in 9ml of KCL (0.15M) 
 - 0.15M KCl was prepared by adding 74.56g KCl to 100ml of distilled water. 
 - Preparation was then autoclaved. 
- After homogenizing liver tissue, 1 ml of this homogenate was extracted and 
 stored. This is known as the whole homogenate. 
- The remaining homogenate was then centrifuged at 9000rpm for 10 minutes at 
 4°C. 
- The resulting supernatant was retrieved and stored. This is known as the S9 
 fraction. 
- The volume of S9 retrieved was measured and replaced with an equal 
 volume of 0.15M KCl. 
- The mixture was then homogenized. 1ml was then extracted. This is known as 
 the nucleosomal homogenate. 
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-  The remaining mixture was then transferred into Beckman tubes and 
 ultracentrifuged at 40 000rpm for 1 hour at 4°C. 
- The resulting supernatant was then removed and stored as the cytosolic 
 fraction. 
- The volume of supernatant removed was replaced with 0.15M KCl. The 
 mixture was homogenized and stored as the microsomal fraction. 
5.13.6. Characterization of TA97, TA98, TA100, TA102 strains (donated by 
Ames Lab, USA). 
A. Upon receipt of discs impregnated with the Salomonella strains, each disc was 
dropped into separate tubes containing 10ml nutrient broth and incubated 
overnight at 37oC. with shaking. 
B. The overnight culture was plated on nutrient agar plates to obtain single 
colonies and incubated at 37oC overnight. (This is referred to as the master 
plate.) 
C. Six (6) culture tubes were filled with 10ml nutrient broth. Single colonies were 
transferred into each of the tubes and incubated overnight at 37oC with 
shaking. 
D The following markers were performed on each of the tubes and the tube that 
satisfied all criteria was selected. Where none was suitable a repeat was 
carried out using single colonies from step B. 
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5.13.6.1 Test for Histidine Requirement 
- Requirement  - Minimum glucose plates 
- 0.1M Histidine 
- 0.5M Biotin 
- dH2O (autoclaved) 
- Two circles were marked on the bottom of the culture plates and labeled H2O 
& H/B. (Figure 15.13.6). 
- A sterile loop was dipped into autoclaved ddH2O and plated within the H2O 
circle. Similarly, a loop-full of 0.1M Histidine was plated within the H/B 
circle ff by a loop-full of 0.5M Biotin. 
- Finally a loop-full i.e. TA97 from one of the six tubes was plated within the 
ddH2O circle and another within the H/B circle. 
 - The a/m procedure was repeated for two other minimum glucose plates. Thus, 
triplicates were produced for each of the 6 tubes. 
- The whole procedure for each of the 6 tubes of TA98, TA100 & TA102 was 
repeated. 
- The minimum glucose plates were incubated at 37oC overnight. 
 
5.13.6.2 rfa (Permeability) Test 
- Requirement  - Nutrient agar plates (NA) 
    - Top agar 
    - 0.1% Crystal violet soln
- The Top agar was placed in a water bath with temperature 45oC. 
- 2.5ml of Top agar was dispensed into culture tubes and capped. 
- 0.1ml i.e. TA98 was added to each tube and vortexed for about 5sec.  
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- This was quickly poured onto the NA plate. The plate was gently swirled to 
allow even distribution. 
- Work was done in triplicate. 
- The above procedure was repeated for the other strains.         
- An HPLC syringe was rinsed with HPLC MeOH. Using the syringe, 10μl of 
the crystal violet solution was drawn onto an autoclaved filter paper disc.  
- The crystal violet-soaked disc was placed in the center of the plate (i.e. TA98 
plate).  
- For all 6 tubes of TA97, TA98, TA100, TA102 the above-mentioned 
procedure was repeated. Sterile filter paper discs were handled by flamed 
forceps. 
- The Nutrient agar plates were incubated at 37oC for 24hr (Figure 15.13.6). 
 
5.13.6.3 uvβ    Mutation Test 
- Requirement  - NA Plates 
- Work was done in triplicates and plates labeled TA98, TA100 etc. 
- A line was drawn under each plate (dividing it into two halves) 
- A loop-full of i.e. TA 97 from tube 1 was streaked across the plate. In all 4-6 
parallel streaks were made. Two streaks were made from each tube. 
Additionally, streaks were made at right angles to the dividing line. Samples 
from all 6 tubes of i.e. TA97 were treated in a similar manner.  
- A piece of sterile cardboard or paper towel (sprayed with 70% EtOH) was 
placed across the plate along the vertical line that divided the plate. 
- The plates were irradiated by a 15W UV lamp for 6sec at a vertical distance of 
about 33cm from above (Figure 15.13.6). 
- Finally, the plates were incubated at 37oC for 12-24hrs. 
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5.13.6.4 R-factor  Test 
- Requirement  - Minimum glucose plates 
    - Top agar 
    - 0.5mM His/Bio Soln  
- 10ml of His/Bio Soln was added to the Top agar held at 45oC. 
- 2.0ml of the Top agar (with His/Bio) was added to culture tubes (incubating at 
37oC). 
- 0.1ml of i.e. TA98 (tube 1) was then added to each of the tubes containing the 
Top agar. 
- This was vortexed for 3sec and quickly poured onto the Minimum glucose 
plate. The plate was swirled gently and the Top agar allowed to settle.  
- Ampicillin discs (Bacto - sensitivity disc 10 μg 6363-33 DIFCO) was gently 
dropped onto the plates.  
- The procedure was repeated for all 6 tubes of i.e. TA98, TA100, TA102 & 
TA97. 
- Plates were incubated at 37oC for 48 hr (Figure 15.13.6). 
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Figure 15.13.6   Characterization of Salmonella strains using the various 
markers. 
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5.13.6.5 Spontaneous Revertant Test 
 
- Requirement  - Nutrient agar plates 
- Top agar 
- 0.5mM Histidine/Biotin Soln
- Five plates were prepared for each of the 6 tubes from a particular strain i.e. 
TA97(1), TA97(2)……..TA97(6). 
- The Top agar was incubated at 45oC and the culture tubes at 37oC. 
- 2.5ml Top agar was dispensed into each (cupped) culture tube under sterile 
conditions. 
- 0.6ml of the tester strain i.e. TA97(1) was quickly pipetted and 0.1ml was 
 dispensed into the five culture tubes. 
- The culture tube was vortexed for 3sec. and quickly poured onto the Nutrient 
agar plate. 
- The labeled culture plate was gently swirled on a flat top and allowed to settle. 
-  The above procedure was repeated for all samples and culture plates were 
incubated at 37oC for 48 hrs undisturbed. 
- Colonies (revertants against the background lawn) were counted (i.e. Figure 
 16l).  
- For TA97, the acceptable range was:             90-180 colonies  
                 TA98,   “  30-50        “ 
                 TA100,   “  120-200      “ 
                 TA102,   “  240-360      “ 
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Finally, one tube from each Salmonella typhimurium strain that strictly adhered to all 
five conditions was selected. The selected tube was referred to as “master copies”. 
Master copies were stored at 4oC and used over the next few days. Master plates (first 
culture, 8.16.5 sec B) were stored at -70oC for some few months. For long term 
storage the following procedure was followed:    
- 50ml of Nutrient broth was prepared and autoclaved for each strain. 
- The Nutrient broth was allowed to partially cool down. This was incubated for 
30 min with continuous shaking at 37oC.        
- The 50ml Nutrient broth was inoculated with 1ml of the cultured bacteria from 
the selected tube and incubated for 12hrs, with continuous shaking at 37oC. 
- 0.09ml DMSO (filtered through a 0.22μm filter) was added per 1ml of culture 
and gently mixed. 1ml was then aliquot into ‘nunc’ tubes. This was stored at -
70oC for years. 
5.13.6.6 Mutagenicity Test 
- The procedure was the same as that described for the Spontaneous revertant 
test. However, 0.1ml of the suspected mutagenic substance was first added to 
the 2.0ml Top agar, followed by 0.1ml of the tester strain i.e. TA97. 
- Test samples were challenged with 0.1ml S9 mix. This was added to the Top 
agar.  
 
 
 
 
 
 
 
 
 
 
 
 
 114
Histidine requirement test
Rfa test (Permeability)
uvβ test (Mutation)
R-factor test (Ampicillin )
Spontaneous reversion test
• 2.0ml Top agar 
• 0.1ml Substance X 
• 0.1ml TA97                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13.7.  Summary of the steps involved in the characterization of the 
Salmonella tester strains. 
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5.14.Cytokines 
5.14.1. Principle 
The Bio-Plex cytokine reagent kit (BioRad, UK) is a suspension array system built 
around the following three core technologies: 
 
1) The family of fluorescently dyed microspheres (beads) to which biomolecules 
are bound. 
2) A flow cytometer with two lasers and associated optics to measure reactions 
that occur on the surface of the microspheres 
3) A high-speed digital signal processor that efficiently manages the fluorescent 
output 
 
The Bio-Plex suspension array system uses multiplexing technology that uses up to 
100 colour-coded bead sets, each of which can be conjugated with a different specific 
reactant. Each reactant is specific for a different target molecule. Three different sets 
of colour-coated beads were used, each designated to IL-1β, IL-6 and IL-10 detection. 
The cytokine assays are designed in a capture sandwich immunoassay format. 
Antibodies specifically directed against the cytokine of interest are covalently coupled 
to a colour-coded 5.5 μm polystyrene bead. Antibody-coupled beads are allowed to 
react with a sample containing an unknown amount of cytokine, or with a standard 
solution containing a known amount of cytokine. A series of washes are performed to 
remove any unbound protein. Thereafter a biotinylated detection antibody specific for 
a different epitope on the cytokine is added to the beads. The result is the formation of 
a sandwich of antibodies around the cytokine. The reaction mixture is detected by the 
addition of streptavidin-phycoerythrin (strepatavidin-PE), which binds to the 
biotinylated detection antibodies. The constituents of each well are drawn up into the 
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flow-based Bio-Plex suspension array system, which identifies and quantitates each 
specific reaction based on bead colour and fluorescence. The magnitude of the 
reaction is measured using fluorescently labeled reporter molecules associated with 
each target protein. Unknown cytokine concentrations are automatically calculated by 
the Bio-Plex Manager software using a standard curve derived from a recombinant 
cytokine standard.  
 
5.14.2. Reagents 
Bio-Plex Cytokine Reagent Kit contains the following: 
- Bio-Plex Assay Buffer 
- Bio-Plex Wash Buffer 
- Bio-Plex Detection Antibody Diluent 
- Streptavidin PE (100x) 
- Anti-cytokine Conjugated Beads (25X Concentration) 
- Cytokine Detection Antibody (50X Concentration -70 µl) 
- Cytokine Standard (2 vials, lyophilized) 
Bio-Plex Rat Serum Diluent Kit: 
- Bio-Plex Rat Serum Sample Diluent 
- Bio-Plex Rat Serum Standard Diluent 
Note: This assay was performed on a Bio-Plex Luminex 100 System 
 
5.14.3. Reagent Preparation 
All preparations were kept on ice throughout preparation procedures. 
a) 1 volume of serum was diluted with 3 volumes of Bio-Plex sample diluent. 
(30μl sample was diluted with 90μl of diluent). 
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b) Reconstitution of the cytokine standard was performed as follows: A 30 
second quick-spin centrifugation of the lyophilized standard was followed by 
reconstituting 1 tube of lyophilized cytokine standard with 500 μl of rat serum 
diluent. Brief mixing followed and the cytokine standard was stored on ice for 
30 minutes. 
c) Preparation of the standards: (Two sets of standards were prepared 
representing two sets of concentrations) 
 
Table 5.14.3a. 1.95-32000 pg/ml Cytokine Standard Curve 
 
128μl 
 
 
 
 
 
 
Multiplex 
Standard 
Stock 
(50000pg/ml) 
        
Concentration 
(pg/ml) 
32000 8000 2000 500 125 31.3 7.8 1.95 
Stock (μl) 128 50 50 50 50 50 50 50 
Standard 
Diluent (μl) 
72 150 150 150 150 150 150 150 
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Table 5.14.3b. 0.2-3200 pg/ml Cytokine Standard Curve 
 
12.8μl 
 
 
 
 
 
 
Multiplex 
Standard 
Stock 
(50000pg/ml) 
        
Concentration 
(pg/ml) 
3200 800 200 50 12.5 3.13 0.78 0.2 
Stock (μl) 12.8 50 50 50 50 50 50 50 
Standard 
Diluent (μl) 
187.2 150 150 150 150 150 150 150 
 
d) Conjugated bead preparation: Beads were protected from light by covering 
with aluminum foil. The anti-cytokine conjugated beads were vortexed at a 
medium speed for 15-20 seconds. 240μl of the (25X) stock beads was added to 
5760 µl of the Bio-Plex assay buffer to give a total volume of 6000 µl. 
 
e) Detection antibody preparation: A 30 second quick spin centrifugation was 
performed on the detection antibody vial prior to pipetting, so as to collect the 
entire volume at the bottom of the vial. 120µl of the 50X stock detection 
antibody was added to 2880µl of the detection antibody diluent giving a total 
volume of 3000µl. 
 
f) Streptavidin-PE Preparation: A 30 second quick spin centrifugation of the 
streptavidin-PE vial was performed prior to pipetting. 60µl of the (100X) 
streptavidin-PE was diluted with 5940µl of the Bio-Plex assay buffer giving a 
total volume of 6000µl. This solution was stored in the dark until ready for 
use. 
5.14.4. Assay Procedure 
The assay procedure is represented by the flow chart below. 
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 1. Power up Bio-Plex System 
2. Pre-wet FILTER 
PLATE with 200μl 
ASSAY BUFFER 
(Leave with buffer 
for 1 hour) 
3. Vortex BEADS and add 50μl to 
wells 
4. Add STANDARDS 
and SAMPLES (50μl) 
5. Seal PLATE, 30 sec at 1100rpm, 60 min at 300rpm at room 
temperature and in the dark 
6. Vortex DETECTION ANTIBODY, Add 
25μl to wells 
7. Seal PLATE, 30 sec at 1100rpm, 30 min at 300rpm at room 
temperature and in the dark 
8. Vortex STREPTAVIDIN-PE, Add 50μl to 
wells 
9. Seal PLATE, 30 sec at 1100rpm, 10 min at 300rpm at room 
temperature and in the dark 
10. Add 125μl of ASSAY BUFFER to 
wells 
11. Seal PLATE, 30 sec at 1100rpm, Remove Seal, Immediately 
Read PLATE 
Filter
100μl of Wash Buffer was used to filter wash (2X)
100μl of Wash Buffer was used to filter wash (3X)
100μl of Wash Buffer was used to filter wash (3X)
100μl of Wash Buffer was used to filter wash (3X)
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5.14.5. Calculations 
 The assay was run on the Luminex 100 System. An example of data presentation 
generated by the software is shown below. 
 
Type Well Outlier Sample FI 
FI - 
Bkgd 
Std 
Dev %CV
Obs 
Conc 
Exp 
Conc 
(Obs/Exp) * 
100 
B G11,H11 0  74 74 1.41 1.91     
S1 A1 1  --- ---    32000   
S2 B1 0  24973 24899 0 0 6779 8000 85
S3 C1 0  15475 15401 0 0 2166 2000 108
S4 D1 0  4834 4760 0 0 518 500 104
S5 E1 0  1262 1188 0 0 121 125 96
S6 F1 0  371 297 0 0 30 31 94
S7 G1 0  144 70 0 0 8 8 97
S8 H1 0  81 7 0 0 2 2 91
S9 A2 0  20544 20470 0 0 3664 3200 115
S10 B2 0  6187 6113 0 0 681 800 85
S11 C2 0  2515 2441 0 0 255 200 127
S12 D2 0  557 483 0 0 48 50 96
S13 E2 0  226 152 0 0 15 12.5 123
S14 F2 0  93 19 0 0 3 3.1 91
S15 G2 0  72 -2 0 0 1 0.8 126
S16 H2 1  --- ---    0.2   
X1 A3,B3 0 228 277 204 9 4.5 81.1    
X2 C3,D3 0 222 134 61 2 3.5 26.6    
X3 E3,F3 0 247 235 161 21 13.2 64.7    
X4 G3,H3 0 276 107 34 8 23.2 16.6    
X5 A4,B4 0 314 229 155 10 6.4 62.4    
X6 C4,D4 0 315 345 271 6 2.4 107.4    
X7 E4,F4 0 190 119 45 21 46.1 20.7    
X8 G4,H4 0 191 108 34 6 16.6 16.8    
X9 A5,B5 0 325 199 125 37 29.4 50.9    
X10 C5,D5 0 189 169 95 15 15.7 39.3     
 
5.15. Hydroxyproline 
The following protocol was taken from Ruwart et al. (1989). 
5.15.1. Reagents and Preparation 
a) 6N HCl 
b) 50% isopropanol 
c) 0.84% chlormaine-T solution 
d) Ehrlich’s Solution: 1ml Ehrlich’s Reagent + 4ml acetone 
e) Hydroxyproline standard  
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5.15.2. Assay Procedure 
- Liver tissue was homogenized in a weight to volume ratio of 3:1 in 6N HCl. 
- This homogenate was then hydrolyzed at 110°C for 16 hours. 
- The hydrosylate was then filtered.  
- 25μl aliquotes of filtered hydrosylate were then dried in triplicate at 90°C. 
- The sediment was then dissolved in 1.2ml of 50% isopropanol. 
- 0.2ml of 0.84% chloramine-T solution was added. 
- 1ml of Ehrlich’s solution was added after 10 minutes. 
- The mixture was then incubated at 50°C for 90 minutes, and allowed to cool 
 thereafter at room temperature. 
- The absorbencies of the samples were then read against a reagent blank at 
 558nm. Reagent blank contained the complete system without the added 
 tissue. 
- The concentration of hydroxyproline in each sample was determined from a 
 standard curve generated from known quantities of hydroxyproline which had 
 been hydrolyzed as above (Range of standard curve:0-100μM/g liver). 
 
5.15.3. Calculations 
- Absorbance values obtained were multiplied by the dilution factor of 4 and the 
 following standard curve used to find the concentration of hydroxyproline. 
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Hydroxyproline Standard Curve
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Fig. 5.15.3. Hydroxyproline Standard Curve 
 
5.16. AFP and Haematological Differentials 
 
AFP was determined using an auto-analyser (Advia Centaur) and kits from Bayer 
(Tarrytown, USA). Haematological differentials were determined using an auto-
analyser (Cobas Integra 400) and kits from Roche Diagnostics (Indianapolis, USA). 
Haematological differentials measured include: haemoglobin concentration, white 
blood cell count (WBC), red blood cell count (RBC), Platelet count and mean platelet 
volume (MPV). 
 
5.17. Statistics 
 
Statistical Analysis was be performed by an independent student’s t-test at the level of 
0.05 for unpaired and paired data. A probability value of <0.05 was considered 
statistically significant. For multiple groups, analysis of variance was performed by 
Bonferroni (Dunn) Multiple comparison t-test. Two-way analysis of variance was 
used to determine the effect of time on parameters, with a Tukey post hoc test being 
used to determine specific group significance. Pearson’s correlation was determined 
across groups. The GraphPad Instat software (San Diego, USA) was used to perform 
basic student’s t-tests. The Statistica software by Statsoft Inc.  (Tulsa, OK) was used 
to perform the analysis of variance and correlations. 
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6.0. Results 
 
The focus of this study was to investigate the synergy and extent thereof between 
dietary iron overloading and AFB1 in hepatocarcinogenesis in an animal model. In 
terms of presenting the acquired data, the focus will be on representing the synergy 
observed. Hence, data shown in the results section will contain only those which show 
synergy. Assays not showing synergy will be mentioned, and detailed representations 
thereof are available in the appendix. Synergy will be defined as a significant 
difference between the (Fe + AFB1) group in comparison to the Fe and / or the AFB1 
groups. The extent of synergy will be described as a ratio calculated as follows:  
 
 
Fe group  + AFB1 group : Fe + AFB1 group 
 
 
This ratio will be referred to as the extent of synergy ratio. A 1:1 ratio represents an 
additive effect, not considered synergistic. An additive effect is considered as being 
synergistic (1<1). A ratio of 1<1 ratio implies an additive and possible synergistic 
effect. This depicts that the combined diet of the two carcinogens has an additive or 
synergistic effect on the measured parameter. The results of all analyses are presented 
in figures and tables 6.1 to 6.19 in the results section, and figures A1.1(i) to A3.1(x) 
and tables A1.1(i) to A4.1(viii) in the appendix. The error bars in graphical 
presentations represent the standard deviation. Data is denoted as (mean ± standard 
deviation). The colour codes for the graphs illustrate the following groups: 
 
Control
Aflatoxin B1
Iron
Iron and Aflatoxin B1
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6.0.1. Indicators of Iron Overload and Liver Disease
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Table 6.1. Bonferroni Dunn and T-Tests for 
Serum Iron at 12 months
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
2.991 
2.856   
0.762   
0.334   
2.805   
3.797   
*    P<0.05 
**  P<0.01 
ns   P>0.05 
ns   P>0.05 
*    P<0.05 
**  P<0.01 Fe + AFB1 vs. AFB1
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 6.2. Bonferroni (Dunn) and t-tests for 
ALT at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
Fe + AFB1 vs. AFB1
  5.573 
11.881 
  1.162  
  5.176 
  4.223  
  9.964 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
*** P<0.001 
**   P<0.01 
*** P<0.001 
Figure 6.1. Bar Graph of 
Serum Iron Levels of Wistar 
Albino Rats at 12 months 
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Figure 6.2.  Bar Graph of 
Serum ALT Levels of Wistar 
Albino Rats at 12 months 
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Table 6.3. Bonferroni (Dunn) and t-tests for 
AST at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
Fe + AFB1 vs. AFB1
  7.053 
10.432 
  2.188   
  2.201   
  4.658 
  7.482 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 
*** P<0.001 
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Figure 6.3.  Bar Graph of 
Serum AST Levels of Wistar 
Albino Rats at 12 months 
 
Table 6.4. Bonferroni (Dunn) and t-tests for 
GGT at 6 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
4.555 
7.027 
0.132  
1.720   
4.916 
7.698 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
  ns  P>0.05 
*** P<0.001 
*** P<0.001 Fe + AFB1 vs. AFB1
Figure 6.4. Bar Graph of Serum 
GGT Levels of Wistar Albino 
Rats at 6 months 
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6.0.2. Reactive Oxygen Species and Reactive Nitrogen Species 
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Table 6.5. Bonferroni (Dunn) and t-tests for 
Serum Nitrite at 6 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
1.317  
5.256 
1.428   
3.618   
0.111   
3.480   
  ns  P>0.05 
*** P<0.001 
  ns  P>0.05 
 **  P<0.01 
  ns  P>0.05 
 **  P<0.01 Fe + AFB1 vs. AFB1
 
 
 
 
 
Figure 6.5. Bar Graph of Serum 
Nitrite Levels of Wistar Albino 
Rats at 6 months 
 
 
6.0.3. Indicators of Lipid Peroxidation 
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Table 6.6. Bonferroni (Dunn) and t-tests for 
Liver Liver Peroxidation at 6 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
  5.931 
10.747 
  3.234  
  4.055  
  2.553  
  6.786  
*** P<0.001 
*** P<0.001 
*     P<0.05 
**   P<0.01 
ns    P>0.05 
*** P<0.001 Fe + AFB1 vs. AFB1
 
 
 
 
 
Figure 6.6. Bar Graph of Liver 
Lipid Peroxidation Levels of 
Wistar Albino Rats at 6 months 
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Table 6.7. Bonferroni (Dunn) and t-tests for 
Serum Lipid Peroxidation at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
3.816  
7.868 
0.024   
3.093   
3.623   
7.225 
**   P<0.01 
*** P<0.001 
ns    P>0.05 
*     P<0.05 
**   P<0.01 
*** P<0.001 Fe + AFB1 vs. AFB1
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Figure 6.7.  Bar Graph of Serum 
Lipid Peroxidation Levels of 
Wistar Albino Rats at 12 months
Figure 6.8.  Bar Graph of Liver 8-
Isoprostane Levels of Wistar 
Albino Rats at 12 months 
Table 6.8. Bonferroni (Dunn) and t-tests for 
Liver 8-Isoprostane at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
2.202   
5.154 
2.560   
2.713   
0.471  
1.971   
ns    P>0.05 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 Fe + AFB1 vs. AFB1
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6.0.4 Indicators of DNA Changes  
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Table 6.9. Bonferroni (Dunn) and t-tests for 
Serum 8OHdG at 6 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
Fe + AFB1 vs. AFB1
  9.410 
13.160 
  6.846 
  1.545   
  2.564   
  4.709 
*** P<0.001 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
  ns  P>0.05 
*** P<0.001 
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Figure 6.9. Bar Graph of Serum 
8-Hydroxyguanosine Levels of 
Wistar Albino Rats at 6 months 
Table 6.10.  Bonferroni (Dunn) and t-tests for 
Liver 8OHdG at 6 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
  8.116 
14.294 
  0.049   
  4.204   
  8.166 
14.356 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
 **  P<0.01 
*** P<0.001 
*** P<0.001 Fe + AFB1 vs. AFB1
Figure 6.10. Bar Graph of Liver 
8-Hydroxyguanosine Levels of 
Wistar Albino Rats at 6 months 
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Table 6.11. Bonferroni (Dunn) and t-tests for 
Serum 8-Hydroxyguanosine at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
  8.116 
14.294 
  0.049   
  4.204   
  8.166 
14.356 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
 **  P<0.01 
*** P<0.001 
*** P<0.001 Fe + AFB1 vs. AFB1
 
 
 
6.0.5. Indicators of Mutagenicity (Ames Test) (These results represent fractions 
that were charged with the S9 mix) 
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Table 6.12. Bonferroni (Dunn) and t-tests for 
Salmonella typhimurium strain TA100 – 
Whole Fraction at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
2.700 
5.142 
0.152   
2.184   
2.422   
4.693 
ns    P>0.05 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 Fe + AFB1 vs. AFB1
Figure 6.11.  Bar Graph of Serum 
8-hydroxyguanosine Levels of 
Wistar Albino Rats at 12 months 
 
 
 
  
Figure. 6.12. Bar Graph Showing 
Spontaneous Revertant Colony 
Counts of TA100 from Whole 
Fraction of Wistar Albino Rat 
Liver Tissue at 12 months 
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s Table 6.13. Bonferroni (Dunn) and t-tests for 
Salmonella typhimurium strain TA102 – 
Nucleosomal Fraction at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
2.165  
6.952 
5.135 
4.581 
3.071   
Fe + AFB1 vs. AFB1 0.995   
ns    P>0.05 
*** P<0.001 
*** P<0.001 
*** P<0.001 
*     P<0.05 
ns    P>0.05 
Table 6.14. Bonferroni (Dunn) and t-tests for 
Salmonella typhimurium strain TA102 – 
Cytosolic Fraction at 12 months
Treatment 
Comparison 
t P-Value 
Figure. 6.13. Bar Graph Showing 
Spontaneous Revertant Colony 
Counts of TA102 from 
Nucleosomal Fraction of Wistar 
Albino Rat Liver Tissue at 12 
months 
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Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
2.165  
6.952 
5.135 
4.581 
3.071   
0.995   
ns    P>0.05 
*** P<0.001 
*** P<0.001 
*** P<0.001 
*     P<0.05 
ns    P>0.05 Fe + AFB1 vs. AFB1
Figure. 6.14. Bar Graph Showing 
Spontaneous Revertant Colony 
Counts of TA102 from Cytosolic 
Fraction of Wistar Albino Rat 
Liver Tissue at 12 months
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Table 6.15. Bonferroni (Dunn) and t-tests for 
Salmonella typhimurium strain TA102 – 
Microsomal Fraction at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB
5.883 
9.233 
0.424   
2.788   
5.185 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 1
Fe + AFB1 vs. AFB1 8.264 *** P<0.001 
Table 6.16. Bonferroni (Dunn) and t-tests for 
Salmonella typhimurium strain TA97 – 
 12 monthsWhole Homogenate at
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB
7.782 
4.511   
1.637   
4.013   
5.783 
*** P<0.001 
**   P<0.01 
ns    P>0.05 
**   P<0.01 
*** P<0.001 1
Fe + AFB1 vs. AFB1 2.486   ns    P>0.05 
Figure. 6.15. Bar Graph Showing 
Spontaneous Revertant Colony 
Counts of TA102 from Microsomal 
Fraction of Wistar Albino Rat 
Liver Tissue at 12 months 
 
Figure. 6.16. Bar Graph Showing 
Spontaneous Revertant Colony 
Counts of TA97 from Whole 
Fraction of Wistar Albino Rat 
Liver Tissue at 12 months 
 
 132
 
6.0.6. Cytokine Indicators 
 
  
 
 
 
 
 
 
 
 
 
Table 6.17. Bonferroni (Dunn) and t-tests for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interleukin-1β at 12 months
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFB1
Fe vs. Fe + AFB1
Fe vs. AFB1
Fe + AFB1 vs. AFB1
0.146 
0.609   
1.447   
0.430   
1.593   
2.381   
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
Table 6.18. Bonferroni (Dunn) and t-tests for 
Interleukin-6 at 12 months 
Tr
Com
eatment 
parison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1
Control vs. AFBB
F
1
e vs. Fe + AFBB
F
1
e vs. AFBB
F
1
e + AFBB 1
5.814 
2
1
0
2
*** P<0.001 
n
1 vs. AFB
3.413  *     P<0.05 
.802   
.571   n
.610   n
.330    n
s    P>0.05 
s    P>0.05 
s    P>0.05 
s    P>0.05 
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Figure. 6.17. Bar Graph of 
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Albino Rats at 12 months 
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Figure. 6.18. Bar Graph of 
Interleukin-6 Levels of Wistar 
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6.1. Results of Assays Showing Synergy 
se
 
6.1.1. Indicators of Iron Overload and Liver Disea   
 
 
Figure 6.1 shows the serum iron levels o 2 T
roups showed to have the greatest seru nifican e
ontrol and AFB1 groups. The relative trati o
ontrol (59.7 ± 9.7); Fe (127.0 ± 28.0); Fe + AFB1 (133.3 ± 44.1); AFB1 (61.8 ± 
7.1) (Appendix). The extent of synergy ratio was 1:0.7. Subsequent to a significant 
ukey post-hoc test was used to determine significant 
me effects per group at an a priori p level of 0.05. Figure A3.1(i) (appendix) shows 
 rats at the two time intervals. The Fe + 
Figure 6.2 shows the levels of serum ALT of wistar albino rats at 12 months. The iron 
fed groups had significantly elevated levels in comparison to the control group 
(P<0.001). The Fe +AFB1 group levels was also significantly elevated in relation to 
Table 6.19. Bonferroni (Dunn) and t-tests for 
f wistar albino rats at 1 months. he Fe fed 
g m iron levels, sig tly high r than the 
c  serum iron concen ons (μm l/l) were: 
C
1
two-way ANOVA (P<0.005), a T
ti
serum iron concentrations of wistar albino
AFB1 is elevated significantly at 12 months.   
 
Interleukin-10 at 12 months
Treatm
Comparison 
ent t P-Value 
Contr
Control vs. Fe + AFB1
Contr
ol vs. Fe 
ol vs. AFBB
Fe vs
1
. Fe + AFBB
Fe vs
1
. AFBB
Fe + 
1
AFBB
0.481
4.126   
1.943
2
1.462
1.728
ns   P
**  P<0.01 
P
 P
1 vs. AFB1
 
   ns   
3.53    ** 
   ns   P
   ns   P
>0.05 
>0.05 
<0.01 
>0.05 
>0.05 
0
10
20
30
40
50
60
Control
Fe (Fe + AFB1)
AFB1
Groups
IL
-1
0 
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
Figure. 6.19. Bar Graph of 
In erleut kin-10 Levels of Wistar 
Albino Rats at 12 months 
 134
the Fe (P<0.001), and the AFB1 groups (P<0.001). The Fe group levels were found to 
be elevated with respect to the AFB1 group (P<0.01). The respective ALT 
concentrations (U/I) were: Control (107.5 ± 24.3); Fe (311.3 ± 44.2); Fe + AFB1 
(485.6 ± 87.2); AFB1 (150.0 ± 35.4). The extent of synergy ratio was 1:1.05. The ALT 
levels of the Fe, Fe + AFBB s were all elevated at 12 months (Fig. 
3.1(ii).) (Appendix). 
erum GGT Levels of wistar albino rats at 6 months. The iron 
d groups showed significantly higher GGT levels in comparison to the control group 
3.1(iv).). 
ppendix). 
1, and AFB1 group
A
 
Figure 6.3 shows the serum AST levels of wistar albino rats at 12 months. The iron 
fed groups showed AST levels greater than those of the control group and the AFB1 
group (P<0.001). The respective AST concentrations (U/I) were: Control (173.8 ± 
35.6); Fe (391.8 ±16.5); Fe + AFB1 (454.4 ± 75.2); AFB1 (241.4 ± 22.5). The extent 
of synergy ratio was 1:0.71. The AST levels of all four experimental groups were 
shown to be elevated at the 12 month time point (Fig. A3.1(iii)). (Appendix) 
 
Figure 6.4 shows the s
fe
and the AFB1 group (P<0.001) (Table 6.4). The relative GGT levels (U/I) were as 
follows: Control (3.1 ± 0.7); Fe (44.2 ± 14.6); Fe + AFB1 (56.4 ± 18.7); AFB1 (1.9 ± 
0.8) (Appendix). The extent of synergy ratio was 1:1.22. No significant differences 
were found between the control and AFB1 groups, or between the Fe and Fe + AFB1 
groups. The GGT concentration of the Fe + AFB1 group was shown to be lowered at 
the 12 month time point in comparison to the 6 month levels (Fig. A
(A
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6.1.2. Reactive Oxygen Species and Reactive Nitrogen Species 
Figure 6.5 shows the serum nitrite levels of wistar albino rats at 6 months. The Fe + 
AFB  groups showed to be significantly elevated in comparison with all three of the 
other groups. The p-values were as follows: Control vs.. Fe + AFB  (P<0.001); Fe vs. 
Fe + AFB  (P<0.01); AFB  vs. Fe + AFB  (P<0.01) (Table 6.7). The respective serum 
nitrite levels (μM/l) were as follows: Control (7.9 ± 1.1); Fe (17.3 ± 1.0); Fe + AFB  
(18.8 ± 5.3); A
 
FB1 (11.6 ± 1.2). The extent of synergy ratio was 1:0.65. 
.1.3. Indicators of Lipid Peroxidation
1
1
1 1 1
1
 
6  
 
ar albino rats at 6 
ison to the 6 
onth point (Fig A3.1(viii)) (Appendix). 
Figure 6.6 shows the levels of liver lipid peroxidation of wist
months. All experimental groups were found to have higher LPO levels than the 
control group (Table 6.8). The Fe + AFB1 was found to have the highest measure of 
LPO amongst groups (Table and figure 6.8.). The respective LPO concentrations 
(μmol/l) were as follows: Control (41.6 ± 8.8); Fe (96.6 ± 5.3); Fe + AFB1 (126.6 ± 
18.3); AFB1 (72.9 ± 17.2). The extent of synergy ratio was 1:0.75. The control and Fe 
groups showed increased levels at the 12 month time point in compar
m
 
Figure 6.7 shows the levels of serum LPO of wistar albino rats at 12 months. The iron 
fed groups showed the greatest elevations with respect to the control and AFB1 
groups. The Fe + AFB1 group in particular had the highest levels (64.3 ± 14.8), and 
being significantly greater than the iron group (P<0.05). The respective serum LPO 
concentrations (μmol/l) of the groups were: Control (15.2 ± 2.6); Fe (45.0 ± 11.4); 
AFB1 (15.0 ± 0.9). The extent of synergy ratio was 1:1.07. The Fe group showed a 
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decreased LPO concentration at the 12 month time point in comparison to the 6 month 
time point (Fig.A3.1(ix)) (Appendix). 
 
Figure 6.8 shows the levels of 8-isoprostane in liver tissue of wistar albino rats at 12 
months. The Fe + AFB1 group is the only group showing significantly elevated levels 
in comparison to the control. The respective liver 8-isoprostane (pg/ml) levels were: 
Control (736 ± 208); Fe (1264 ± 272); Fe + AFB1 (1773 ± 415); AFB1 (1376 ± 554). 
The extent of synergy ratio was 1:0.67. Both the Fe-fed groups showed raised levels 
at the 12 month time point (Fig A3.1(vii)) (Appendix). 
 
6.1.4. Indicators of DNA Changes 
 
Figure 6.9 shows the levels of serum 8-hydroxyguanosine of wistar albino rats at 6 
months. All experimental groups showed elevated levels in comparison to the control 
group (P<0.001). The Fe + AFB1 group had levels significantly higher than the AFB1 
group (P<0.001). The respective serum 8-hydroxyguanosine concentrations (ng/ml) 
were as follows: Control (22.2 ± 4.1); Fe (120.2 ± 24.7); Fe + AFB1 (133.3 ± 17.2); 
AFB1 (93.5 ± 9.9). The extent of synergy ratio was 1:0.62. 
 
Figure 6.10 show the levels of liver 8-hydroxyguanosine of wistar albino rats at 6 
onths. The iron fed groups show significant elevation in comparison to both control m
and AFB1 groups (P<0.001). The Fe + AFB1 group shows higher levels than those of 
the Fe group (P<0.01). The respective 8-hydroxyguanosine concentrations (ng/ml) in 
liver tissue were as follows: Control (702.4 ± 48.2); Fe (3323.6 ± 542.0); Fe + AFB1 
(4415.8 ± 617.0); AFB1 (686.4 ± 80.4). The extent of synergy ratio was 1:1.1. The Fe-
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fed groups showed increased levels at the 12 month time point (Fig. A3.1(x)). 
(Appendix) 
 
Figure 6.11 shows the levels of serum 8-hydroxyguanosine of wistar albino rats at 12 
months. The Fe-fed groups showed increased concentrations with respect to both the 
control and the AFB1 groups (P<0.001). The Fe + AFB1 group showed significantly 
greater concentrations than the Fe group (P<0.01). The respective 8-
hydroxyguanosine levels (ng/ml) were: Control (58.8 ± 34.3); Fe (74.9 ± 12.6); Fe + 
AFB1 (146.5 ± 85.4); AFB1 (71.3 ± 41.2). The extent of synergy ratio was 1:1. 
 
6.1.5. Indicators of Mutagenicity (Ames Test) 
ing graphs show the results obtained from the Ames test after being 
challenged with the S9 enzymes. This challenge produced results showing a clearer 
differentiation between groups in terms of colony counts. Only the 12 month data 
showing synergy is shown, whilst the remaining data is discussed and respective 
graphs and statistical data are shown in the appendix. 
 
Figure 6.12 shows the colony counts of spontaneous revertants of TA100 from the 
whole fraction of wistar albino rat liver homogenate at 12 months. The Fe + AFB1 
roup showed to have increased counts in comparison to both the control and the 
 
The preced
 
g
AFB1 group (P<0.001). The respective colony counts per group were: Control (125 ± 
18); Fe (154 ± 22); Fe + AFB1 (176 ± 21); AFB1 (126 ± 3). The extent of synergy 
ratio was 1:0.63. 
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Figure 6.13 shows the colony counts of spontaneous revertants of TA102 from the 
nucleosomal fraction of wistar albino rat liver homogenate at 12 months. The AFB1 
fed groups showed elevated colony counts in comparison to both the control and Fe 
groups. The respective colony counts per group were: Control (329 ± 49); Fe (405 ± 
20); Fe + AFBB
s the colony counts of spontaneous revertants of TA102 from the 
ytosolic fraction of wistar albino rat liver homogenate at 12 months. The Fe + AFB1 
 
icrosomal fraction of wistar albino rat liver homogenate at 12 months. The iron fed 
1 (553 ± 83); AFB1 (519 ± 58). The extent of synergy ratio was 1:0.6. 
 
Figure 6.14 show
c
group is shown to be elevated in comparison to the control and AFB1 groups 
(P<0.001). The respective colony counts per group were: Control (338 ± 9); Fe (417 ± 
6); Fe + AFB1 (485 ± 68); AFB1 (345 ± 52). The extent of synergy ratio was 1:0.64. 
 
Figure 6.15 shows the colony counts of spontaneous revertants of TA102 from the
m
groups showed significantly elevated colony counts in comparison to both the control 
and AFB1 groups (P<0.001). The respective colony counts per group were: Control 
(296 ± 170); Fe (412 ± 6); Fe + AFBB
 
1 (463 ± 50); AFB1 (305 ± 5). The extent of 
synergy ratio was 1:0.65. 
Figure 6.16 shows the colony counts of spontaneous revertants of TA97 from the 
whole homogenate of wistar albino rat liver homogenate at 12 months. The iron fed 
groups showed to have elevated counts in comparison the control group. The Fe group 
had the highest counts in relation to all other groups, and in particular a higher count 
than that of the Fe + AFBB1 group (P<0.01). The respective colony counts per group 
were: Control (137 ± 4); Fe (234 ± 31); Fe + AFB1 (188 ± 25); AFB1 (158 ± 4). The 
extent of synergy ratio was 1:0.48. 
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6.1.6. Cytokine Indicators 
Figure 6.18 shows the levels of interleukin-6 of wistar rats at 12 months. Both the Fe 
(P<0.05) and the Fe + AFB1 (P<0.001) groups have significantly lowered interleukin-
6 concentrations with respect to the control group. The respective IL-6 concentrations 
1 group is shown to have significantly elevated levels in comparison to both the 
 
Figure 6.17 shows the levels of interleukin-1β of wistar rats at 12 months. No 
significant differences were noted between experimental groups. The respective 
interleukin-1β (ng/ml) levels were: Control (31.3 ± 6.9); Fe (32.2 ± 10.4); Fe + AFB1 
(34.4 ± 10.9); AFB1 (22.4 ± 6.9). The extent of synergy ratio was 1:0.63. 
 
(pg/ml) were: Control (135.6 ± 44.9); Fe (67.4 ± 39.2); Fe + AFB1 (42.1 ± 24.0); 
AFB1 (79.6 ± 33.8). The extent of synergy ratio was 1:0.3.  
 
Figure 6.19 shows the levels of interleukin-10 of wistar rats at 12 months. The Fe + 
AFB
control and Fe groups (P<0.01). The respective IL-10 concentrations (pg/ml) were: 
Control (12.0 ± 5.1); Fe (16.2 ± 5.4); Fe + AFB1 (41.0 ± 15.7); AFB1 (28.9 ± 17.3). 
The extent of synergy ratio was 1:0.91. 
 
6.2. Correlations  
6.2.1. Correlations at 6 months 
erum nitrite levels. Table A4.1(ii) shows the 
orrelation matrix for the iron group. AST is positively correlated with serum nitrite 
Tables A4.1(i) to A4.1(iv) (Appendix) are the correlation matrices developed from the 
6 month data. Highlighted data represents correlations significant at a 5% level. The 
matrix has been split into the four experimental groups for ease of reading. Table 
A4.1(i) shows the correlation matrix for 6 month data for the control group. ALT is 
significantly positively correlated with s
c
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levels. ALT is negatively correlated to serum 8-Isoprostane and, liver nitrite levels are 
eroxide production. Table A4.1(iii) shows the 
ith NTBI, RBC and MPV. MPV was also 
 levels. RBC was found to be positively 
ly correlated with WBC and TIBC. Hb was found 
negatively correlated with sup
correlation matrix for the iron plus aflatoxin B1 group. ALT show positive 
correlations with both hydroxyproline and liver 8-hydroxyguanosine levels. Serum 
nitrite levels show a positive correlation with liver lipid peroxidation. A4.1(iv) shows 
the correlation matrix for the aflatoxin B1 group. ALT shows a positive correlation 
with GGT and liver lipid peoxidation, and a negative correlation with hydroxyproline 
and liver nitrite levels. GGT has a positive correlation with liver lipid peroxidation. 
Liver 8-hydroxyguanosine shows negative correlations with both serum lipid 
peroxidation and liver nitrite levels. Serum 8-isoprostane showed a negative 
correlation with hydroxyproline. 
 
6.2.2. Correlations at 12 months. 
Tables A4.1 (v) to A4.1 (viii) are the correlation matrices developed from the 12 
month data. Highlighted data represents correlations significant at a 5% level. The 
matrix has been split into the four experimental groups for ease of reading. Table 
A4.1 (v) is a correlation matrix for the control group at 12 months. AST was found to 
be positively correlated to serum nitrite levels. ALT was positively correlated with 
liver 8-isoprostane and negatively w
negatively correlated with liver nitrite
correlated with MPV, and negative
to be positively correlated with both platelets and IL-1β. 
 
Table A4.1 (vi) is a correlation matrix for the Fe group at 12 months. Serum 8- 
Isoprostane was shown to be prositively correlated with platelet counts, and NTBI. 
NTBI was also positively correlated with ferritin. ALT and AST were found to be 
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positively correlated with Hb and serum nitrite respectively. Liver lipid peroxidation 
was positively correlated with platelet counts and TIBC. Liver nitrite levels were 
positively correlated with serum 8-hydroxyguanosine levels and Hb, but negatively 
with MPV. In terms of the Ames test, the TA100 strain was found to be positively 
orrelated with TA98. 
with TA 102, whilst liver nitrite levels showed positive 
orrelations with IL-10. The superoxide production was negatively correlated with IL-
nd IL-10. GGT showed positive correlations with NTBI, IL-6 and IL-10. 
c
 
Table A4.1 (vii) is a correlation matrix for the Fe + AFB1 group at 12 months. The 
WB counts were shown to be positively correlated with serum 8-Isoprostane and ALT 
levels, but negatively so with serum 8-hydroxyguanosine. ALT was also shown to be 
positively correlated with liver 8-hydroxyguanosine levels. Serum 8-
hydroxyguanosine was shown to be positively correlated with TIBC. Serum nitrite 
levels were shown to be positively correlated with serum lipid peroxidation levels and 
MPV and negatively 
c
1β and MPV, but positively with TIBC and TA 102. TA 102 was also shown to be 
negatively correlated with TA98. RBC and Hb were shown to be positively 
correlated. 
 
Table A4.1 (viii) is a correlation matrix for the AFB1 group at 12 months. ALT was 
shown to be negatively correlated with WBC. AST showed a negative correlation 
with liver nitrite levels, but a positive correlation with serum lipid peroxidation levels. 
It followed that liver nitrite levels were negatively correlated with serum lipid 
peroxidation levels. Liver nitrite was also shown to be positively correlated with 
ferritin. Serum nitrite levels were shown to be negatively correlated with superoxide 
production a
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RBc and Hb was also positively correlated. Within the Ames test, TA98 and TA100 
were positively correlated. 
 
6.3. Two-Way Analysis of Variance Results calculated between 6 and 12 month 
data. 
The following assays were performed at both the 6 month and 12 month time points. 
Subsequent to a significant two-way ANOVA (P<0.005), a Tukey post-hoc test was 
used to determine significant time effects per group at an a priori p level of 0.05. The 
graphical representations are available in the appendix. Fig A3.1 (i) shows serum iron 
ns of wistar albino rats at the two time intervals. The Fe + AFB1 is 
 were all elevated at 12 months (Fig. A3.1(ii)). The AST levels of all four 
concentratio
elevated significantly at 12 months.  The ALT levels of the Fe, Fe + AFB1, and AFB1 
groups
experimental groups were shown to be elevated at the 12 month time point (Fig. 
A3.1(iii)). The GGT concentration of the Fe + AFB1 group was shown to be lowered 
at the 12 month time point in comparison to the 6 month levels (Fig. A3.1(iv)). The 
superoxide production of the Fe + AFBB1 group was shown to be lowered at 12 months 
(Fig. A3.1(v)). The nitrite concentrations were elevated in all four experimental 
groups at 12 months (Fig. A3.1(vi)). The serum 8-isoprostane levels of both the 
control and AFB1 groups were shown to be lowered at the 12 month time point (Fig. 
A3.1(vii)). The levels of liver lipid peroxidation were elevated in the control and Fe 
groups at 12 months (Fig. A3.1(viii)). The serum lipid peroxidation levels, were 
however only elevated in the Fe group at 12 months (Fig. A3.1(ix)). The liver 8-
hydroxyguanosine concentrations of the Fe and Fe + AFB1 groups were found to be 
significantly elevated at 12 months (Fig. A3.1(x)). 
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6.4. Results of Assays Not Showing Synergy 
6.4.1. Indicators of Iron Overload and Liver Disease  
(Figures and Statistical data for this section may be found in the Appendix). 
6.4.1.1. Assays performed at 6 months 
Figure A1.1(i) shows the serum iron levels of Wistar Albino Rats at 6 months. 
xperimental groups on the ferrocene diet showed significantly greater serum iron 
vels in comparison to the control group (P<0.001) (Table 6.1). The groups showed 
Control (45.8 ± 9.3); Fe (95.2 ± 12.9); 
). No differences were found 
oup. 
Figure A1.1 (ii) shows the ALT levels of Wistar Albino rats at 6 months. The iron 
containing groups both showed higher ALT levels in comparison to the control group 
(P<0.001) and a lesser difference between themselves (P<0.05). The relative ALT 
levels (U/I) were as follows: Control (21.6 ± 6.5); Fe (91.8 ± 13.5); Fe + AFB1 (72.3 
± 14.7); AFB1 (26.3 ± 1.2). No significant differences were found between the AFB1 
and control group. 
igure A1.1 (iii) shows the AST levels of Wistar Albino Rats at 6 months. A high 
significant difference was found with the iron groups in comparison with the control 
and AFB1 groups (P<0.001) (Table A1.1 (iii)). Significant differences were found 
between the control and Fe + AFB1 groups as well as between Fe and Fe + AFB1 
(P<0.05). The relative AST levels (U/I) were as follows: Control (15.2 ± 2.5); Fe 
(30.0 ± 6.9); Fe + AFB1 (22.7 ± 4.6); AFB1 (16.1 ± 5.1) (Appendix).  No significant 
differences were found between the control and Fe + AFB1 groups and the AFB1 and 
E
le
serum iron concentrations (μmol/l) as follows: 
Fe + AFB1 (87.8 ± 14.2); AFB1 (37.6 ± 12.2) (Appendix
between the AFB1 and control group or the Fe and Fe + AFB1 gr
 
 
F
Fe + AFB1 groups. 
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6.4.1.2. Assays performed at 12 months 
Figure A2.1(ii) shows the ferritin levels of wistar albino rats at 12 months. The F
AFB
e + 
 and 
l 
 
r albino rats at 12 months. No significant 
iv) shows the PSAT of wistar albino rats at 12 months. No significant 
ifferences were noted between experimental groups. The respective PSAT’s (%) of 
ls of non-transferrin bound iron (NTBI) of wistar albino 
ts at 12 months. The iron fed groups showed significantly elevated NTBI level with 
igure A2.1(viii) shows GGT levels of wistar albino rats at 12 months. The iron fed 
groups showed significantly elevated GGT levels in relation to both the control and 
1 group showed to have decreased ferritin levels in comparison to the control
Fe groups (P<0.05). The respective Ferritin concentrations (ng/ml) were: Contro
(105.2 ± 23.5); Fe (107.5 ± 9.6); Fe + AFB1 (79.4 ± 16.2); AFB1 (80.9 ± 23.1)
(Appendix). 
 
Figure A2.1(iii) shows the TIBC of wista
differences were found between experimental groups. The respective TIBC (μmol/l) 
for each group was: Control (67.5 ± 2.1); Fe (124.6 ± 13.9); Fe + AFB1 (126.6 ± 
108.6); AFB1 (68.4 ± 18.9). 
 
Figure A2.1(
d
groups was: Control (81.7 ± 26.8); Fe (96.5 ± 18.8); Fe + AFB1 (97.9 ± 23.8); AFB1 
(78.2 ± 45.9). 
 
Figure A2.1(v) show the leve
ra
respect to the control and AFB1 groups (P<0.001). There were no differences between 
the iron fed groups themselves. The respective NTBI concentrations (μM) were: 
Control (6.6 ± 4.8); Fe (4.99 ± 9.13); Fe + AFB1 (48.8 ± 17.71); AFB1 (3.9 ± 4.55).  
 
F
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AFB1 groups. The respective group GGT levels were: Control (3.1 ± 0.6); Fe (27.4 ± 
3.8); Fe + AFBB1 (22.5 ± 8.4); AFB1 (3.4 ± 1.0). 
 
6.4.2. Reactive Oxygen Species and Reactive Nitrogen Species 
6.4.2.1. Assays performed at 6 months 
Figure A1.2(i) shows the superoxide anion levels of wistar albino rats at 6 months. No 
significant differences were found between any of the groups. The respective 
superoxide production (Max. O2(mV/Neutr.)) values were as follows: Control (0.063 
± 0.022); Fe (0.051 ± 0.014); Fe + AFB1 (0.058 ± 0.062); AFBB
igure A1.2(ii) shows the liver nitrite levels of wistar albino rats at 6 months. No 
pective liver nitrite 
 ± 1.7); Fe (10.7 ± 1.4); Fe + AFB1 (12.8 ± 
t 12 
onths. The AFB1 group levels were significantly higher than those of the control, Fe 
igure A2.2(ii) shows the nitrite levels in liver tissue of wistar albino rats at 12 
ental groups. The 
1 (0.101 ± 0.030). 
 
F
significant differences were found between the groups. The res
levels (μM) were as follows: Control (9.8
3.8); AFB1 (14.2 ± 2.6). 
 
6.4.2.2. Assays performed at 12 months 
Figure A2.2(i) show the levels of superoxide production of wistar albino rats a
m
and Fe + AFB1 groups (P<0.05). The respective levels of superoxide production O2 
(mV)/Neutr.(x109) were: Control (0.038 ± 0.038); Fe (0.028 ± 0.018); Fe + AFB1 
(0.061 ± .064); AFB1 (0.168 ± 0.134). 
 
F
months. No significant differences were found between experim
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respective  liver nitrite levels (μM) were: Control (42.3 ± 3.8); Fe (42.8 ± 4.8); Fe + 
AFB1 (43.8 ± 8.7); AFB1 (39.8 ± 3.3). 
 
Figure A2.2(iii) shows the serum nitrite levels of wistar albino rats at 12 months. The 
Fe group levels are shown to be elevated in comparison to the control (P<0.01) and 
FB1 (P<0.05) groups, but not in comparison to the Fe + AFB1 group. The respective 
n
A
serum nitrite levels (μM) among groups was: Control (9.8 ± 2.0); Fe (21.0 ± 5.8); Fe 
+ AFB1 (15.2 ± 5.1); AFB1 (11.3 ± 3.0). 
 
6.4.3. Indicators of Lipid Peroxidatio  
.4.3.1. Assays performed at 6 months 
.9); AFB1 (33.1 ± 16.3). 
m 8-isoprostane of wistar albino rats at 6 
ave higher serum 8-isoprostane levels than 
6
Figure A1.3(ii) shows the levels of serum lipid peroxidation in wistar albino rats at 6 
months. The iron fed groups showed significantly elevated levels of H2O2 production 
in comparison to both the control group and the AFB1 group (P<0.001) (Table 6.9). 
The respective LPO levels (μmol/l) among groups was as follows: Control (26.1 ± 
6.6); Fe (69.9 ± 6.2); Fe + AFB1 (60.8 ± 9
 
Figure A1.3(iii) shows the levels of seru
months. The iron fed groups showed to h
the control group. The Fe + AFB1 groups showed to be most elevated against the 
control (P<0.001) and AFBB
5.0 ± 178.9). No 
1 (P<0.01) groups respectively. The Fe group was elevated 
with respect to the control (P<0.05) and to the AFB1 groups (P<0.05). The respective 
8-Isoprostane concentrations (pg/ml) were as follows: Control (1969.8 ± 154.0); Fe 
(2259.7 ± 136.1); Fe + AFB1 (2288.1 ± 150.4); AFB1 (198
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differences were noted between AFB1 and the control groups, or the Fe and Fe + 
AFB1 groups. 
 
Figure A2.3(ii) shows the serum 8-isoprostane levels in wistar albino rats at 12 
months. The iron fed groups showed significantly elevated levels in comparison to 
both the control group (P<0.001) and the AFB1 group (P<0.001). The respective 
serum 8-isoprostane levels (pg/ml) were: Control (979 ± 253); Fe (2578 ± 333); Fe + 
AFB1 (2444 ± 537); AFB1 (1122 ± 193). 
 
Figure A2.3(iii) shows the levels of liver lipid peroxidation of wisar albino rats at 12 
months. The Fe + AFB1 group showed the only significantly elevated levels in 
comparison to the control group (P<0.01). The respective lipid peroxidation levels 
(H2O2 μM/g) were: Control (332.8 ± 35.5); Fe (308.2 ± 12.6); Fe + AFBB
.4.4. Indicators of DNA Changes
1 (286.2 ± 
21.60; AFB1 (305.9 ± 16.8). 
 
6   
els of 8-hydroxyguanosine (ng/ml) were: Control (1405 
 79); Fe (5800 ± 941); Fe + AFB1 (6635 ± 1366); AFB1 (1815 ± 231). 
 
 
 
 
6.4.4.1. Assays performed at 12 months 
Figure A2.4 (i) shows the levels of 8-hydroxyguanosine in liver tissue of wistar rats at 
12 months. The iron fed groups showed significantly lowered liver 8-
hydroxyguanosine levels in comparison to both the control and AFB1 groups 
(P<0.001). The respective lev
±
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6.4.5. Indicators of Mutagenicity (Ames Test) 
6.4.5.1. Assays performed at 12 months 
The following table shows all the colony counts obtained from using the four different 
Salmonella typhimirium strains. The data showing significant differences has been 
depicted in the above figures and is included amongst the rest of the data below. 
 
 
Table 6.4.5.1. Ames Mutagenicity Test 
 
Salmonella typhimurium Strains 
 TA97 TA98 TA100 TA102 
12 Months 12 Months 12 Months 12 Months Gr
Fraction Mean SD Mean SD Mean SD Mean SD 
oup Liver 
C 39 2.1 125 20.5 295 15.0 ontrol (W) 137 4.5 
 (N) 127 18.5 30 0.6 203 14.2 329 54.7 
 (C) 116 21.9 22 5.2 190 22.5 358 10.6 
 (S9) 80 18.9 29 4.4 124 15.0 331 52.3 
 (M) 108 10.2 30 8.4 216 30.1 296 15.8 
Fe (W) 234 35.1 54 13.0 154 24.6 490 33.1 
 (N) 286 40.3 29 11.8 204 27.2 405 22.3 
 (C) 189 38.4 26 2.1 170 28.0 417 6.0 
 (S9) 173 29.0 50 6.1 147 8.9 441 12.9 
 (M) 22.6 152 20.2 29 6.7 182 412 26.9 
Fe + AFB1 (W) 181 25.8 39 7.8 176 11.1 399 16.4 
 (N) 0 21.6 144 50.6 34 6.2 15 554 22.0 
 (C) 12 .9 21 .0 18 6 3 25  5 0 6. 476 46.5 
 (S9) 185 17.1 51 9.9 153 18.5 502 24.7 
 (M) 138 26.8 31 6.7 205 20.8 465 19.7 
AFB1 (W) 158 4.0 33 2.3 126 3.2 313 9.2 
 (N) 131 8.7 27 3.8 183 18.1 525 60.2 
 (C) 122 23.9 20 3.8 191 16.3 359 65.1 
 (S9) 239 45.2 41 10.7 122 11.0 461 22.0 
 (M) 131 34.7 33 8.0 198 47.9 452 21.8 
 
Detailed results e Am ut ity  us lm  t uri rai
TA97, TA98, TA100, and TA102. High-lighted a ind  co ou bov
180, 50, 200 and 360 spontaneous reverta or 7, T , T , a 1
respectively. W hole  ho nate  = n som act  = so
 S9 = hom te n a 00rp  = oso rac
 
 
 
 of th es m agenic  test ing Sa onella yphim um st ns 
reas icate lony c nts a e 
nts f TA9 A98 A100 nd TA 02 
 = W  liver moge ; N ucleo al fr ion; C  Cyto lic 
Fraction;
 
Liver ogena fractio t 90 m; M  Micr mal f tion. 
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6.4.6. Haematological D ntiiffere als
No  of the h olog nd ea s sh  s f y. da
acquired is however available in the appendix. 
ne aemat ical i ices m sure owed igns o synerg  The ta 
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7.0. Discussion 
The aim of this project was to ascertain the presence and the extent of synergy between the 
hepatocarcinogenicity of Fe overloading and aflatoxin B1 exposure in an animal model. 
Through a series of investigations focusing on sequential steps associated with 
hepatocarcinogenesis, the synergistic relationship between these two toxins has been 
somewhat established. 
 
The Fe profiling showed that Fe overload occurred within the Fe-fed groups. These groups 
showed raised serum Fe levels as well as a Fe content histology of 4+ at both the 6 and 12 
month time points. In cases of Fe overloading, typical Fe profiling would involve increased 
serum Fe, ferritin, PSAT and NTBI along with a lowered TIBC (Sinniah, 1969; Walker et 
al., 1973; McNamara et al., 1999; Adams et al., 2000). The Fe profiling performed in the 
present study showed that Fe overloading did occur. The serum Fe and NTBI levels within 
the Fe-fed groups were raised, which is expected in cases of Fe overload (Fig. 6.1 & Fig 
A2.1(v)). Because ferrocene was used as the Fe delivery molecule, an atypical trend in 
TIBC and PSAT occurred. TIBC in the Fe-fed groups is expected to be lowered in Fe 
overloading, but is shown to be raised in this study (Fig.A2.1(iii)).The PSAT in the Fe-fed 
groups is uncharacteristically not greater, but statistically equal to that of the control group 
(Fig. A2.1(iv)). Ferrocene’s mode of action in Fe overloading explains this atypical Fe 
profile. It has been shown that diets enriched with (3,5,5-trimethylhexanoyl)ferrocene 
(TMH-ferrocene) produce a severe experimental Fe overload in rats (Nielsen & Heinrich, 
1993). After intestinal absorption, TMH-ferrocene Fe in the portal blood is transported to 
the liver independently from transferrin (Nielsen & Heinrich, 1993). It could be assumed 
that ferrocene itself, albeit not containing the same lipophilic character, would act in the 
same manner. As the ferrocene is delivered independently of transferrin, the TIBC would 
not be altered in any way. The Fe being introduced through the diet would not bind to 
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transferrin, and hence transferrin’s Fe binding capacity would either remain normal or be 
slightly raised. PSAT is calculated by dividing the serum Fe by TIBC. Because the TIBC is 
raised, the PSAT is decreased. It is therefore evident that Fe overloading did occur in the 
present study in the subjects exposed to the Fe diet. 
 
Liver disease indicators measured in this study include, ALT, AST and GGT. ALT is a 
more specific indicator if liver inflammation than AST. The level of ALT in blood is 
increased in conditions which hepatocytes are damaged and denatured. As cells are 
damaged, ALT leaks out into the bloodstream. At 6 months, the Fe-fed groups both 
showed higher ALT levels in comparison to the control group (P<0.001) and a lesser 
difference between themselves (P<0.05) (Fig. A1.1(ii)). At 12 months the same trend was 
noted, including a significant elevation of ALT in all groups over time, with the exception 
of the control group. Because both Fe and AFBB1 are known hepatotoxins, this was an 
expected outcome. The Fe + AFB1 group showed significantly raised ALT levels in 
comparison to both the Fe and the AFB1 groups. Although no difference is noted between 
the control and AFB1 group, it is clear that the AFB1 is increasing Fe’s potential to raise 
ALT levels. This suggests that Fe may be the driving force in terms of liver damage, and 
AFB1 a co-factor. The extent of synergy ratio was 1:1.05. This ratio was calculated using 
the following: Fe group  + AFB1 group : Fe + AFB1 group. A ratio of 1:1 indicates an 
additive effect. At 12 months, an additive synergistic effect on ALT is noted in the Fe + 
AFB1 group (485.6 ± 87.2 U/I) with reference to the Fe (311.3 ± 44.2 U/I) and AFB1B  
(150.0 ± 35.4 U/I).  
 
AST is less specific to liver disease than is ALT, since it is also produced in muscle tissue 
and can be raised in other conditions. In many liver inflammation cases however, ALT and 
AST activities are raised in a 1:1 ratio. At the 6 month time point, the Fe fed groups 
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showed increased AST levels in comparison to both the control and AFB1 groups (Fig. 
A1.1(iii)). The Fe group had significantly higher AST than the Fe + AFB1 group. At 12 
months, however, the Fe + AFB1 (454.4 ± 75.2 U/I) group showed the highest AST levels, 
although not significantly greater than the Fe group (391.8 ±16.5 U/I) (Fig.6.3.) Liver 
inflammation was occurring at this time point, as is collaborated by the ALT levels. AST 
showed signs of synergy, although not of an additive nature. The extent of synergy ratio 
was 1:0.71. The control group also showed an increase in AST over time, but not so with 
respect to ALT. AST has been shown to be elevated in the elderly (Inafuku & Nozaki, 
2000), indicating that age may have been a contributing factor to the control group 
showing elevated AST levels, and hence a pre-existing baseline AST concentration. At 12 
months, the rat model used would’ve surpassed adulthood.  
 
While GGT is very useful in assisting in the diagnosis of liver disease, the enzyme is found 
in the cells lining secretory ducts. Therefore, it is raised in a number of inflammatory 
diseases and disorders including, pancreatitis, mononucleosis, hyperthyroidism and 
virtually any liver disease. At both the 6 month and 12 month time points, the Fe-fed 
groups showed raised GGT levels in comparison to both the control and AFB1 groups. At 
the 6 month time point, the extent of synergy ratio was 1:1.22. An additive synergistic 
effective was therefore observed in terms of GGT activity. The graph showing GGT levels 
over the two time points show that GGT drops significantly amongst groups at the 12 
month time point. GGT is considered a marker of acute liver damage, hence its levels are 
higher at 6 months than at 12 months. Because the development of liver inflammation in 
this study is of a chronic nature, GGT levels drop over time. At the 6 month time point 
GGT was shown to be positively correlated in the AFB1 group with ALT, liver LPO, and 
liver 8OHdG levels at 6 months. GGT’s positive correlation with ALT at 6 months and 
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lack thereof at 12 months, substantiates its use as a marker for acute liver inflammation. 
The positive correlations with liver LPO and 8OHdG are in accordance with their expected 
presence in liver damage.  
 
 In terms of cytokine indicators, this study showed that the joint administration of Fe and 
AFB1 produced raised levels of the anti-inflammatory interleukin-10 (IL-10) and decreased 
levels of pro-inflammatory interleukin-6 (IL-6). The levels of pro-inflammatory 
interleukin-1β (IL-1β) were not affected by Fe, AFB1 or their joint administration. In terms 
of IL-10, the extent of synergy ratio was 1:0.91, and hence a synergistic additive effect is 
noted. The Fe group produced a mean IL-10 concentration of 16.2pg/ml, the AFB1 group 
28.9pg/ml and the Fe + AFB1 group, a concentration of 41pg/ml. Similar results were 
shown when the ingestion of AFB1-contaminated feed in weaning piglets produced varying 
expressions of cytokine mRNA. (Marin et al., 2002). It was indicated that AFB1 decreased 
the pro-inflammatory IL-1β and increased the anti-inflammatory IL-10. IL-10 is known to 
inhibit the synthesis of type 1 helper T cell (Th1)–derived cytokines, which includes IL-1β 
and IL-6 (Cortes & Kurzrock, 1997). The down-regulation of inflammatory cytokines such 
as IL-1β and IL-6 could be a consequence of the induction of IL-10. Hence an inverse 
relationship is noted between IL10 and IL-6. AFBB1 has been shown to markedly inhibit   
IL-6 production by lipopolysaccharide stimulated (LPS-stimulated) macrophages (Moon et 
al. 1999), which is in accordance with what was found in this study. IL-6 has been shown 
to decrease during dietary Fe overload (Olynyk & Clarke, 2001). It is evident that when 
jointly administered, Fe and AFB1 would be expected to have a decreased IL-6, and since 
IL-6 and IL-10 have an inverse relationship, a raised IL-10. This is the observation made in 
the present study.  
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The present study did not, in contrast to Marin et al. (2002), find a significantly decreased 
IL-1β concentration in the AFB1 group, although the tendency to be lower in the AFB1 
group in comparison to the other groups does exist. Although the incubation of AFB1 
reduced the amount of IL-1β mRNA in LPS-stimulated bovine monocytes, it was only 
observed at high concentrations of AFB1 that non-specifically reduced steady-state 
transcription of actin mRNA (Kurtz & Czuprynski, 1992). The AFB1 dosage used in the 
Kurtz & Czuprynski (1992) study was 10 μg/ml and it was perfomed in vitro. Therefore, 
the dosage cannot be directly equated to the in vivo nature of the current project. It is 
possible that a dosage of 250ug of AFB1 over 10 days was not high enough to produce a 
significantly decreased IL-1β level.  
 
It has been previously elucidated that both Fe overloading and AFB1 ingestion causes a 
state of increased reactive oxygen and nitrogen species (Meneghini, 1997; Heinomen & 
Fisher, 1996). The link between oxidative stress and cancer has been well documented and 
is associated with the mutagenic potential of reactive forms of oxygen (Cerutti, 1994). The 
present study showed that serum nitrite levels at 6 months had an extent of synergy ratio of 
1:0.65, not quite additive (Fig. 6.5). When administered individually, the serum nitrite 
concentrations of the Fe and the AFB1 groups respectively were 11.3 and 11.6 μM/l, whilst 
the Fe + AFB1 group had a level of 18.8 μM/l.  . In terms of serum nitrite the Fe + AFB1 
group showed significantly elevated levels (Fig 6.5). This is accordingly reflected with the 
pattern noted with the lipid peroxidation graphs (Fig 6.6 & Fig 6.7). The serum nitrite 
pattern at 12 months is slightly different in that the Fe groups’ levels are also elevated, but 
not significantly so with respect to the Fe + AFB1 group. Although the AFB1 group was 
not significantly increased, it suggests that AFB1 is speeding up the potentially 
carcinogenic process in a time dependent process, in terms of Fe overloading. Nitric oxide 
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synthase 2 and hence nitric oxide is known to be increased in cases of HH (Marrogi et al., 
2001). AFB1 ingestion in rats has been implicated with a slight reduction in nitric oxide 
concentration (Meki et al., 2001). The superoxide levels showed that the AFB1 group had 
significantly raised levels (Fig. 2.2(i)). The superoxide graphs display the same pattern at 
the two time points, with the tendency being that the AFB1 group had elevated levels, 
significantly so at the 12 month time point (Fig. 2.2(i)). A resultant synergistic effect is 
observed in the Fe + AFBB1 group in terms of serum nitrite, because the superoxide being 
produced by the AFB1 is interacting with the nitric oxide produced from the Fe, and 
peroxynitrite is forming. The serum nitrite assay used is detecting the peroxynitrite. 
Peroxynitrite is a potent oxidant and cytotoxic ROS (Xia et al., 1996).   
 
Lipid-containing structures, such as cell membranes and lipoproteins are well known 
targets of ROS, which can result in lipid peroxidation, a degenerative process that disturbs 
the structure or function of the target system.  The induction of lipid peroxidation by AFB1 
and Fe overloading has been clearly elucidated by previous reports (Shen et al., 1994; Wu 
et al., 1990). It is noted that synergistic effects are seen initially in the liver at the 6-month 
time point (Fig. 6.6) and later in the serum (Fig 6.7) at the 12-month time point. This 
follows, considering that the tested substances are known hepatocarcinogens, that the liver 
would show the first signs of lipid peroxidation, and that the same trend would follow in 
the serum at a later stage. This explains what is seen in Fig A3.1 (viii). The drop in liver 
lipid peroxidation over time in the Fe group is not fully understood (Fig A3.1 (ix)), which 
is why the discussion was based on the serum results and not the liver homogenate. 
At 12 months, the Fe group had a mean LPO concentration of 45 ± 11.4μM, the AFB1 
group 15 ± 0.9μM and the Fe + AFB1 group 64.3 ± 14.8μM.   An additive synergistic 
effect is observed, with an extent of synergy ratio of 1:1.07. An assay to detect 8-
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Isoprostane was performed, and at 12 months, the liver 8-Isoprostane showed that the Fe + 
AFB1 group had raised levels in comparison to the control group only. An extent of 
synergy ratio of 1:0.67 was observed, however no statistically significant differences were 
noted between groups. No synergy was observed. AFB1 is unable to stimulate either 
arachidonic acid metabolism or initiate a respiratory burst of human leukocytes (Geissler & 
Henderson, 1988). In the event of free radical attack, arachidonic acid is oxidized to 8-
isoprostane. It appears that this pathway is not involved in the genotoxic mechanisms of 
AFB1, and therefore the driving force behind this assay’s results is the presence of Fe and 
not AFB1.  
 
The presence of guanine analogue 8-hydroxyguanosine (8OHdG) has been found in both 
cases of Fe overloading and also in cases of AFB1 exposure (Horvath et al., 2001; Shen et 
al., 1995). 8-OHdG is an abundant base modification in DNA whose levels increase with 
oxidative stress. The present study showed an interesting negative correlation between 8-
isoprostane and 8OHdG. The metabolism of 8-isoprostane is liver dependent, and 8OHdG 
is a result of free radical attack which results in liver dysfunction. An increased 8OHdG 
would lead to liver dysfunction and would hence lead to impaired 8-isoprostane 
production. At 6 months, the 8OHdG levels produced within the groups showed that the 
Fe, AFB1 and Fe + AFB1 groups had raised levels (Fig. 6.9). An extent of synergy ratio of 
1:0.62 was observed at this time point. 8OHdG measured from serum samples at 12 
months (Fig. 6.10) showed an additive synergistic effect occurring, with an extent of 
synergy ratio of 1:1.1. It was observed in this study that the amount of 8OHdG present is 
increased between the two time points. An additive synergistic relationship therefore exists 
in terms of 8OHdG production, where the two compounds are producing these adducts at a 
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higher rate. This is consistent with the observation that oxidative stress is being boosted 
when these two carcinogens act together.  
 
The Ames mutagenicity test is commonly used to determine whether a substance has 
mutagenic activity or not. A set of histidine-requiring strains is used for mutagenicity 
testing. Each tester strain is sensitive to different types of mutations. In this study, the 
following four tester strains were used, TA97, TA98, TA100 and TA102. TA97 is known 
to be sensitive to the same mutations which TA98 is sensitive to. In this study, TA97 failed 
to show any synergy, although the Fe group did produce high colony counts from this 
strain. Perhaps Fe’s ability to induce free radical attacks caused TA97 nucleic acid 
mutations regardless of its specificity to other mutations. TA97 contains a ‘hotspot’ with 
alternating G-C base pairs. It is suggested that 8-OHdG adducts would form within this 
region when under free radical attack, hence triggering TA97 spontaneous revertants. The 
AFB1 group and Fe + AFBB1 did not cause a significantly altered spontaneous reversion rate 
in this strain.  
 
TA98 detects various frame-shift mutations, and TA100 detects mutagens that cause base-
pair substitutions primarily at one of the G-C pairs. The TA98 and TA100 strains have the 
broadest specificity. Interestingly, this study shows a positive correlation between these 
two strains at the 12 month point. TA98 has previously been used to understand the 
mutagenicity of AFB1, and its use lead to the elucidation that the key structure to AFB1 
mutagenicity is a bisfuran ring moiety (Wong et al., 1977). These strains are also known to 
be sensitive to polycyclic aromatic hydrocarbons (Perez et al., 2003), 40% of which makes 
up the ferrocene molecule. The assumption that TA98 would be sensitive to mutagenicty 
caused by both carcinogens would hence be substantiated. TA98 showed that the Fe-fed 
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groups had raised colony counts with respect to the control group, but no synergistic effect 
was noted, regardless of activation with S9 enzymes. This finding is not well understood. 
TA100 results show that when administered simultaneously, the Fe + AFB1 group had 
elevated colony counts in comparison to the AFB1 group (Fig. 6.12). In terms of AFB1, it 
seems as though a slight synergistic effect is observed. An extent of synergy ratio of 1:0.63 
was observed. 
 
TA102 detects efficiently a variety of mutagens such as formaldehyde, hydroperoxides, 
bleomycin and is predominantly used to detect mutations generated through oxidative 
stress (Stayos et al., 2004). Knowing that both Fe and AFB1 are ROS/RNS inducers, it is 
understood why the results of TA102 colony counts show signs of synergy. The 
nuceleosomal (Fig.6.13), microsomal (Fig.14) and cytosolic (Fig.6.15) fractions 
particularly illustrate this point. The extent of synergy ratios for these fractions 
respectively was 1:0.6; 1:0.64; 1:0.65. When both carcinogens are administered, the result 
shows an increase in colony counts. This is expected because it is known that both 
carcinogens used are capable of eliciting ROS/RNS production. The results shown by 
testing with the TA102 strain are substantiated by the synergy shown by the serum nitrite, 
lipid peroxidation and 8OHdG assays. These measures are all increased in conjunction 
with an increased presence of ROS/RNS, and all show raised levels when both Fe and 
AFB1 are administered. With respect to oxidative stress, it would seem that a collective 
additive synergistic relationship is observed between Fe and AFB1. 
 
8.0. Conclusion 
Hepatocarcinogenesis is a disease of multifactorial etiology and involves a multistep 
process involving different genetic alterations that ultimately lead to malignant 
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transformation of hepatocytes. Oxidative stress is one of the major pathways involved in 
this transformation. Fe overload predominantly promotes hepatic carcinogenesis through 
DNA damage and lipid peroxidation attributed to oxidative stress. AFB1 is renown for 
exerting it hepatotoxic effects through the formation of guanyl adducts, but more recently 
also for its ability to enhance ROS/RNS production. To obtain a carcinogenic level of 
oxidative stress requires a multistep process. The generation of ROS/RNS, ultimately leads 
to LPO, DNA destruction and consequent malignant transformation. Examples of these 
steps were analyzed in the present study, and an additive synergistic relationship has been 
shown in terms of ALT, GGT, IL-10, lipid hydroperoxides, 8OHdG formation and nitrite 
production. The Ames mutagenicity TA102 tester strain, sensitive to oxidative stress, 
showed synergy, although not of an additive nature. It may seem that the effect of AFB1 is 
debatable, based on the fact that in some of the presented parameters, the AFB1 group was 
not significantly different to the control group. It is important to note that in some of these 
parameters there was a significant difference between the Fe group and the Fe + AFB1 
group. The implication of which is that the presence of AFB1 is increasing the activity of 
Fe as a carcinogen, thereby acting as a co-carcinogen. Examples of such parameters 
illustrating this are presented in the results section including serum ALT, serum nitrite, 
liver and serum lipid peroxidation, liver and serum 8-hydroxyguanosine, some of the 
mutagenicity assays, and interleukin-10. Further markers of oxidative stress and lipid 
peroxidation need to be utilized to substantiate these findings. The use of liver histology, in 
particular with reference to Fe-free foci development, gamma GT production, AFP 
presence and other signs of hepatocarcinogenesis and tumour formation are necessary to 
substantiate these findings further. The mechanisms behind this synergy need to be 
analyzed and elaborated upon in further studies. 
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Appendix A  
 
A. Appendix to Results 
 
A1.  Analysis of Variance Results for 6 Month Data 
 
A1.1. Indicators of Iron Overload and Liver Disease 
 
Table A1.1(i). Bonferroni Dunn and T-Tests 
for Serum Iron at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
2.043  
2.856   
0.762   
0.334   
2.805   
3.797   
ns   P>0.05 
*    P<0.05 
ns   P>0.05 
ns   P>0.05 
ns   P>0.05 
**  P<0.01 
 
 
 
 
 
 
 
 
A1.1i) ANOVA Data of Serum Iron at 6 months.   
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 7 45.8 9.3 3.5 50.1 32.3      56.9 37.2           54.4 
Fe 6 95.2 12.9 5.3 92.9 79.6    114.0 81.7         108.8 
Fe + AFB1 17 87.8 14.2 3.5 92.7 69.0    118.2 80.5           95.0 
AFB1 5 37.6 12.2 5.4 39.2 25.7      55.5 22.5           52.7 
 
A1.1i) Intermediate Calculations. ANOVA Table (Serum Iron at 6 months) 
 
        Source of                             Degrees of         Sum of     Mean   
        variation                               freedom            squares    square  
======================  ==========  ========  ======== 
Treatments (between columns)           3                   18129      6043.1 
Residuals (within columns)               31                  5192.1     167.49 
----------------------------                  ----------            -------- 
Total                                                  34                   23321 
 
F = 36.081  =(MStreatment/MSresidual) 
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Table A1.1(ii). Bonferroni (Dunn) and t-tests 
for ALT at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
9.959 
8.602 
0.639   
3.302   
8.856 
7.296 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
  *   P<0.05 
*** P<0.001 
*** P<0.001 
 
 
 
 
 
 
 
 
A1.1ii) ANOVA Data of ALT at 6 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 21.6 6.5 2.6 20.0 16.0      34.1 14.8           28.4 
Fe 6 91.8 13.5 5.5 88.1 81.0    114.8 77.6         106.0 
Fe + AFB1 15 72.3 14.7 3.8 75.2 45.0      92.7 64.2           80.5 
AFB1 5 26.3 1.2 0.5 26.6 25.2      27.9 24.9           27.8 
 
 
 
A1.1. ii) Intermediate Calculations. ANOVA Table (ALT at 6 months) 
 
 
        Source of                                            Degrees of        Sum of       Mean   
        variation                                             freedom             squares      square  
============================  ==========  ========  ======== 
Treatments (between columns)                      3                    22816        7605.4 
Residuals (within columns)                           28                  4168.0       148.86 
----------------------------                              ----------            -------- 
Total                                                              31                   26984 
 
F = 51.092  =(MStreatment/MSresidual) 
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Table A1.1(iii). Bonferroni (Dunn) and t-tests 
for AST at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
4.915 
2.944   
0.268   
3.066   
4.635 
2.613   
*** P<0.001 
  *   P<0.05 
  ns  P>0.05 
  *   P<0.05 
*** P<0.001 
  ns  P>0.05 
 
 
 
 
 
 
 
 
 
A1.1(iii) ANOVA Data of AST at 6 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 15.2 2.5 1.1 14.6 12.3      18.5 12.2           18.3 
Fe 6 30.0 6.9 2.8 28.8 20.6      41.1 22.7           37.3 
Fe + AFB1 16 22.7 4.6 1.2 23.2 15.1      30.5 20.3           25.2 
AFB1 5 16.1 5.1 2.3 15.7 8.6        22.2   9.8           22.4 
 
 
 
A1.1(iii) Intermediate Calculations. ANOVA Table (AST at 6 months) 
 
 
        Source of                                             Degrees of      Sum of        Mean   
        variation                                               freedom         squares       square  
============================  ==========  ========  ======== 
Treatments (between columns)                        3                  793.72        264.57 
Residuals (within columns)                           28                   687.15         24.541 
----------------------------                              ----------             -------- 
Total                                                               31                 1480.9 
 
F = 10.781  =(MStreatment/MSresidual) 
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A1.1 (iv)  ANOVA Data of GGT at 6 months. (Figure 6.4 in Results) 
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   3.1   0.7 0.2   3.2   2.1        3.9   2.2             3.9 
Fe   6 44.2 14.6 5.9 45.8 25.5      60.2 28.9           59.5 
Fe + AFB1 17 56.4 18.7 4.5 49.8 28.7      89.9 46.8           66.0 
AFB1   6   1.9  0.8 0.3   1.6   1.2        3.2   1.1             2.7 
 
 
A1.1. (iv) Intermediate Calculations. ANOVA Table (GGT at 6 months) 
 
        Source of                                              Degrees of     Sum of         Mean   
        variation                                               freedom         squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 19857          6619.0 
Residuals (within columns)                            30                  6671.6         222.39 
----------------------------                               ----------            -------- 
Total                                                               33                  26529 
 
F = 29.764  =(MStreatment/MSresidual) 
 
 
A1.2. Reactive Oxygen Species and Reactive Nitrogen Species 
 
 
  
Table A1.2(i). Bonferroni (Dunn) and t-tests 
for Superoxide Anion in Whole Blood at 6 
months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.397 
0.211   
1.226   
0.282   
1.623   
1.735   
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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A1.2(i) ANOVA Data of Superoxide Anion in Whole Blood at 6 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 0.063 0.022 0.010 0.066 0.031  0.085 0.036       0.090 
Fe 5 0.051 0.014 0.006 0.051 0.032  0.068 0.033       0.068 
Fe + AFB1 17 0.058 0.062 0.015 0.043 0.011  0.285 0.026       0.090 
AFB1 5 0.101 0.030 0.013 0.101 0.062  0.132 0.064       0.138 
 
 
A1.2 (i) Intermediate Calculations. ANOVA Table (Superoxide Anion in Whole 
Blood at 6 months) 
 
       Source of                                            Degrees of          Sum of       Mean   
        variation                                            freedom              squares       square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3              0.008460      0.002820 
Residuals (within columns)                             28               0.06772       0.002419 
----------------------------                                ----------            -------- 
Total                                                                 31                0.07618 
 
F = 1.166  =(MStreatment/MSresidual)  
 
 
Table A1.2(ii). Bonferroni (Dunn) and t-tests 
for Liver Nitrite Levels at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.476 
2.079   
2.337   
1.374   
1.782   
0.841    
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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A1.2(ii)  ANOVA Data of Liver Nitrite at 6 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   6   9.8 1.7 0.69   9.5   7.6      12.0   8.0           11.6 
Fe   5 10.7 1.4 0.62 11.1   8.5      12.3   8.9           12.4 
Fe + AFB1 17 12.8 3.8 0.92 11.4   7.9      22.5 10.9           14.8 
AFB1   5 14.2 2.6 1.18 13.3 11.7      17.7 10.9           17.4 
 
 
A1.2(ii) Intermediate Calculations. ANOVA Table (Liver Nitrite at 6 months) 
 
        Source of                                          Degrees of         Sum of        Mean   
        variation                                            freedom             squares       square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 72.964        24.321 
Residuals (within columns)                            29                 278.45          9.602 
----------------------------                              ----------            -------- 
Total                                                               32                  351.42 
 
F = 2.533  =(MStreatment/MSresidual) 
 
 
A1.2(iii) ANOVA Data of Serum Nitrite at 6 months (Figure 6.5 in Results).  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   7.9 1.1 0.5   8.6   6.3        8.9   6.5             9.3 
Fe   5 11.3 1.0 0.5 11.9   9.7      12.2 10.0           12.6 
Fe + AFB1 17 18.8 5.3 1.3 18.0 10.6      30.9 16.1           21.5 
AFB1   5 11.6 1.2 0.5 11.1 10.6      13.5 10.2           13.0 
 
 
A1.2(iii) Intermediate Calculations. ANOVA Table (Serum Nitrite at 6 months) 
 
        Source of                                           Degrees of        Sum of         Mean   
        variation                                            freedom            squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 620.28         206.76 
Residuals (within columns)                            28                  463.08         16.538 
----------------------------                               ----------            -------- 
Total                                                               31                 1083.4 
 
F = 12.502  =(MStreatment/MSresidual) 
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A.1.3. Indicators of Lipid Peroxidation 
 
A1.3(i) ANOVA Data of Liver Lipid Peroxidation at 6 months (Figure 6.6 in 
Results).  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 41.6 8.8 3.9 46.2   31.1    50.1   30.7         52.5 
Fe   6 96.6 5.3 2.1 98.6   86.9  100.4   91.1       102.1 
Fe + AFB1 15 126.6 18.3 4.7 119.9 108.6  180.6 116.4       136.7 
AFB1   5 72.9 17.2 7.7 77.1   44.1    89.1   51.6         94.3 
 
A1.3(i) Intermediate Calculations. ANOVA Table (Liver Lipid Peroxidation at 6 
months) 
 
 
       Source of                                             Degrees of       Sum of         Mean   
        variation                                             freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                31304           10435 
Residuals (within columns)                              27               6329.5           234.43 
----------------------------                                ----------           -------- 
Total                                                                  30               37634 
 
F = 44.512  =(MStreatment/MSresidual) 
 
 
Table A1.3(ii). Bonferroni (Dunn) and t-tests 
Serum Lipid Peroxidation Levels at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
6.725 
6.512 
1.071   
1.724   
5.654 
5.200 
*** P<0.001 
*** P<0.001 
  ns  P>0.05 
  ns  P>0.05 
*** P<0.001 
*** P<0.001 
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A1.3(ii) ANOVA Data of Serum Lipid Peroxidation at 6 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 26.1   6.6 3.0 22.9 27.7      37.6 17.9           34.4 
Fe   5 69.9   6.2 2.8 68.5 63.8      80.2 62.3           77.6 
Fe + AFB1 15 60.8   9.9 2.6 58.5 50.8      88.2 55.3           66.3 
AFB1   5 33.1 16.3 7.3 28.8 18.5      61.1 12.9           53.3 
 
A1.3(ii) Intermediate Calculations. ANOVA Table (Liver Lipid Peroxidation at 6 
months) 
 
   Source of                                                 Degrees of      Sum of          Mean   
    variation                                                 freedom          squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                7892.6        2630.9 
Residuals (within columns)                              26                2758.3        106.09 
----------------------------                                ----------           -------- 
Total                                                                 29                10651 
 
F = 24.799  =(MStreatment/MSresidual) 
 
 
 
  
Table A1.3(iii). Bonferroni (Dunn) and t-tests 
of Serum 8-Isoprostane Levels at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
3.283   
4.383 
0.164   
0.392   
2.966   
3.897   
  *   P<0.05 
*** P<0.001 
  ns  P>0.05 
  ns  P>0.05 
  *   P<0.05 
 **  P<0.01 
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A1.3(iii) ANOVA Data of Serum 8-Isoprostane at 6 months.  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 1969.8 154.0 62.9 1977.5 1738    2213   1808         2131 
Fe 6 2259.7 136.1 55.6 2300.0 2005    2377   2116         2402 
Fe + AFB1 17 2288.1 150.4 36.5 2300.0 2061    2552   2210         2365 
AFB1 5 1985.0 178.9 80.0 1898.0 1816    2262   1762         2207 
 
 
A1.3(iii) Intermediate Calculations. ANOVA Table (Serum 8-Isoprostane at 6 
months) 
 
 
       Source of                                             Degrees of       Sum of         Mean   
       variation                                              freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3               691758         230586 
Residuals (within columns)                            30                701432          23381 
----------------------------                               ----------           -------- 
Total                                                                33               1393190 
 
F = 9.862  =(MStreatment/MSresidual) 
 
 
A1.4. Indicators of Collagen Expression 
 
 
 
 
 
 
 
 
 
Table A1.4(i). Bonferroni (Dunn) and t-tests 
of Liver Hydroxyproline Levels at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
1.684  
2.177   
1.492   
0.114   
0.192   
0.349   
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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A1.4(i) ANOVA Data of Hydroxyproline at 6 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 3.3 0.3 0.2 3.4 2.73      3.60   2.83           3.68 
Fe 5 4.5 1.4 0.6 4.1 2.74      6.16 2.75           6.15 
Fe + AFB1 15 4.5 1.1 0.3 4.8 2.74      6.32   3.92           5.11 
AFB1 5 4.3 1.5 0.7 5.1 2.40      5.48 2.49           6.13 
 
A4.1(i) Intermediate Calculations. ANOVA Table (Hydroxyproline at 6 months) 
 
   Source of                                                Degrees of        Sum of          Mean   
   variation                                                  freedom           squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                 6.235            2.078 
Residuals (within columns)                              26              32.756            1.260 
----------------------------                               ----------          -------- 
Total                                                                 29               38.991 
 
F = 1.650  =(MStreatment/MSresidual) 
 
 
 
A1.5. Indicators of DNA Changes 
 
 
A1.5(i) ANOVA Data of Liver 8-OHdG at 6 months (Figure 6.10 in Results).  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5   702.4 48.2 21.6 709.0 641        750     643           762 
Fe 5 3323.6 542.0 242.4 3190.0 2575    3874   2651         3997 
Fe + AFB1 17 4415.8 617.0 149.6 4293.0 3433    5951   4099         4733 
AFB1 5   686.4 80.2 35.9 713.0 558        750     587           786 
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A1.5 (i) Intermediate Calculations. ANOVA Table (Liver 8-OHdG at 6 months) 
    
        Source of                                            Degrees of      Sum of         Mean   
        variation                                             freedom          squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3            8.754E+07   2.918E+07 
Residuals (within columns)                             28            7300724         260740 
----------------------------                               ----------            -------- 
Total                                                                 31            9.484E+07 
 
F = 111.92  =(MStreatment/MSresidual) 
 
 
A1.5(ii) ANOVA Data of Serum 8-OHdG at 6 months (Figure 6.9 in Results).  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   22.2      4.1   1.8   20.0 18.1      26.6     17.1        27.3 
Fe   5 120.2 24.7 11.1 118.8 95.6    150.7     89.5      151.0 
Fe + AFB1 16 133.3   17.2   4.3 141.9 90.5    150.7   124.1      142.4 
AFB1   5   93.5      9.9   4.4   90.1 81.2    104.0     81.2      105.8 
 
 
A1.5(ii) Intermediate Calculations. ANOVA Table (Serum 8-OHdG at 6 months) 
 
 
        Source of                                            Degrees of        Sum of      Mean   
        variation                                              freedom           squares      square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                 48809         16270 
Residuals (within columns)                              27                 7330.8       271.51 
----------------------------                                 ----------          -------- 
Total                                                                  30                 56140 
 
F = 59.923  =(MStreatment/MSresidual) 
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A2.  Analysis of Variance Results for 12 Month Data 
 
A2.1(i) ANOVA Data of Serum Iron at 12 months (Figure 6.1 in Results).  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   59.7      9.7       4.4       62.0 45.8      70.0     47.9       72.1 
Fe   5 127.0    28.0      12.5     118.7 98.8    173.7     92.2     161.8 
Fe + AFB1 16 133.3    44.1      11.0     129.0 86.7    263.0   109.8     156.7 
AFB1   5   61.8    17.1         7.7       57.2 41.1        3.4     40.6       83.1 
 
 
 
 
A2.1(i) Intermediate Calculations. ANOVA Table (Serum Iron at 12 months) 
 
   Source of                                                Degrees of       Sum of        Mean   
    variation                                                freedom           squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                 34176         11392 
Residuals (within columns)                             27                  33866        1254.3 
----------------------------                               ----------            -------- 
Total                                                                30                  68041 
 
F = 9.082  =(MStreatment/MSresidual) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1(ii). Bonferroni (Dunn) and t-tests 
of Liver Ferritin Levels at 6 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.205 
2.878   
2.169   
3.135   
2.374   
0.165  
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
ns  P>0.05 
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A2.1(ii) ANOVA Data of Ferritin at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 105.2    23.5      10.5     111.0 64.3   123.9    76.1         134.4 
Fe   5 107.5      9.6        4.3     108.0 92.0   117.4    95.6         119.5 
Fe + AFB1 18   79.4    16.2         3.8       80.1 37.7   101.4    71.3           87.4 
AFB1   5   80.9    23.1      10.3       84.7 54.3   112.0    52.2         109.5 
 
 
 A2.1(ii) Intermediate Calculations. ANOVA Table (Ferritin at 12 months) 
 
        Source of                                            Degrees of       Sum of          Mean   
        variation                                             freedom           squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                4983.2        1661.1 
Residuals (within columns)                              29               9154.0         315.65 
----------------------------                               ----------           -------- 
Total                                                                 32                14137 
 
F = 5.262  =(MStreatment/MSresidual) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1(iii). Bonferroni (Dunn) and t-tests 
of  Total Iron Binding Capacity (TIBC)at 6 
months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.205 
2.878   
2.169   
3.135   
2.374   
0.165  
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
ns  P>0.05 
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(TIBC) of Wistar Albino Rats 
at 12 months 
 174
 
A2.1(iii) ANOVA Data of Total Iron Binding Capacity (TIBC) at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   67.5     2.13 0.96 67.5  64.2    70.1     64.87     70.18 
Fe   5 124.6   13.92 6.23 124.6 105.3  143.7   107.30   141.86 
Fe + AFB1 12 126.6 108.64 31.36 98.9  65.9  466.6     57.56   195.62 
AFB1   5   68.4   18.91 8.46 64.2  47.1    98.0     44.95     91.89 
 
 
A2.1(iii) Intermediate Calculations. ANOVA Table (Total Iron Binding Capacity 
(TIBC)  at 12 months) 
 
        Source of                                            Degrees of      Sum of        Mean   
        variation                                             freedom          squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 21219         7073.0 
Residuals (within columns)                             23               132058        5741.6 
----------------------------                              ----------            -------- 
Total                                                                26               153277 
 
F = 1.232  =(MStreatment/MSresidual) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1(iv). Bonferroni (Dunn) and t-tests 
for Percentage Saturation of Iron (PSAT) at 
12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.205 
2.878   
2.169   
3.135   
2.374   
0.165  
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
ns  P>0.05 
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A2.1(iv) ANOVA Data of Percentage Saturation of Iron (PSAT)at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 81.7    26.8      12.0     91.4 36.4   105.6    48.4     114.9 
Fe   5 96.5    18.8       8.4     98.1 68.2   120.9    73.2     119.8 
Fe + AFB1 12 97.9    23.8       6.9     107.3 56.4   132.4    82.8     113.0 
AFB1   5 78.2    45.9      20.5     62.3 35.0   130.1    21.3     135.1 
 
A2.1(iv) Intermediate Calculations. ANOVA Table (Percentage Saturation of 
Iron (PSAT) at 12 months) 
 
        Source of                                            Degrees of        Sum of       Mean   
        variation                                             freedom            squares       square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                 1979.3        659.75 
Residuals (within columns)                              23                 18909        822.14 
----------------------------                               ----------            -------- 
Total                                                                 26                 20888 
 
F = 0.8025  =(MStreatment/MSresidual) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1(v). Bonferroni (Dunn) and t-tests 
for Non-Transferrin Bound Iron (NTBI) at 
12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
6.992 
8.416 
0.426   
0.216   
7.418 
8.941 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 
*** P<0.001 
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A2.1(v) ANOVA Data of Non-Transferrin Bound Iron (NTBI)at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   6.6       4.18      1.87      6.4  0.90  12.70   1.37     11.75 
Fe   5 49.9       9.13      4.09     50.0 36.10    1.70   38.58     61.26 
Fe + AFB1 16 48.8    17.71      4.43     45.6 23.40    7.50   39.40     58.27 
AFB1   5   3.9       4.55      2.03     0.7  0.40    9.10   -1.73      9.57 
  
A2.1(v) Intermediate Calculations. ANOVA Table (NTBI at 12 months) 
 
        Source of                                           Degrees of       Sum of          Mean   
        variation                                            freedom           squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                13051          4350.2 
Residuals (within columns)                              27               5191.5         192.28 
----------------------------                               ----------           -------- 
Total                                                                 30                18242 
 
F = 22.624  =(MStreatment/MSresidual) 
 
 
A2.1(vi) ANOVA Data of ALT at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 107.5    24.3         9.9     103.5  81.0  150.0     82.0     133.0 
Fe 5 311.3    44.2      19.8     311.3 256.0  375.0   256.4     366.1 
Fe + AFB1 9 485.6    87.2      29.1     452.0 370.3  608.0   418.6     552.6 
AFB1 5 150.0    35.4      15.8     170.0  93.0  177.0   106.1     193.9 
  
A2.1(vi) Intermediate Calculations. ANOVA Table (ALT at 12 months) 
 
 
        Source of                                            Degrees of       Sum of        Mean   
        variation                                             freedom           squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3               644187        214729 
Residuals (within columns)                              21               76563          3645.9 
----------------------------                               ----------           -------- 
Total                                                                 24               720751 
 
F = 58.897  =(MStreatment/MSresidual) 
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A2.1(vii) ANOVA Data of AST at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 173.8    35.6      14.6     160.0 144.0   33.0    136.4     211.2 
Fe 5 391.8    16.5 7.4     391.8 367.0  411.0   371.3     412.2 
Fe + AFB1 9 454.4 75.2 25.1     455.0 342.3   14.0    396.6     512.2 
AFB1 5 241.4 22.5      10.1     232.0 222.0  279.8   213.5     269.4 
 
A2.1(vii) Intermediate Calculations. ANOVA Table (AST at 12 months) 
 
     Source of                                              Degrees of       Sum of         Mean   
      variation                                              freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3               343798        114599 
Residuals (within columns)                              21               54682          2603.9 
----------------------------                               ----------           -------- 
Total                                                                 24               398480 
 
F = 44.010  =(MStreatment/MSresidual) 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1(viii) Bonferroni (Dunn) and t-
tests for GGT at 12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
5.920 
5.888 
0.065   
1.471   
5.855 
5.807 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 
*** P<0.001 
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A2.1(viii) ANOVA Data of GGT at 12 months.  
 
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 3.1    0.6 0.3 3.5  2.49    3.64     2.40         3.81 
Fe 5 27.4 3.8 1.7 27.4 22.04  32.68   22.67       32.10 
Fe + AFB1 17 22.5 8.4 2.0 23.0   7.28  39.87 18.24       26.82 
AFB1 5 3.4 1.0 0.4 3.1  2.49    4.98     2.17         4.57 
 
 A2.1(viii) Intermediate Calculations. ANOVA Table (GGT at 12 months) 
 
       
      Source of                                             Degrees of        Sum of     Mean   
      variation                                              freedom             squares    square  
============================  ==========  ========  ======== 
Treatments (between columns)                           3               2951.2        983.75 
Residuals (within columns)                               28               1177.6       42.056 
----------------------------                                ----------           -------- 
Total                                                                  31               4128.8 
 
F = 23.391  =(MStreatment/MSresidual) 
 
 
 
A2.2. Reactive Oxygen Species and Reactive Nitrogen Species 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.2(i)  Bonferroni (Dunn) and t-tests 
for Superoxide Anion at 12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.220 
0.619   
2.865   
0.893   
3.085   
2.943 
ns  P>0.05 
ns  P>0.05 
*   P<0.05 
ns  P>0.05 
*   P<0.05 
*   P<0.05 
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A2.2(i) ANOVA Data of Superoxide Production at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 0.038   0.038     0.017    0.03 0.00      0.10   -0.009      0.085 
Fe 5 0.028   0.018    0.008    0.03 0.00      0.05     0.006     0.050 
Fe + AFB1 17 0.061   0.064     0.016    0.04 0.00      0.23     0.028     0.093 
AFB1 5 0.168    0.134     0.060     0.17 0.02      0.35     0.002     0.334 
             
A2.2(i) Intermediate Calculations. ANOVA Table (Superoxide Production at 12 
months) 
 
        Source of                                           Degrees of        Sum of         Mean   
        variation                                            freedom            squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3               0.06342      0.02114 
Residuals (within columns)                              28               0.1441        0.005148 
----------------------------                                ----------           -------- 
Total                                                                  31              0.2076 
 
F = 4.106  =(MStreatment/MSresidual) 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.2(ii). Bonferroni (Dunn) and t-tests 
for Liver Nitrite Concentration at 12 months 
 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.098 
0.422   
0.551   
0.299   
0.649   
1.111    
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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A2.2(ii) ANOVA Data of Liver Nitrite Levels at 12 months.  
  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 5 42.3 3.8       1.60     42.32 38.0   46.8      37.9     46.8 
Fe 5 42.8     4.8       2.13     44.88 34.5   45.9      36.8     48.7 
Fe + AFB1 18 43.8     8.7       2.05     41.08 36.8   73.0      39.5     48.2 
AFB1 5 39.8     3.3       1.47     39.84 36.6   43.5      35.8     44.0 
 
A.2.2(ii) Intermediate Calculations. ANOVA Table (Liver Nitrite Levels at 12 
months) 
 
        Source of                                             Degrees of      Sum of         Mean   
        variation                                              freedom          squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 64.087        21.362 
Residuals (within columns)                             29                1464.9        50.513 
----------------------------                              ----------            -------- 
Total                                                                32                 1529.0 
 
F = 0.4229  =(MStreatment/MSresidual) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.2(iii). Bonferroni (Dunn) and t-tests 
for Serum Nitrite Concentration at 12 
months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
3.548 
2.092   
0.479   
2.420 
3.255 
1.652 
**  P<0.01 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
*    P<0.05 
ns  P>0.05 
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Figure A2.2(iii) Bar Graph of 
Serum Nitrite Levels of Wistar 
Albino Rats at 12 months 
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A2.2(iii) ANOVA Data of Serum Nitrite Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 4 9.8       2.0       1.0      9.8  8.0      11.6     6.6           13.0 
Fe 5 21.0      5.8       2.6     18.7 15.9      31.0   13.8           28.3 
Fe + AFB1 18 15.2     5.1      1.2     12.4  9.8      24.3   12.7           17.8 
AFB1 5 11.3 3.0      1.4     10.4  9.1      16.6     7.6           15.1 
 
 
   A2.2(iii) Intermediate Calculations. ANOVA Table (Serum Nitrite Levels at 12 
months) 
     
        Source of                                           Degrees of       Sum of        Mean   
        variation                                            freedom           squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                  357.55       119.18 
Residuals (within columns)                             28                 621.95       22.212 
----------------------------                               ----------            -------- 
Total                                                                31                 979.50 
 
F = 5.366  =(MStreatment/MSresidual) 
 
A2.3. Indicators of Lipid Peroxidation 
 
A2.3(i) ANOVA Data of Liver 8-Isoprostane Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 736 208 93 737  525    1073     478           995 
Fe   6 1264 272 111 1250  969    1765     978         1550 
Fe + AFB1 17 1773 415 101 1881 1033    2398   1560         1986 
AFB1   5 1376    554 248 1129  957    2308     689         2065 
 
   A2.3(i) Intermediate Calculations. ANOVA Table (Liver 8-Isoprostane Levels 
at 12 months) 
 
        Source of                                            Degrees of      Sum of        Mean   
        variation                                             freedom          squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3               4548381      1516127 
Residuals (within columns)                             29              4531985      156275 
----------------------------                               ----------           -------- 
Total                                                                32              9080366 
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F = 9.702  =(MStreatment/MSresidual)   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2.3(ii) ANOVA Data of Serum 8-Isoprostane Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 979 253 113 921  741    1403     666         1293 
Fe   5 2578 333 149 2588 2057    2979   2164         2992 
Fe + AFB1 20 2444 537 120 2540 1033    3135   2192         2695 
AFB1   5 1122 193 86 1121  853    1350     882         1361 
   
 A2.3(ii) Intermediate Calculations. ANOVA Table (Serum 8-Isoprostane Levels 
at 12 months) 
 
 
        Source of                                             Degrees of      Sum of        Mean   
        variation                                               freedom         squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3             1.452E+07    4841337 
Residuals (within columns)                              31               6325580      204051 
----------------------------                                ----------            -------- 
Total                                                                 34             2.085E+07 
 
F = 23.726  =(MStreatment/MSresidual) 
 
 
 
 
 
Table A2.3(ii). Bonferroni (Dunn) and t-tests 
for  Serum 8-Isoprostane Levels at 12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
5.596 
6.482 
0.498 
0.597 
5.098 
5.853 
***P<0.001 
***P<0.001 
ns   P>0.05 
ns   P>0.05 
***P<0.001  
***P<0.001 
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Figure A2.3(ii) Bar Graph of 
Serum 8-Isoprostane Levels of 
Wistar Albino Rats at 12 months 
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A2.3(iii) ANOVA Data of Liver Lipid Peroxidation Levels at 12 months.  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 332.8    35.5      15.9     326.8 297.5  369.6   288.7     376.9 
Fe   5 308.2    12.6       5.6     308.0 293.2  326.1   292.6     323.8 
Fe + AFB1 19 286.2    21.6       5.0     283.2 241.8  335.4   275.7     296.6 
AFB1   5 305.9    16.8       7.5     304.6 281.8  328.9   285.1     326.8 
 
 
A2.3(iii) Intermediate Calculations. ANOVA Table (Liver Lipid Peroxidation 
Levels at 12 months) 
 
        Source of                                             Degrees of      Sum of        Mean   
        variation                                              freedom          squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                9506.0        3168.7 
Residuals (within columns)                              30               15232         507.74 
----------------------------                               ----------           -------- 
Total                                                                 33                24738 
 
F = 6.241  =(MStreatment/MSresidual) 
 
 
 
 
Table A2.3(iii) Bonferroni (Dunn) and t-tests 
for Liver Lipid Peroxidation at 12 months 
Treatment 
Comparison 
t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
1.727  
4.118   
1.885   
1.945   
0.158   
1.747   
ns  P>0.05 
** P<0.01 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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Figure A2.3(iii) Bar Graph of Liver 
Lipid Peroxidation Levels of 
Wistar Albino Rats at 12 months 
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A2.3(iv) ANOVA Data of Serum Lipid Peroxidation Levels at 12 months.  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 15.2       2.6       1.2     15.2 12.0      18.8   11.9           18.4 
Fe   5 45.0    11.4       5.1     41.4 36.0      64.5   30.9           59.2 
Fe + AFB1 18 64.3    14.8       3.5     63.5 37.9    101.3   57.0           71.7 
AFB1   4 15.0      0.9      0.5     15.3 13.6      15.6   13.5           16.5 
 
A2.3(iv) Intermediate Calculations. ANOVA Table (Serum Lipid Peroxidation 
Levels at 12 months) 
 
 
        Source of                                             Degrees of      Sum of        Mean   
        variation                                              freedom          squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 14599          4866.4 
Residuals (within columns)                             28                4280.0         152.86 
----------------------------                               ----------           -------- 
Total                                                                31                 18879 
 
F = 31.836  =(MStreatment/MSresidual) 
 
 
A2.4. Indicators of DNA Change 
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Table A2.4(i) Bonferroni (Dunn) and t-tests for 
Liver 8-Hydroxyguanosine at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
6.340 
9.380 
0.592   
1.498   
5.749 
8.644 
*** P<0.001 
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
*** P<0.001 
*** P<0.001 
Figure A2.4(i)  Bar Graph of 
Liver 8-hydroxyguanosine Levels 
of Wistar Albino Rats at 12 
months 
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A2.4(i) ANOVA Data of Liver 8-Hydroxyguanosine Levels at 12 months.  
  
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 1405 79 35 1405 1290   1500    1307     1503 
Fe   5 5800   941 421 6000 4300   6900    4632     6968 
Fe + AFB1 17 6635 1366 331 6200 5100    9400   5933     7338 
AFB1   5 1815 231 104   1815 1550   2050    1528     2102 
 
A2.4(i) Intermediate Calculations. ANOVA Table (Liver 8-Hydroxyguanosine 
Levels at 12 months) 
        Source of                                            Degrees of      Sum of          Mean   
        variation                                             freedom          squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3             1.639E+08   5.462E+07 
Residuals (within columns)                             28             3.364E+07    1201351 
----------------------------                              ----------             -------- 
Total                                                                31             1.975E+08 
 
F = 45.467  =(MStreatment/MSresidual) 
 
 
A2.4(ii) ANOVA Data of Serum 8-Hydroxyguanosine Levels at 12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 58.8      34.3      15.4      58.8 21.0   100.6    16.2     101.4 
Fe   5 74.9      12.6       5.7     79.7 53.2   84.4      59.2      90.6 
Fe + AFB1 17 146.5    85.4      20.7     112.8 41.0   360.8    102.6     190.4 
AFB1   5 71.3      41.2      18.4     80.1 14.6   126.5    20.2     122.5 
 
A2.4(ii) Intermediate Calculations. ANOVA Table (Serum 8-Hydroxyguanosine 
Levels at 12 months) 
 
        Source of                                           Degrees of       Sum of          Mean   
        variation                                             freedom          squares          square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                49391         16464 
Residuals (within columns)                              28              128895        4603.4 
----------------------------                               ----------           -------- 
Total                                                                 31              178286 
 
F = 3.576  =(MStreatment/MSresidual) 
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A2.5. Indicators of Mutagenicity (Ames Test) 
 
Where one of the Salmonella typhimirium strains used showed a very similar pattern 
in its whole homogenate, the other homogenate’s data was omitted to avoid 
redundancy, and only the whole homogenate shown. Where there were significant 
differences in homogenates, the statistical data is shown.  
 
The TA97 strain is only represented here as the whole fraction. All other fractions 
thereof showed almost identical patterns between groups and it was thought redundant 
to present that data.  
 
A2.5(i) ANOVA Data of Ames Test TA97-Whole Fraction Colony Counts at 12 
months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 137   4   1.7 138 132        141   133             141 
Fe 6 234 31 12.8 224 205        273   201             267 
Fe + AFB1 9 188 25   8.5 189 138        236   169             208 
AFB1 5 158   4   1.6 157 154        162   154             163 
 
A2.5(i) Intermediate Calculations. ANOVA Table (TA97-Whole Fraction Colony 
Counts at 12 months) 
 
        Source of                                            Degrees of       Sum of        Mean   
        variation                                             freedom           squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                 31506        10502 
Residuals (within columns)                              22                10255        466.15 
----------------------------                                ----------          -------- 
Total                                                                 25                 41761 
 
F = 22.529  =(MStreatment/MSresidual) 
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A2.5(ii) ANOVA Data of Ames Test TA98-Whole Fraction Colony Counts at 12 
months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 39.333  1.862      0.7601    40 37            41 37                 41 
Fe 6 54.000  11.628      4.747     47 46            69 42                 66 
Fe + AFB1 5 43.800  10.281      4.598     40 37            62 31                 57 
AFB1 6 33.333  2.066      0.8433    32 32            36 31                 36 
 
A2.5(ii) Intermediate Calculations. ANOVA Table (TA98-Whole Fraction 
Colony Counts at 12 months) 
 
        Source of                                            Degrees of      Sum of         Mean   
        variation                                             freedom          squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                1366.2          455.40 
Residuals (within columns)                             19               1137.5          59.867 
----------------------------                               ----------           -------- 
Total                                                                22                2503.7 
 
F = 7.607  =(MStreatment/MSresidual) 
 
 
A2.5(iii) ANOVA Data of Ames Test TA98-S9 Fraction Colony Counts at 12 
months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 29   4 2 27 26            34   24.9           33.1 
Fe 6 49   6 2 50 42            54   42.9           54.4 
Fe + AFB1 9 48 16 5 43 21            71   35.9           61.0 
AFB1 5 43 10 4 37 33            53   30.6           54.6 
 
A2.5(iii) Intermediate Calculations. ANOVA Table (TA98-S9 Fraction Colony 
Counts at 12 months) 
 
        Source of                                            Degrees of       Sum of         Mean   
        variation                                             freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3               1635.9          545.30 
Residuals (within columns)                              22               2726.8         123.94 
----------------------------                                ----------          -------- 
Total                                                                 25               4362.7 
 
F = 4.400  =(MStreatment/MSresidual) 
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A2.5(iv) ANOVA Data of Ames Test TA100 - Whole Fraction Colony Counts at 
12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 125 18 8 136 101    137      105.4     143.9 
Fe 6 154 22 9 151 131   180      130.9     177.1 
Fe + AFB1 9 176 21 7 169 147   211      159.2     192.1 
AFB1 5 126 3 1 127 122   128      123.3     129.5 
 
A2.5(iv) Intermediate Calculations. ANOVA Table (TA100 - Whole Fraction 
Colony Counts at 12 months) 
 
        Source of                                           Degrees of       Sum of        Mean   
        variation                                            freedom           squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 12652         4217.3 
Residuals (within columns)                             22                7792.5        354.21 
----------------------------                               ----------           -------- 
Total                                                                25                 20444 
 
F = 11.906  =(MStreatment/MSresidual) 
 
 
A2.5(v) ANOVA Data of Ames Test TA102 - Whole Fraction Colony Counts at 
12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 358      9       4     361 347        367 349             368 
Fe 6 417      6         2 420 410        422 411             423 
Fe + AFB1 6 439  111  45  425 305        572 323             556 
AFB1 6 451      24  10     467 420        467 426             477 
 
 
A2.5(iv) Intermediate Calculations. ANOVA Table (TA102 - Whole Fraction 
Colony Counts at 12 months) 
 
        Source of                                           Degrees of        Sum of         Mean   
        variation                                            freedom            squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 30667          10222 
Residuals (within columns)                             20                 65179         3258.9 
----------------------------                               ----------           -------- 
Total                                                                23                95846 
 
F = 3.137  =(MStreatment/MSresidual) 
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A2.5(v) ANOVA Data of Ames Test TA102 - Nucleosomal Fraction Colony 
Counts at 12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 329 49 20 357 266    363      277.6     379.7 
Fe 6 405 20 8 398 388   430     384.7     425.9 
Fe + AFB1 9 553 83 28 531 457   698      489.4     617.5 
AFB1 5 519 58 26 551 456   567      447.1     591.7 
       
A2.5(v) Intermediate Calculations. ANOVA Table (TA102 - Nucleosomal 
Fraction Colony Counts at 12 months) 
 
        Source of                                             Degrees of     Sum of         Mean   
        variation                                              freedom         squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                           3              217631        72544 
Residuals (within columns)                               22              82788         3763.1 
----------------------------                                ----------          -------- 
Total                                                                  25              300419 
 
F = 19.278  =(MStreatment/MSresidual) 
 
A2.5(vi) ANOVA Data of Ames Test TA102 - Cytosolic Fraction Colony Counts 
at 12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 358   9   4 361 347        367   348.7     368.0 
Fe 6 417   6   2 420 410        422   411.3     423.4 
Fe + AFB1 6 485 68 28 467 419        572   413.4     556.9 
AFB1 5 345 52 23 342 305        431   281.1       49.0 
 
A2.5(vi) Intermediate Calculations. ANOVA Table (TA102 – Cytosolic Fraction 
Colony Counts at 12 months) 
         
        Source of                                          Degrees of         Sum of        Mean   
        variation                                           freedom             squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 70512          23504 
Residuals (within columns)                             19                 34560         1818.9 
----------------------------                              ----------           -------- 
Total                                                                22               105072 
 
F = 12.922  =(MStreatment/MSresidual)                          
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A2.5(vii) ANOVA Data of Ames Test TA102 - Microsomal Fraction Colony 
Counts at 12 months.  
             
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control 6 296 17 7 295 278   315      278.6     313.4 
Fe 6 412 30 12 415 378   444      381.3     443.4 
Fe + AFB1 9 463 50 17 448 413   569      424.3     501.1 
AFB1 5 305 5 2 303 302   314      298.4     311.2 
 
A2.5(vii) Intermediate Calculations. ANOVA Table (TA102 – Microsomal 
Fraction Colony Counts at 12 months) 
 
        Source of                                            Degrees of      Sum of         Mean   
        variation                                             freedom          squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3              138258          46086 
Residuals (within columns)                              22              25806          1173.0 
----------------------------                               ----------           -------- 
Total                                                                 25              164065 
 
F = 39.289  =(MStreatment/MSresidual) 
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Table 2.5.A. Ames Mutagenicity Test (With added S9 Enzymes) 
 
Salmonella typhimurium Strains 
 TA97 TA98 TA100 TA102 
12 Months 12 Months 12 Months 12 Months Group Liver 
Fraction Mean SD Mean SD Mean SD Mean SD 
Control (W) 137 4.5 39 2.1 125 20.5 295 15.0 
 (N) 127 18.5 30 0.6 203 14.2 329 54.7 
 (C) 116 21.9 22 5.2 190 22.5 358 10.6 
 (S9) 80 18.9 29 4.4 124 15.0 331 52.3 
 (M) 108 10.2 30 8.4 216 30.1 296 15.8 
Fe (W) 234 35.1 54 13.0 154 24.6 490 33.1 
 (N) 286 40.3 29 11.8 204 27.2 405 22.3 
 (C) 189 38.4 26 2.1 170 28.0 417 6.0 
 (S9) 173 29.0 50 6.1 147 8.9 441 12.9 
 (M) 152 20.2 29 6.7 182 22.6 412 26.9 
Fe + AFB1 (W) 181 25.8 39 7.8 176 11.1 399 16.4 
 (N) 144 50.6 34 6.2 150 21.6 554 22.0 
 (C) 123 25.9 21 5.0 180 6.6 476 46.5 
 (S9) 185 17.1 51 9.9 153 18.5 502 24.7 
 (M) 138 26.8 31 6.7 205 20.8 465 19.7 
AFB1 (W) 158 4.0 33 2.3 126 3.2 313 9.2 
 (N) 131 8.7 27 3.8 183 18.1 525 60.2 
 (C) 122 23.9 20 3.8 191 16.3 359 65.1 
 (S9) 239 45.2 41 10.7 122 11.0 461 22.0 
 (M) 131 34.7 33 8.0 198 47.9 452 21.8 
 
Detailed results of the Ames mutagenicity test using Salmonella typhimurium strains 
TA97, TA98, TA100, and TA102. High-lighted areas indicate colony counts above 
180, 50, 200 and 360 spontaneous revertants for TA97, TA98, TA100, and TA102 
respectively. W = Whole liver homogenate; N = nucleosomal fraction; C = Cytosolic 
Fraction; S9 = Liver homogenate fraction at 9000rpm; M = Microsomal fraction. 
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Table 2.5.B. Ames Mutagenicity Test (Without added S9 Enzymes) 
(No significant differences were found between groups. All P-values were greater 
than 0.05) 
 
Salmonella typhimurium Strains 
 TA97 TA98 TA100 TA102 
12 Months 12 Months 12 Months 12 Months Group Liver 
Fraction Mean SD Mean SD Mean SD Mean SD 
Control (W) 112 7.8 32 1.8 133 18.1 189 20.4 
 (N) 102 9.0 26 3.3 189 11.7 256 19.7 
 (C) 105 13.2 20 3.8 192 27.7 278 33.4 
 (S9) 83 4.5 17 2.1 122 14.2 299 17.5 
 (M) 120 11.0 27 3.7 159 30.2 222 31.9 
Fe (W) 145 12.8 39 4.0 154 16.3 255 37.2 
 (N) 201 23.4 27 4.8 221 20.5 326 18.5 
 (C) 165 40.3 23 0.8 171 30.1 359 17.9 
 (S9) 172 25.8 32 1.1 174 22.6 366 11.0 
 (M) 122 8.7 27 7.1 213 27.8 400 47.6 
Fe + AFB1 (W) 100 6.8 33 3.7 176 21.6 322 28.7 
 (N) 148 2.3 31 3.3 156 26.6 452 53.8 
 (C) 129 10.7 21 2.4 122 12.5 412 18.3 
 (S9) 123 24.6 44 0.9 153 15.0 487 34.5 
 (M) 111 11.7 28 0.7 121 14.6 456 44.1 
AFB1 (W) 132 47.9 30 1.3 126 17.4 289 40.2 
 (N) 118 7.8 21 4.0 205 40.6 368 47.8 
 (C) 106 27.4 25 5.1 156 17.4 321 12.3 
 (S9) 182 17.3 36 0.4 106 22.5 378 19.3 
 (M) 144 0.6 32 3.1 157 13.0 391 51.6 
Detailed results of the Ames mutagenicity test using Salmonella typhimurium strains 
TA97, TA98, TA100, and TA102. High-lighted areas indicate colony counts above 
180, 50, 200 and 360 spontaneous revertants for TA97, TA98, TA100, and TA102 
respectively. W = Whole liver homogenate; N = nucleosomal fraction; C = Cytosolic 
Fraction; S9 = Liver homogenate fraction at 9000rpm; M = Microsomal fraction. 
 
 
A2.6. Cytokine Indicators 
 
A2.6(i) ANOVA Data of Interleukin-1β Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 31.3     6.9       3.1     31.3 20.7      39.3   22.8          39.9 
Fe   5 32.2    10.4       4.7     32.2 19.6      47.7   19.3          45.2 
Fe + AFB1 15 34.4    10.9      2.8     34.8 16.6      53.4   28.4          40.4 
AFB1   5 22.4     6.9       3.1     20.7 15.2      30.1   13.8          31.0 
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A2.6(i) Intermediate Calculations. ANOVA Table (Interleukin-1β Levels at 12 
months) 
 
        Source of                                           Degrees of        Sum of        Mean   
        variation                                            freedom            squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                        3                 541.79         180.60 
Residuals (within columns)                            26                2470.8          95.031 
----------------------------                             ----------            -------- 
Total                                                               29                3012.6 
 
F = 1.900  =(MStreatment/MSresidual) 
 
 
 
A2.6(ii) ANOVA Data of Interleukin-6 Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 135.6    44.9      20.1    135.6 69.4    195.9   79.9         191.3 
Fe   5   67.4    39.2      17.5       67.4 23.5    129.2   18.7         116.1 
Fe + AFB1 17   42.1    24.0         5.8       39.8  4.2      83.3   29.8           54.5 
AFB1   5   79.6    33.8      15.1       69.4 47.5    135.5   37.6         121.6 
 
A2.6(ii) Intermediate Calculations. ANOVA Table (Interleukin-6 Levels at 12 
months) 
 
        Source of                                            Degrees of         Sum of      Mean   
        variation                                             freedom             squares      square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 34837         11612 
Residuals (within columns)                             28                27970         998.93 
----------------------------                              ----------            -------- 
Total                                                                31                62807 
 
F = 11.625  =(MStreatment/MSresidual) 
 
 
A2.6(iii) ANOVA Data of Interleukin-10 Levels at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 12.0       5.1       2.3     12.0  6.3      18.2     5.7           18.3 
Fe   5 16.2       5.4       2.4     16.2  9.1      23.0     9.5           22.9 
Fe + AFB1 16 41.0    15.7       3.9     32.4 23.0      70.0   32.7           49.4 
AFB1   5 28.9    17.3       7.8     23.0 15.7      58.5     7.4           50.4 
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A2.6(iii) Intermediate Calculations. ANOVA Table (Interleukin-10 Levels at 12 
months) 
 
        Source of             Degrees of   Sum of     Mean   
        variation              freedom    squares    square  
============================  ==========  ========  ======== 
Treatments (between columns)           3    4528.4    1509.5 
Residuals (within columns)            27    5096.9    188.77 
----------------------------  ----------  -------- 
Total                                 30    9625.3 
 
F = 7.996  =(MStreatment/MSresidual) 
 
A2.7. Haematology Differentials 
 
A2.7(i) ANOVA Data of Haemoglobin Concentration at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 15.1    0.88 0.39 15.0 14.1      16.3   14.0           16.2 
Fe   5 14.5 0.12 0.06 14.5 14.3      14.6   14.3           14.7 
Fe + AFB1 17 13.6 1.73 0.42 14.0  7.6      15.1   12.7           14.5 
AFB1   5 14.5 0.77 0.34 14.5 13.7     15.7   13.6           15.5 
  
 
 
 
 
 
 
 
 
 
 
 
 
A2.7(i) Intermediate Calculations. ANOVA Table (Haemoglobin Concentration 
at 12 months) 
         
        Source of                                           Degrees of       Sum of         Mean   
        variation                                            freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                10.867           3.622 
Residuals (within columns)                             28               53.403           1.907 
----------------------------                              ----------            -------- 
Total                                                                31                64.270 
 
Table A2.7(i) Bonferroni (Dunn) and t-tests 
for Haemoglobin Concentration at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.6411 
2.112   
0.6411  
1.314   
0.000   
1.314    
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
ns    P>0.05 
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F = 1.899  =(MStreatment/MSresidual)    
A2.7(ii) ANOVA Data of White Blood Cell  (WBC) Count at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   7.8      4.7       2.12       8.6  1.8      14.4     1.9           13.7 
Fe   5 19.5      3.7       1.65     20.0 14.7      23.0   14.9           24.1 
Fe + AFB1 17 11.0      4.0      0.96     11.5  2.7      18.2     8.9           13.0 
AFB1   5 10.9      2.5       1.13     10.0  7.8      13.5     7.7           14.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2.7(ii) Intermediate Calculations. ANOVA Table (White Blood Cell  (WBC) 
Count at 12 months)  
 
        Source of                                            Degrees of       Sum of         Mean   
        variation                                             freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                 388.43         129.48 
Residuals (within columns)                            28                 419.11         14.968 
----------------------------                              ----------            -------- 
Total                                                               31                 807.53 
 
F = 8.650  =(MStreatment/MSresidual) 
 
 
A2.7(iii) ANOVA Data of Red Blood Cell  (RBC) Count at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 8.3    0.66 0.30 8.25 7.64      9.34   7.47           9.11 
Fe   5 7.0    0.28 0.13 7.00 6.55      7.29 6.60           7.31 
Fe + AFB1 17 6.7    0.96 0.23 6.94 3.50      7.78   6.16           7.14 
AFB1   5 7.6    0.59 0.27 7.37 6.97      8.52   6.87           8.34 
 
 
Table A2.7(ii) Bonferroni (Dunn) and t-tests 
for White Blood Cell Count at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
4.757 
1.605   
1.242   
4.308   
3.515   
0.061   
*** P<0.001 
ns    P>0.05 
ns    P>0.05 
**   P<0.01 
**   P<0.01 
ns    P>0.05 
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A2.7(iii) Intermediate Calculations. ANOVA Table (Red Blood Cell  (RBC)) 
Count at 12 months 
        
        Source of                                           Degrees of        Sum of        Mean   
        variation                                            freedom            squares        square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                11.878         3.959 
Residuals (within columns)                              28               18.158        0.6485 
----------------------------                               ----------           -------- 
Total                                                                 31               30.036 
 
F = 6.105  =(MStreatment/MSresidual) 
 
 
A2.7(iv) ANOVA Data of Platelet Count at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5   88.6   53.2   23.8   85.0 16.0    162.0   22.6         154.7 
Fe   5 231.2 138.1   61.7 235.0 90.0    407.0   59.8         402.6 
Fe + AFB1 17 196.7 206.4   50.1 158.0 59.0    943.0   90.5         302.8 
AFB1   5 433.4 334.1 149.4 345.0 81.0    868.0   18.7         848.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.7(iii) Bonferroni (Dunn) and t-tests 
for Red Blood Cell Count at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
 2.623  
4.000   
1.347   
0.7386  
1.276   
2.325   
ns  P>0.05 
**  P<0.01 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
Table A2.7(iv) Bonferroni (Dunn) and t-tests 
for Platelet Count at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
1.082   
1.019   
2.617   
0.3260  
1.535   
2.234   
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
 197
 
A2.7(iv) Intermediate Calculations. ANOVA Table (Platelet Count) at 12 months 
  
 
        Source of                                            Degrees of        Sum of       Mean   
        variation                                             freedom            squares       square  
============================  ==========  ========  ======== 
Treatments (between columns)                         3                323777         107926 
Residuals (within columns)                             28               1215341         43405 
----------------------------                              ----------             -------- 
Total                                                                31               1539118 
 
F = 2.486  =(MStreatment/MSresidual) 
 
 
A2.7(v) ANOVA Data of Mean Platelet Volume at 12 months.  
 
Group Number 
of 
points 
Mean Standard 
Deviation 
Standard 
Error of 
Mean 
Median Max         Min 95% Confidence 
Interval 
       From            To 
Control   5 7.1 1.06 0.47 7.3 5.40      8.30   5.79           8.41 
Fe   5 7.3 0.54 0.24 7.2 6.80      8.20   6.63           7.97 
Fe + AFB1 16 7.4 0.54 0.14 7.3 6.60      8.60   7.12           7.68 
AFB1   5 7.2 0.73 0.33 7.0 6.50      8.40   6.27           8.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2.7(v) Intermediate Calculations. ANOVA Table (Mean Platelet Volume) at 12 
months 
 
        Source of                                           Degrees of       Sum of         Mean   
        variation                                            freedom           squares         square  
============================  ==========  ========  ======== 
Treatments (between columns)                          3                0.4123        0.1374 
Residuals (within columns)                              27               12.137        0.4495 
----------------------------                               ----------           -------- 
Total                                                                 30               12.550 
 
F = 0.3057  =(MStreatment/MSresidual) 
Table A2.7(v) Bonferroni (Dunn) and t-tests 
for Mean Platelet Volume at 12 months 
Treatment Comparison t P-Value 
Control vs. Fe 
Control vs. Fe + AFB1 
Control vs. AFB1 
Fe vs. Fe + AFB1 
Fe vs. AFB1 
Fe + AFB1 vs. AFB1 
0.4716 
0.8551  
0.1887  
0.2729  
0.2830  
0.6222   
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
ns  P>0.05 
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A3.1. Two-Way Analysis of Variance Results calculated between 6 
and 12 month data. 
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Fig. A3.1(i) Bar Graph of Serum Iron 
Levels of Wistar Albino Rats at 6 and 
12 Month Intervals 
Fig. A3.1(ii) Bar Graph of Serum ALT 
Concentration in Wistar Albino Rats 
at 6 and 12 Month Intervals 
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Fig. A3.1(iii) Bar Graph of Serum AST 
Concentration of Wistar Albino Rats at 
6 and 12 Month Intervals 
Fig. A3.1(iv) Bar Graph of GGT 
Concentration of Wistar Albino Rats 
at 6 and 12 Month Intervals 
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Fig. A3.1(v) Bar Graph of Superoxide 
Anion Production in Wistar Albino Rats 
at 6 and 12 Month Intervals 
Fig. A3.1(vi) Bar Graph of Liver Nitrite 
Concentration of Wistar Albino Rat at 6 
and 12 Month Intervals 
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A4.1 Correlation Tables 
 
A4.1(i) to A4.1(iv) represent correlation tables at 6 months. A4.1(v) to A4.1(viii) 
represent correlation tables at 12 months. 
 
 
 
 
Fig. A3.1(vii) Bar Graph of Serum 8-
Isoprostane Concentration in Wistar 
Albino Rats at 6 and 12 Month 
Intervals 
Fig. A3.1(viii) Bar Graph of Liver 
Lipid Peroxidation of Wistar Albino 
Rats at 6 and 12 Month Intervals 
Fig. A3.1(ix)Bar Graph of Serum 
Lipid Peroxidation of Wistar Albino 
Rats at 6 and 12 Months 
 
Fig. A3.1(x) Bar Graph of Liver 8-
Hydroxyguanosine Concentration of 
Wistar Albino Rats at 6 and 12 
months 
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Table A4.1(i) Correlation Matrix of 6 
Month Data     
  
Highlighted Correlations are 
Significant at p<0.05   
    Group: Control      
 
Hydroxy- 
proline 
GGT 
 
AST 
 
ALT 
 
Serum  
8- IsoP 
Liver  
8OHdG 
Serum 
LPO 
Liver 
Nitrite 
Serum 
Nitrite 
Superoxide 
Anion 
Liver  
LPO 
Hydroxyproline 1.00 -0.30 -0.70 -0.85 0.26 -0.41 -0.80 0.50 0.65 -0.27 0.33 
GGT -0.30 1.00 0.71 0.28 0.24 0.55 -0.14 0.33 -0.01 0.68 0.79 
AST -0.70 0.71 1.00 0.41 0.24 0.31 0.30 -0.41 0.00 0.81 0.30 
ALT -0.85 0.28 0.41 1.00 -0.66 0.36 0.86 -0.06 -0.88 -0.14 -0.32 
8 Isoprostane 0.26 0.24 0.24 -0.66 1.00 0.30 -0.72 -0.02 0.67 0.76 0.52 
Liver 8OHdG -0.41 0.55 0.31 0.36 0.30 1.00 -0.07 0.20 -0.46 0.38 0.31 
Serum LPO -0.80 -0.14 0.30 0.86 -0.72 -0.70 1.00 -0.43 -0.72 -0.28 -0.69 
Liver Nitrite 0.50 0.33 -0.41 -0.06 -0.20 0.20 -0.43 1.00 -0.10 -0.31 0.56 
Serum Nitrite 0.65 -0.01 0.00 -0.88 0.67 -0.46 -0.72 -0.10 1.00 0.43 0.46 
Superoxide -0.27 0.68 0.81 -0.14 0.76 0.38 -0.28 -0.31 0.43 1.00 0.59 
Liver LPO 0.33 0.79 0.30 -0.32 0.52 0.31 -0.69 0.56 0.46 0.59 1.00 
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Table A4.1(ii) Correlation Matrix of 6 
Month Data     
  
Highlighted Correlations are 
Significant at p<0.05   
    Group: Iron      
 
Hydroxy- 
proline 
GGT 
 
AST 
 
ALT 
 
Serum  
8- IsoP 
Liver  
8OHdG 
Serum 
LPO 
Liver 
Nitrite 
Serum 
Nitrite 
Superoxide 
Anion 
Liver  
LPO 
Hydroxyproline 1.00 -0.10 -0.59 0.02 -0.55 -0.56 -0.47 -0.13 -0.65 -0.18 0.58 
GGT -0.10 1.00 0.38 0.16 -0.20 0.85 -0.76 -0.83 0.06 0.83 0.62 
AST -0.59 0.38 1.00 -0.35 0.17 0.76 -0.17 0.14 0.87 0.05 -0.37 
ALT 0.62 0.16 -0.35 1.00 -0.98 -0.22 -0.27 -0.48 -0.18 0.34 0.31 
8 Isoprostane -0.55 -0.20 0.17 -0.98 1.00 0.11 0.30 0.43 0.00 -0.33 -0.23 
Liver 8OHdG -0.56 0.85 0.76 -0.22 0.11 1.00 -0.45 -0.48 0.17 0.64 0.15 
Serum LPO -0.47 -0.76 -0.17 -0.27 0.30 -0.45 1.00 0.58 0.24 -0.39 -0.82 
Liver NO -0.13 -0.83 0.14 -0.48 0.43 -0.48 0.58 1.00 0.31 -0.94 -0.74 
Serum NO -0.65 0.60 0.87 -0.18 0.00 0.50 0.24 0.31 1.00 -0.05 -0.71 
Superoxide -0.18 0.83 0.05 0.34 -0.33 0.64 -0.39 -0.94 -0.05 1.00 0.50 
Liver LPO 0.58 0.62 -0.37 0.31 -0.23 0.15 -0.82 -0.74 -0.71 0.50 1.00 
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Table A4.1(iii) Correlation Matrix of 6 
Month Data     
  
Highlighted Correlations are Significant 
at p<0.05   
    Group: Iron and Aflatoxin B1      
 
Hydroxy- 
proline 
GGT 
 
AST 
 
ALT 
 
Serum  
8- IsoP 
Liver  
8OHdG 
Serum 
LPO 
Liver 
Nitrite 
Serum 
Nitrite 
Superoxide 
Anion 
Liver  
LPO 
Hydroxyproline 1.00 0.51 0.27 0.96 -0.60 0.80 0.03 -0.05 -0.31 -0.66 -0.23 
GGT 0.51 1.00 -0.39 0.71 -0.65 0.85 0.38 0.16 0.62 -0.74 0.53 
AST 0.27 -0.39 1.00 0.08 0.47 0.04 -0.61 -0.42 -0.54 0.46 -0.19 
ALT 0.96 0.71 0.08 1.00 -0.74 0.92 0.07 0.11 -0.09 -0.80 -0.08 
8 Isoprostane -0.60 -0.65 0.47 -0.74 1.00 -0.70 -0.09 -0.66 0.01 0.99 0.26 
Liver 8OHdG 0.80 0.85 0.40 0.92 -0.70 1.00 -0.05 -0.16 0.42 0.54 0.18 
Serum LPO 0.03 0.38 0.61 0.07 0.09 -0.05 1.00 -0.43 0.48 -0.16 0.42 
Liver NO -0.05 0.16 -0.42 0.11 -0.66 0.23 -0.43 1.00 -0.05 -0.57 -0.38 
Serum NO -0.31 0.62 -0.54 -0.09 0.01 0.18 0.48 -0.05 1.00 -0.07 0.92 
Superoxide -0.66 -0.74 0.46 -0.80 0.99 -0.77 -0.16 -0.57 -0.07 1.00 0.14 
Liver LPO -0.23 0.53 -0.19 -0.08 0.26 0.18 0.42 -0.38 0.92 0.16 1.00 
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Table A4.1(iv) Correlation Matrix of 6 
Month Data     
  
Highlighted Correlations are Significant 
at p<0.05   
    Group: Aflatoxin B1      
 
Hydroxy- 
proline 
GGT 
 
AST 
 
ALT 
 
Serum  
8- IsoP 
Liver  
8OHdG 
Serum 
LPO 
Liver 
Nitrite 
Serum 
Nitrite 
Superoxide 
Anion 
Liver  
LPO 
Hydroxyproline 1.00 0.10 -0.79 -0.95 -0.96 -0.10 0.30 -0.07 -0.40 -0.12 0.40 
GGT 0.10 1.00 -0.65 0.96 -0.14 0.76 -0.49 -0.76 -0.70 0.56 0.90 
AST -0.79 -0.65 1.00 -0.67 0.74 -0.26 -0.09 0.40 0.74 -0.37 -0.87 
ALT -0.95 0.96 -0.67 1.00 -0.16 0.82 -0.55 -0.88 -0.84 0.60 0.90 
8 Isoprostane -0.96 -0.14 0.74 -0.16 1.00 0.00 -0.15 0.10 0.25 0.33 -0.33 
Liver 8OHdG -0.10 0.76 -0.26 0.82 0.00 1.00 -0.93 -0.96 -0.54 0.22 0.50 
Serum LPO 0.30 -0.49 -0.09 -0.55 -0.15 -0.93 1.00 0.83 0.23 0.05 -0.14 
Liver NO -0.07 -0.76 0.40 -0.88 0.10 -0.96 0.83 1.00 0.73 -0.36 -0.62 
Serum NO -0.40 -0.70 0.74 -0.84 0.25 -0.54 0.23 0.73 1.00 -0.74 -0.87 
Superoxide -0.12 0.56 -0.37 0.60 0.33 0.22 0.05 -0.36 -0.74 1.00 0.70 
Liver LPO 0.40 0.90 -0.87 0.90 -0.33 0.50 -0.14 -0.76 -0.70 0.56 1.00 
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Table A4.1(v) 
Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Control (Part 1)    
 Serum 
8-IsoP 
Liver 
8IsoP ALT AST 
Liver 
8OHdG 
Serum 
8OHdG 
Liver 
LPO 
Serum 
LPO 
Liver 
NO 
Serum 
NO 
Super- 
oxide 
GGT Ferritin NTBI 
Serum 8IsoP 1 1 1 1 0.5 -0.16 -0.96 0.7 -0.83 -0.9 -0.37 -1 0.34 -0.96 
Liver 8IsoP 0.99 1 1 1 0.3 -0.01 -0.91 0.5 -0.91 -1 -0.22 -1 -0.97 -0.19 
ALT 0.98 1 1 1 0.3 0.02 -0.9 0.5 -0.92 -1 -0.19 -1 0.09 -1 
AST 0.95 1 1 1 0.2 0.15 -0.84 0.4 -0.96 -1 -0.6 -0.9 0.79 -0.65 
Liver 8OHdG 0.47 0.3 0.3 0.2 1 -0.95 -0.68 1 0.1 -1 -0.99 -0.6 -0.17 0.99 
Serum 8OHdG -0.16 0 0 0.1 -0.9 1 0.42 -0.9 -0.41 -0.2 0.98 0.3 -0.23 -0.96 
Liver LPO -0.96 -0.9 -0.9 -0.8 -0.7 0.42 1 -0.8 0.66 0.8 0.6 1 1 0.04 
Serum LPO 0.66 0.5 0.5 0.4 1 -0.85 -0.83 1 -0.13 -0.4 -0.94 -0.7 0.7 0.67 
Liver NO -0.83 -0.9 -0.9 -1 0.1 -0.41 0.66 -0.1 1 1 -0.21 0.8 -0.3 0.97 
Serum NO -0.94 -1 -1 1 -0.1 -0.019 0.81 -0.4 0.97 1 0.02 0.9 0.39 0.9 
Superoxide -0.37 -0.2 -0.2 -0.1 -1 0.98 0.6 -0.9 -0.21 0 1 0.5 0.8 -0.65 
GGT -0.99 -1 -1 -0.9 -0.6 0.27 0.99 -0.7 0.77 0.9 0.47 1 0.97 0.19 
IL-1b 0.89 0.9 1 1 0 0.31 -0.73 0.2 -0.99 -1 0.1 -0.8 -0.8 -0.56 
IL-6 -0.72 -0.6 -0.6 -0.5 -0.9 0.8 0.88 -1 0.22 0.4 -0.25 -1 0.5 -0.89 
IL-10 0.56 0.7 0.7 0.8 -0.5 0.73 -0.32 -0.3 -0.92 -0.8 0.91 0.8 0.48 -0.9 
Serum Fe 0.32 0.2 0.1 0 1 -0.99 -0.56 0.9 0.25 0 0.57 -0.5 -0.63 0.81 
TIBC -0.54 -0.4 -0.4 -0.3 -1 0.92 0.74 -1 -0.1 0.2 -1 -0.4 0.98 -0.25 
WBC -0.34 0.12 0.87 0.7 -0.64 0.35 0.59 -0.72 -0.75 0.71 -0.24 -0.58 -0.86 0.56 
RBC 0.5 0.23 -0.92 -0.63 0.34 -0.44 -0.74 0.8 -0.7 0.09 0.63 0.47 -0.43 0.93 
Hb 0.27 -0.17 -0.59 -0.64 0.15 -0.92 -0.04 0.65 -0.82 0.01 0.45 0.33 -0.25 0.98 
Platelets -0.9 0.01 -0.63 -0.53 0 -0.89 -0.2 0.7 -0.74 0.68 -0.33 -0.66 -0.84 0.59 
MPV 0.6 0.24 -0.93 -0.53 0.29 -0.39 -0.82 0.82 -0.98 -0.05 -0.23 -0.28 -0.19 0.99 
TA97 0.56 0.29 -0.75 -0.02 -0.35 -0.65 -0.76 0.88 0.51 0.7 -0.28 -0.5 -0.69 -0.68 
TA98 0.9 -0.33 0.07 -0.03 0.53 0.51 -0.01 -0.21 -0.01 0.92 -0.31 -0.67 -0.98 -0.15 
TA100 0.27 -0.34 -0.36 -0.19 0.54 0.14 -0.32 0.25 0.13 0.93 -0.3 -0.68 -1 -0.04 
TA102 0.3 -0.33 -0.44 -0.22 0.53 0.06 -0.38 0.34 0.69 0.55 -0.24 -0.39 -0.47 -0.86 
Ferritin 0.34 -0.97 0.09 0.79 -0.17 -0.23 1 0.7 -0.3 0.39 0.8 0.97 1 -0.05 
NTBI -0.96 -0.19 -1 -0.65 0.99 -0.96 0.04 0.67 0.97 0.9 -0.65 0.19 -0.05 1 
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  Table A4.1(v) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Control (Part 2)    
 
IL-1b IL-6 IL-10 
Serum 
Fe TIBC WBC RBC Hb Platelets MPV TA97 TA98 TA100 TA102 
Serum 8IsoP 0.9 -0.7 0.56 0.32 -0.5 -0.34 0.5 -0.27 -0.9 0.6 0.56 0.9 0.27 0.3 
Liver 8IsoP 0.9 -0.6 0.68 0.17 -0.4 0.12 0.23 -0.17 0.01 0.24 0.29 -0.33 -0.34 -0.33 
ALT 1 -0.6 0.7 0.14 -0.4 0.87 -0.92 -0.59 -0.63 -0.93 -0.75 0.07 -0.36 -0.44 
AST 1 -0.5 0.79 0.01 -0.3 0.7 -0.63 -0.64 -0.53 -0.53 -0.02 -0.03 -0.19 -0.22 
Liver 8OHdG 0 -0.9 -0.47 0.99 -1 -0.64 0.34 0.15 0 0.29 -0.35 0.53 0.54 0.53 
Serum 8OHdG 0.3 0.8 0.73 -0.99 0.9 0.35 -0.44 -0.92 -0.89 -0.39 -0.65 0.51 0.14 0.06 
Liver LPO -0.7 0.9 -0.32 -0.56 0.7 0.59 -0.74 -0.04 -0.2 -0.82 -0.76 -0.01 -0.32 -0.38 
Serum LPO 0.2 -1 -0.26 0.92 -1 -0.72 0.8 0.65 0.7 0.82 0.88 -0.21 0.25 0.34 
Liver NO -1 0.2 -0.92 0.25 0 -0.75 -0.7 -0.82 -0.74 -0.98 0.51 -0.01 -0.13 0.69 
Serum NO -1 0.4 -0.81 0.03 0.2 0.71 0.09 0.01 0.68 -0.05 0.7 0.92 0.93 0.55 
Superoxide 0.1 0.9 0.57 1 1 -0.24 0.63 0.45 -0.33 -0.23 -0.28 -0.31 -0.3 -0.24 
GGT -0.8 0.8 -0.46 -0.42 0.6 -0.58 0.47 0.33 -0.66 -0.28 -0.5 -0.67 -0.68 -0.39 
IL-1b 1 -0.3 0.88 -0.15 -0.1 0.47 0.94 0.99 0.43 0.84 -0.74 -0.3 -0.18 -0.87 
IL-6 0.9 1 0.17 -0.89 1 -0.26 -0.76 -0.87 -0.25 -0.87 0.9 0.54 0.43 0.97 
IL-10 -0.3 0.2 1 -0.61 0.4 -0.49 -0.81 -0.69 -0.39 -0.21 0.08 -0.23 -0.29 0.2 
Serum Fe 0.9 -0.9 -0.61 1 -1 -0.14 0.8 0.81 -0.19 0.49 -0.95 -0.78 -0.71 -0.93 
TIBC -0.2 1 0.4 -0.97 1 -0.39 -0.89 -0.25 -0.25 -0.91 -0.37 -0.38 -0.67 -0.71 
WBC 0.47 -0.26 -0.49 -0.14 -0.39 1 -0.89 -0.65 -0.82 0.88 -0.21 0.14 0.34 0.34 
RBC 0.94 -0.76 -0.81 0.8 -0.89 -0.89 1 0.47 0.53 0.98 0.58 -0.02 0.31 0.37 
Hb 0.99 -0.87 -0.69 0.81 -0.25 -0.65 0.47 1 0.98 0.36 0.52 -0.7 -0.42 -0.35 
Platelets 0.43 -0.25 -0.39 -0.19 -0.25 -0.82 0.53 0.98 1 0.43 0.65 -0.76 -0.45 -0.37 
MPV 0.84 -0.87 -0.21 0.49 -0.91 0.88 0.98 0.36 0.43 1 0.63 0.08 0.43 0.49 
TA97 -0.74 0.9 0.08 -0.95 -0.37 -0.21 0.58 0.52 0.65 0.63 1 -0.44 -0.01 0.09 
TA98 -0.3 0.54 -0.23 -0.78 -0.38 0.14 -0.02 -0.7 -0.76 0.08 -0.44 1 0.89 0.84 
TA100 -0.18 0.43 -0.29 -0.71 -0.67 0.34 0.31 -0.42 -0.45 0.43 -0.01 0.89 1 1 
TA102 -0.87 0.97 0.2 -0.93 -0.71 0.34 0.37 -0.35 -0.37 0.49 0.09 0.84 1 1 
Ferritin -0.8 0.5 0.48 -0.63 0.98 -0.86 -0.43 -0.25 -0.84 -0.19 -0.69 -0.98 -1 -0.47 
NTBI -0.56 -0.89 -0.9 0.81 -0.25 0.56 0.93 0.98 0.59 0.99 -0.68 -0.15 -0.04 -0.86 
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  Table A4.1(vi) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Iron (Part 1)    
 Serum 
8-IsoP 
Liver 
8IsoP ALT AST 
Liver 
8OHdG 
Serum 
8OHdG 
Liver 
LPO 
Serum 
LPO 
Liver 
NO 
Serum 
NO 
Super- 
oxide 
GGT Ferritin NTBI 
Serum 8IsoP 1 0.62 0.53 0.33 -0.53 0.92 -0.42 -0.74 -0.93 0.62 0.13 -0.44 -0.83 0.95 
Liver 8IsoP 0.62 1 -0.3 -0.5 -1 0.9 0.4 -1 0.9 -0.2 0.9 -1 0.22 0.26 
ALT 0.53 -0.3 1 1 0.4 0.2 -1 0.2 0.2 1 -0.8 0.5 -0.13 0.24 
AST 0.33 -0.5 1 1 0.6 -1 -1 0.4 0 0.9 -0.9 0.7 0.13 0.02 
Liver 8OHdG -0.53 -1 0.4 0.6 1 -0.81 -0.54 0.96 -0.81 0.33 -0.91 0.99 0.73 -0.76 
Serum 8OHdG 0.92 0.9 0.2 -1 -0.81 1 -0.05 -0.94 1 0.28 0.5 -0.75 -0.59 0.9 
Liver LPO -0.42 0.4 -1 -1 -0.54 -0.05 1 -0.3 -0.1 -1 0.8 -0.6 0.07 -0.12 
Serum LPO -0.74 -1 0.2 0.4 0.96 -0.94 -0.3 1 -0.94 0.06 -0.76 0.93 0.6 -0.15 
Liver NO 0.93 0.9 0.2 0 -0.81 1 -0.1 -0.94 1 0.29 0.49 -0.74 -0.63 0.92 
Serum NO 0.62 -0.2 1 0.9 0.33 0.28 -1 0.06 0.29 1 -0.69 0.43 -0.41 0.34 
Superoxide 0.13 0.9 -0.8 -0.9 -0.91 0.5 0.8 -0.76 0.49 -0.69 1 -0.95 -0.6 0.24 
GGT -0.44 -1 0.5 0.7 0.99 -0.75 -0.6 0.93 -0.74 0.43 -0.95 1 0.74 -0.41 
IL-1b -0.18 0.7 -0.9 -1 0.74 0.21 1 -0.53 0.2 -0.88 0.95 -0.8 -0.41 0.09 
IL-6 -0.05 0.8 -0.9 -1 -0.82 0.33 0.9 -0.63 0.32 -0.81 0.98 -0.9 -0.48 0.2 
IL-10 0.84 0.9 0 -0.2 -0.9 0.98 0.1 -0.99 0.98 0.11 0.64 -0.9 -0.96 0.92 
Serum Fe -0.96 -0.8 -0.3 -0.1 0.75 -0.99 0.2 0.9 -1 -0.38 -0.4 0.7 0.44 -0.81 
TIBC -0.45 0.4 -1 -1 -0.52 -0.07 1 -0.27 -0.09 -0.2 0.83 -0.6 0.45 -0.09 
WBC 0.26 -0.76 -0.38 0.42 -0.14 -0.09 -0.2 -0.37 0.38 0.78 -0.33 -0.37 -0.25 0.58 
RBC 0.78 -0.47 -0.03 -0.04 0.09 0.19 0.49 -0.78 0.45 -0.57 -0.22 -0.46 -0.87 0.56 
Hb 0.23 0.17 0.9 -0.96 0.77 0.79 0.82 0.01 0.95 0.26 0.24 0.2 -0.88 1 
Platelets 0.92 0.34 0.24 -0.41 0.09 0.2 0.92 -0.81 0.24 0.39 -0.65 -0.75 -0.4 0.52 
MPV 0.54 -0.57 0.41 -0.45 0.52 0.6 0.59 -0.44 -0.98 -0.33 -0.39 -0.18 0.82 -0.99 
TA97 -0.94 -0.43 -0.08 0.26 0.07 -0.03 -0.84 0.87 -0.25 0.84 0.1 0.3 0.7 -0.28 
TA98 0.09 -0.25 -0.7 0.71 -0.56 -0.54 -0.46 -0.27 -0.89 0.07 -0.17 0.08 0.99 -0.94 
TA100 -0.72 -0.39 -0.48 0.64 -0.31 -0.39 -0.94 0.55 -0.75 0.37 -0.09 0.18 0.99 -0.8 
TA102 -0.45 -0.37 -0.63 0.74 -0.45 -0.05 -0.84 0.26 -0.87 -0.62 -0.3 -0.16 0.61 -0.91 
Ferritin -0.83 0.22 -0.13 0.13 0.73 -0.59 0.07 0.6 -0.63 -0.41 -0.6 0.74 1 -0.88 
NTBI 0.95 0.26 0.24 0.02 -0.76 0.9 -0.12 -0.15 0.92 0.34 0.24 -0.41 0.98 1 
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  Table A4.1(vi) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Iron (Part 2)    
 
IL-1b IL-6 IL-10 
Serum 
Fe TIBC WBC RBC Hb Platelets MPV TA97 TA98 TA100 TA102 
Serum 8IsoP -0.18 -0.05 0.84 -0.96 -0.45 0.26 0.78 0.23 0.92 0.54 -0.94 0.09 -0.72 -0.45 
Liver 8IsoP 0.7 0.8 0.9 -0.8 0.4 -0.76 -0.47 0.17 0.34 -0.57 -0.43 -0.25 -0.39 -0.37 
ALT -0.9 -0.9 0 -0.3 -1 -0.38 -0.03 0.9 0.24 0.41 -0.08 -0.7 -0.48 -0.63 
AST -1 -1 -0.2 -0.1 -1 0.42 -0.04 -0.96 -0.41 -0.45 0.26 0.71 0.64 0.74 
Liver 8OHdG -0.74 -0.82 -0.9 0.75 -0.52 -0.14 0.09 0.77 0.09 0.52 0.07 -0.56 -0.31 -0.45 
Serum 8OHdG 0.21 0.33 0.98 -0.99 -0.07 -0.09 0.19 0.79 0.2 0.6 -0.03 -0.54 -0.39 -0.5 
Liver LPO 1 0.9 0.1 0.2 1 -0.2 0.49 0.82 0.92 0.59 -0.84 -0.46 -0.94 -0.84 
Serum LPO -0.53 -0.63 -0.99 0.9 -0.27 -0.37 -0.78 0.01 -0.81 -0.44 0.87 -0.27 0.55 0.26 
Liver NO 0.2 0.32 0.98 -1 -0.09 0.38 0.45 0.95 0.24 -0.98 -0.25 -0.89 -0.75 -0.87 
Serum NO -0.88 -0.81 0.11 -0.38 -0.2 0.78 -0.57 0.26 0.39 -0.33 0.84 0.07 0.37 -0.62 
Superoxide 0.95 0.98 0.64 -0.4 0.83 -0.33 -0.22 0.24 -0.65 -0.39 0.1 -0.17 -0.09 -0.3 
GGT -0.8 -0.9 -0.9 0.7 -0.6 -0.37 -0.46 0.2 -0.75 -0.18 0.3 0.08 0.18 -0.16 
IL-1b 1 0.99 0.38 -0.11 0.96 -0.75 -0.67 -0.76 -0.92 0.65 0.33 0.76 0.68 0.64 
IL-6 0.99 1 0.49 -0.23 0.92 0.8 0.18 0.9 0.58 -0.92 0.17 -0.7 -0.45 1 
IL-10 0.38 0.49 1 -0.04 0.28 0.28 0.43 -0.12 0.68 0.27 -0.31 -0.01 -0.13 0.25 
Serum Fe -0.11 -0.23 -0.4 1 0.42 0.42 -0.89 -0.15 -0.02 0.4 0.99 0.47 0.72 -0.27 
TIBC 0.96 0.92 0.28 0.42 1 0.77 0.02 0.58 0.87 -0.55 0.37 -0.36 -0.12 -0.76 
WBC -0.75 0.8 0.28 0.42 0.77 1 0.02 0.6 0.9 -0.6 0.4 -0.4 -0.1 -0.8 
RBC -0.67 0.18 0.43 -0.89 0.02 0.02 1 0.56 0.39 -0.44 -0.92 -0.8 -0.93 -0.19 
Hb -0.76 0.9 -0.12 -0.15 0.58 0.6 0.56 1 0.52 0.99 0.28 0.94 -0.8 -0.91 
Platelets -0.92 0.58 0.68 -0.02 0.87 0.9 0.39 0.52 1 -0.42 -0.03 -0.45 -0.34 -0.53 
MPV 0.65 -0.92 0.27 0.4 -0.55 -0.6 -0.44 0.99 -0.42 1 0.17 0.89 0.72 0.94 
TA97 0.33 0.17 -0.31 0.99 0.37 0.4 -0.92 0.28 -0.03 0.17 1 0.58 0.8 -0.14 
TA98 0.76 -0.7 -0.01 0.47 -0.36 -0.4 -0.8 0.94 -0.45 0.89 0.58 1 0.95 0.72 
TA100 0.68 -0.45 -0.13 0.72 -0.12 -0.1 -0.93 -0.8 -0.34 0.72 0.8 0.95 1 0.48 
TA102 0.64 1 0.25 -0.72 -0.76 -0.8 -0.19 -0.91 -0.53 0.94 -0.14 0.72 0.45 1 
Ferritin -0.41 -0.48 -0.96 0.44 0.45 -0.25 -0.87 -0.88 -0.4 0.82 0.7 0.99 0.99 0.61 
NTBI 0.09 0.2 0.92 -0.81 -0.09 0.58 0.56 1 0.52 -0.99 -0.28 -0.94 -0.8 -0.91 
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  Table A4.1(vii) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Iron and Aflatoxin B1 (Part 1)    
 Serum 
8-IsoP 
Liver 
8IsoP ALT AST 
Liver 
8OHdG 
Serum 
8OHdG 
Liver 
LPO 
Serum 
LPO 
Liver 
NO 
Serum 
NO 
Super- 
oxide 
GGT Ferritin NTBI 
Serum 8IsoP 1 -1 1 -0.3 1 0.8 -0.3 -0.5 -0.7 -0.6 1 1 -0.64 0.07 
Liver 8IsoP -1 1 -1 0.09 -1 -0.72 0.46 0.39 0.59 0.41 -0.9 -0.96 0.37 0.05 
ALT 1 -1 1 -0.17 1 0.78 -0.38 -0.47 -0.66 -0.49 0.93 0.98 -0.27 -0.16 
AST -0.3 0.09 -0.17 1 -0.15 -0.75 -0.84 0.95 0.85 0.95 -0.52 -0.36 -0.45 -0.41 
Liver 8OHdG 1 -1 1 -0.15 1 0.57 0.62 -0.5 -0.64 -0.46 0.92 0.98 0.13 0.64 
Serum 8OHdG 0.8 -0.72 0.78 -0.75 0.57 1 0.3 -0.9 -1 -0.9 1 0.9 0.49 0.53 
Liver LPO 0.3 0.46 -0.38 -0.84 0.62 0.3 1 -0.63 -0.44 -0.62 -0.02 -0.19 0.06 -0.61 
Serum LPO -0.5 0.39 -0.47 0.95 -0.5 -0.9 -0.63 1 0.97 1 -0.76 -0.64 0.53 0.55 
Liver NO -0.7 0.59 -0.66 0.85 -0.64 -1 -0.44 0.97 1 0.98 -0.89 -0.8 0.39 0.21 
Serum NO -0.6 0.41 -0.49 0.95 -0.46 -0.9 -0.62 1 0.98 1 -0.77 -0.65 0.09 -0.13 
Superoxide 1 -0.9 0.93 -0.52 0.92 1 -0.02 -0.76 -0.89 -0.77 1 1 0.43 0.07 
GGT 1 -0.96 0.98 -0.36 0.98 0.9 -0.19 -0.64 0.8 -0.65 1 1 0.21 0.63 
IL-1b -1 0.9 -0.93 0.52 -0.92 -1 0.03 0.76 0.89 0.77 -1 -1 -0.37 -0.23 
IL-6 -0.9 0.8 -0.85 0.66 -0.84 -1 -0.16 0.86 0.96 0.87 -1 -0.9 0.09 -0.34 
IL-10 -0.7 0.59 -0.66 0.85 -0.64 -1 -0.44 0.97 1 0.98 -0.9 -0.8 -0.08 0.09 
Serum Fe 0.1 -0.26 0.17 0.94 0.2 -0.5 -0.98 0.79 0.62 0.78 -0.2 0 0.05 -0.21 
TIBC 0.9 -0.87 0.91 -0.56 0.9 1 0.3 -0.79 -0.91 -0.8 1 1 -0.17 -0.03 
WBC 0.91 -0.8 0.99 0.71 -0.84 -0.92 -0.12 -0.32 -0.52 -0.58 0.5 0.85 -0.08 0.02 
RBC 0.33 0.38 -0.6 -0.47 -0.21 0.38 -0.55 0.45 -0.25 0.29 -0.38 0.41 -0.63 -0.17 
Hb 0.86 0.83 -0.67 -0.52 0.63 0.7 0.1 0.29 -0.28 0.22 0.31 0.46 -0.45 0.02 
Platelets 0.82 0.79 -0.61 -0.53 0.56 0.68 0.03 0.29 -0.24 -0.17 0.1 0.59 -0.71 -0.35 
MPV 0.56 0.67 -0.44 0.08 0.29 0.42 0.28 0.79 0.32 0.99 -1 -0.51 -0.04 -0.02 
TA97 0.56 0.51 -0.66 0.07 0.87 0.33 0.77 -0.01 -0.59 -0.91 0.87 0.86 -0.13 -0.25 
TA98 -0.02 0.05 0.22 -0.35 -0.63 0.18 -0.81 0.57 0.14 0.97 -0.98 -0.44 0.25 -0.15 
TA100 0.39 0.22 -0.59 -0.26 0.85 0.29 0.51 -0.52 0.5 0.6 0.66 -0.17 -0.37 -0.19 
TA102 0.53 0.51 0.68 0.16 -0.52 -0.54 -0.29 -0.49 -0.28 -0.98 0.99 0.48 -0.34 -0.25 
Ferritin -0.64 0.37 -0.27 -0.45 0.13 0.49 0.06 0.53 0.39 0.09 0.43 0.21 1 0.24 
NTBI 0.07 0.05 -0.16 -0.41 0.64 0.53 -0.61 0.55 0.21 -0.13 0.07 0.63 0.24 1 
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Table A4.1(vii) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Iron and Aflatoxin B1 (Part 2)    
 
IL-1b IL-6 IL-10 
Serum 
Fe TIBC WBC RBC Hb Platelets MPV TA97 TA98 TA100 TA102 
Serum 8IsoP -1 -0.9 -0.7 0.1 0.9 0.91 0.33 0.86 0.82 0.56 0.56 -0.02 0.39 0.53 
Liver 8IsoP 0.9 0.8 0.59 -0.26 -0.87 -0.8 0.38 0.83 0.79 0.67 0.51 0.05 0.22 0.51 
ALT -0.93 -0.85 -0.66 0.17 0.91 0.99 -0.6 -0.67 -0.61 -0.44 -0.66 0.22 -0.59 0.68 
AST 0.52 0.66 0.85 0.94 -0.56 0.71 -0.47 -0.52 -0.53 0.08 0.07 -0.35 -0.26 0.16 
Liver 8OHdG -0.92 -0.84 -0.64 0.2 0.9 -0.84 -0.21 0.62 0.56 0.29 0.87 -0.63 0.85 -0.52 
Serum 8OHdG -1 -1 -1 -0.5 1 -0.92 0.38 0.7 0.68 0.42 0.33 0.18 0.29 -0.54 
Liver LPO 0.03 -0.16 -0.44 -0.98 0.3 -0.12 -0.55 0.1 0.03 0.28 0.77 -0.81 0.51 -0.29 
Serum LPO 0.76 0.86 0.97 0.79 -0.79 -0.32 0.45 0.29 0.29 0.79 -0.01 0.57 -0.52 -0.49 
Liver NO 0.89 0.96 1 0.62 -0.91 -0.52 -0.25 -0.28 -0.24 0.32 -0.59 0.14 0.5 -0.28 
Serum NO 0.77 0.87 0.98 0.78 -0.8 -0.58 0.29 0.22 -0.17 0.99 -0.91 0.97 -0.6 -0.98 
Superoxide -1 -1 -0.9 -0.2 1 0.5 -0.38 -0.31 0.1 -1 0.87 -0.98 0.66 0.99 
GGT -1 -0.9 -0.8 0 1 0.85 0.41 0.46 0.59 -0.51 0.86 -0.44 -0.17 0.48 
IL-1b 1 1 0.9 0.2 1 -0.26 -0.4 -0.39 -0.15 -0.15 -0.17 -0.33 0.84 0.18 
IL-6 1 1 1 0.4 -1 -0.63 -0.12 -0.17 -0.27 0.59 -0.79 0.44 0.21 -0.56 
IL-10 0.9 1 1 -0.73 -0.39 -0.39 -0.5 -0.51 -0.67 -0.14 -0.06 0.11 -0.45 0.13 
Serum Fe 0.2 0.4 -0.75 1 0.17 0.2 0.81 0.78 0.61 0.72 -0.36 0.56 -0.26 -0.73 
TIBC 1 -1 -0.39 0.17 1 0.6 0.61 0.66 0.89 -0.44 0.85 -0.5 0.12 0.41 
WBC -0.26 -0.63 -0.39 0.2 0.6 1 0.6 0.6 0.8 -0.4 0.8 -0.48 0.2 0.39 
RBC -0.4 -0.12 -0.5 0.81 0.61 0.6 1 1 0.86 0.44 0.11 0.36 -0.46 -0.47 
Hb -0.39 -0.17 -0.51 0.78 0.66 0.6 1 1 0.9 0.38 0.18 0.29 -0.42 -41 
Platelets -0.15 -0.27 -0.67 0.61 0.89 0.8 0.86 0.9 1 -0.02 0.52 -0.15 -0.01 0 
MPV -0.15 0.59 -0.14 0.72 -0.44 -0.4 0.44 0.38 -0.02 1 -0.84 0.97 -0.65 -1 
TA97 -0.17 -0.79 -0.06 -0.36 0.85 0.8 0.11 0.18 0.52 -0.84 1 -0.83 0.36 0.82 
TA98 -0.33 0.44 0.11 0.56 -0.5 -0.48 0.36 0.29 -0.15 0.97 -0.83 1 -0.79 -0.97 
TA100 0.84 0.21 -0.45 -0.26 0.12 0.2 -0.46 -0.42 -0.01 -0.65 0.36 -0.79 1 0.67 
TA102 0.18 -0.56 0.13 -0.73 0.41 0.39 -0.47 -0.42 0 -1 0.82 -0.97 0.67 1 
Ferritin -0.37 0.09 -0.08 0.05 -0.17 -0.08 -0.63 -0.45 -0.71 -0.04 -0.13 0.25 -0.37 -0.34 
NTBI -0.23 -0.34 0.09 -0.21 -0.03 0.02 -0.17 0.02 -0.35 -0.02 -0.25 -0.15 -0.19 -0.25 
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  Table A4.1(viii) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Aflatoxin B1 (Part 1)    
 Serum 
8-IsoP 
Liver 
8IsoP ALT AST 
Liver 
8OHdG 
Serum 
8OHdG 
Liver 
LPO 
Serum 
LPO 
Liver 
NO 
Serum 
NO 
Super- 
oxide 
GGT Ferritin NTBI 
Serum 8IsoP 1 -0.8 -0.96 -0.21 -0.9 0.42 0.02 -0.16 0.21 -0.66 0.6 0.51 0.13 0.79 
Liver 8IsoP -0.8 1 0.59 0.76 0.98 0.21 -0.61 0.72 -0.76 0.08 0 0.1 -0.89 -0.06 
ALT -0.96 0.59 1 -1 0.7 -0.7 0.3 -0.1 0.1 0.8 -0.8 -0.7 0.24 -0.9 
AST -0.21 0.76 -1 1 0.6 0.8 -1 1 -1 -0.6 0.7 0.7 0.44 -0.23 
Liver 8OHdG -0.9 0.98 0.7 0.6 1 0.01 -0.44 0.57 -0.61 0.28 -0.21 -0.1 -0.17 -0.5 
Serum 8OHdG 0.42 0.21 -0.7 0.8 0.01 1 -0.9 0.8 -0.8 -1 1 1 -0.59 0.89 
Liver LPO 0.02 -0.61 0.3 -1 -0.44 -0.9 1 -0.99 0.98 0.74 -0.79 -0.85 0.41 -0.41 
Serum LPO -0.16 0.72 -0.1 1 0.57 0.8 -0.99 1 -1 -0.64 0.69 0.76 -0.71 0.45 
Liver NO 0.21 -0.76 0.1 -1 -0.61 -0.8 0.98 -1 1 0.6 -0.7 -0.7 0.98 -0.55 
Serum NO -0.66 0.08 0.8 -0.6 0.28 -1 0.74 -0.64 0.6 1 -1 -1 -0.46 0 
Superoxide 0.6 0 -0.8 0.7 -0.21 1 -0.79 0.69 -0.7 -1 1 0.53 0.23 0.32 
GGT 0.51 0.1 -0.7 0.7 -0.1 1 -0.85 0.76 -0.7 -1 0.53 1 -0.62 0.95 
IL-1b 0.98 -0.91 -0.9 -0.4 -0.98 0.2 0.23 -0.37 0.4 -0.5 0.82 0.64 -0.13 0.61 
IL-6 0.88 -0.42 -1 0.3 -0.59 0.8 -0.46 0.33 -0.3 -0.9 -0.61 0.03 -0.22 0.98 
IL-10 0.71 -0.14 -0.9 0.5 -0.34 0.9 -0.7 0.59 -0.5 -1 -0.03 -0.58 -0.39 0.99 
Serum Fe 0.83 -0.33 -1 0.4 -0.51 0.9 -0.55 0.42 -0.4 -1 -0.5 0.28 -0.49 0.92 
TIBC -0.03 -0.58 0.3 -1 -0.4 -0.9 1 -0.98 1 0.8 -0.38 0.58 0.05 -0.2 
WBC 0.02 -0.08 -0.89 -0.15 0.65 -0.13 -0.33 0.05 0.54 -0.59 -0.38 0.58 0.34 0.58 
RBC 0.23 -0.33 0.87 0.49 0.12 0.61 0.64 0.15 0.73 -74 -0.54 -0.44 0.54 0.17 
Hb 0.4 -0.19 -0.31 0.02 0.74 0.32 0.05 0.19 0.67 -67 -0.5 -0.52 0.5 0.1 
Platelets 0.38 0.07 -0.43 -0.16 0.62 0.27 -0.03 0.28 -0.58 0.51 0.46 -0.51 -0.22 -0.67 
MPV -1 -0.02 -0.86 -0.42 0.03 -0.71 -0.73 -0.39 -0.14 -0.62 0.43 0.92 0.76 -0.27 
TA97 0.78 -0.15 0.75 -0.31 -0.49 -0.19 -0.17 -0.52 -1 0.78 -0.23 -0.12 -0.92 0.52 
TA98 -0.9 -0.2 0.15 0.75 0.1 0.32 0.55 0.31 -0.4 0.8 -0.3 -0.27 -0.97 0.54 
TA100 -0.92 -0.28 0.01 0.79 0.26 0.32 0.53 0.33 -0.02 0.8 -0.33 -0.32 -0.97 0.55 
TA102 0.92 -0.3 -0.03 0.79 0.3 0.32 0.52 0.33 0.37 -0.14 -0.38 -0.87 0.05 -0.05 
Ferritin 0.13 -0.89 0.24 0.44 -0.17 -0.59 0.41 -0.71 0.98 -0.46 0.23 -0.62 1 -0.39 
NTBI 0.79 -0.06 -0.9 -0.23 -0.5 0.89 -0.41 0.45 -0.55 0 0.32 0.95 -0.39 1 
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  Table A4.1(viii) Correlation Matrix of 12 Month Data   
  Highlighted Correlations are Significant at p<0.05   
  Group: Aflatoxin B1 (Part 2)    
 
IL-1b IL-6 IL-10 
Serum 
Fe TIBC WBC RBC Hb Platelets MPV TA97 TA98 TA100 TA102 
Serum 8IsoP 0.98 0.88 0.71 0.83 -0.03 0.02 0.23 0.4 0.38 -1 0.78 -0.9 -0.92 0.92 
Liver 8IsoP -0.91 -0.42 -0.14 -0.33 -0.58 -0.08 -0.33 -0.19 0.07 -0.02 -0.15 -0.2 -0.28 -0.3 
ALT -0.9 -1 -0.9 -1 0.3 -0.89 0.87 -0.31 -0.43 -0.86 0.75 0.15 0.01 -0.03 
AST -0.4 0.3 0.5 0.4 -1 -0.15 0.49 0.02 -0.16 -0.42 -0.31 0.75 0.79 0.79 
Liver 8OHdG -0.98 -0.59 -0.34 -0.51 -0.4 0.65 0.12 0.74 0.62 0.03 -0.49 0.1 0.26 0.3 
Serum 8OHdG 0.2 0.8 0.9 0.9 -0.9 -0.13 0.61 0.32 0.27 -0.71 -0.19 0.32 0.52 0.32 
Liver LPO 0.23 -0.46 -0.7 -0.55 1 -0.33 0.64 0.05 -0.03 -0.73 -0.17 0.55 0.53 0.52 
Serum LPO -0.37 0.33 0.59 0.42 -0.98 0.05 0.15 0.19 0.28 -0.39 -0.52 0.31 0.33 0.33 
Liver NO 0.4 -0.3 -0.5 -0.4 1 0.54 0.73 0.67 -0.58 -0.14 -1 -0.4 -0.02 0.37 
Serum NO -0.5 -0.9 -1 -1 0.8 -0.59 -0.74 -0.67 0.51 -0.62 0.78 0.8 0.8 -0.14 
Superoxide 0.82 -0.61 -0.03 -0.05 -0.38 -0.38 -0.54 -0.5 0.46 0.43 -0.23 -0.3 -0.33 -0.38 
GGT 0.64 0.03 -0.58 0.28 -0.58 0.58 -0.44 -0.52 -0.51 0.92 -0.12 0.27 -0.32 -0.87 
IL-1b 1 -0.06 -0.57 0.52 -0.13 -0.13 -0.91 -0.9 0.16 0.35 0.31 0.2 0.17 -0.75 
IL-6 -0.06 1 -0.76 0.81 0.55 0.5 -0.29 -0.37 -0.65 -0.18 0.79 0.76 0.75 -0.42 
IL-10 -0.57 -0.76 1 -0.94 -0.53 -0.48 0.75 0.82 0.58 -0.26 -0.72 -0.61 -0.57 0.9 
Serum Fe 0.52 0.81 -0.94 1 0.27 0.3 -0.8 -0.84 -0.35 -0.09 0.92 0.84 0.82 -0.72 
TIBC -0.13 0.55 -0.53 0.27 1 0.3 0.11 -0.08 -0.99 0.63 0 -0.09 -0.12 -0.54 
WBC -0.13 0.5 -0.48 0.3 0.3 1 0.1 -0.15 -0.78 0.6 0.5 -0.04 -0.22 -0.64 
RBC -0.91 -0.29 0.75 -0.8 0.11 0.1 1 0.99 -0.08 -0.06 -0.68 -0.59 -0.56 0.75 
Hb -0.9 -0.37 0.82 -0.84 -0.02 -0.15 0.99 1 0.04 -0.14 -0.68 -0.57 -0.54 0.82 
Platelets 0.16 -0.65 0.58 -0.35 -0.99 -0.78 -0.08 0.04 1 -0.53 -0.11 -0.03 0 0.53 
MPV 0.35 -0.18 -0.26 -0.09 0.63 0.6 -0.06 -0.14 -0.53 1 -0.47 -0.61 -0.64 -0.61 
TA97 0.31 0.79 -0.72 0.92 0 0.5 -0.68 -0.68 -0.11 -0.47 1 0.99 0.98 -0.39 
TA98 0.2 0.76 -0.61 0.84 -0.09 -0.04 -0.59 -0.57 -0.03 -0.61 0.99 1 1 -0.24 
TA100 0.17 0.75 -0.57 0.82 -0.12 -0.22 -0.56 -0.54 0 -0.64 0.98 1 1 -0.2 
TA102 -0.75 -0.42 0.9 -0.72 -0.54 -0.64 0.75 0.82 0.53 -0.61 -0.39 -0.24 -0.2 1 
Ferritin -0.13 -0.22 -0.39 -0.49 0.05 0.34 0.54 0.5 -0.22 0.76 -0.92 -0.97 -0.97 0.05 
NTBI 0.61 0.98 0.99 0.92 -0.2 0.58 0.17 0.1 -0.67 -0.27 0.52 0.54 0.55 -0.05 
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